myok-10q_20200930.htm

0001564590-20-051420.txt : 20201105 0001564590-20-051420.hdr.sgml : 20201105 20201105164949 ACCESSION NUMBER: 0001564590-20-051420 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 69 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201105 DATE AS OF CHANGE: 20201105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MyoKardia, Inc. CENTRAL INDEX KEY: 0001552451 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455500552 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37609 FILM NUMBER: 201291267 BUSINESS ADDRESS: STREET 1: 1000 SIERRA POINT PARKWAY CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 650-741-0900 MAIL ADDRESS: STREET 1: 1000 SIERRA POINT PARKWAY CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: MyoKardia Inc DATE OF NAME CHANGE: 20120618 10-Q 1 myok-10q_20200930.htm 10-Q myok-10q_20200930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-37609

MYOKARDIA, INC.

(Exact name of registrant as specified in its charter)

Delaware

44-5500552

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

1000 Sierra Point Parkway

Brisbane, CA

(Address of principal executive offices)

94005

(Zip Code)

(650) 741-0900

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock	MYOK	NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of outstanding shares of the registrant’s common stock on November 1, 2020 was 53,322,904 shares.

MYOKARDIA, INC.

TABLE OF CONTENTS

	Page
PART I—FINANCIAL INFORMATION		3
Item 1. Unaudited Condensed Consolidated Financial Statements		3
Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019		3
Condensed Consolidated Statements of Operations and Comprehensive Loss for the Nine Months Ended September 30, 2020 and 2019		4
Condensed Consolidated Statements of Stockholders’ Equity for the Nine Months Ended September 30, 2020 and 2019		5
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019		6
Notes to Condensed Consolidated Financial Statements		7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		18
Item 3. Quantitative and Qualitative Disclosures About Market Risk		26
Item 4. Controls and Procedures		26
PART II—OTHER INFORMATION		27
Item 1. Legal Proceedings		27
Item 1A. Risk Factors		27
Item 6. Exhibits		61
SIGNATURES		62

PART I—FINANCIAL INFORMATION

Item 1.

Unaudited Condensed Consolidated Financial Statements

MYOKARDIA, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

	September 30, 2020			December 31, 2019
Assets
Current assets
Cash and cash equivalents	$	675,541		$	101,436
Short-term investments		220,338			314,691
Consideration due from related party		35,000			—
Prepaid expenses and other current assets		12,865			7,709
Total current assets		943,744			423,836
Property and equipment, net		19,982			15,743
Operating lease right-of-use assets		50,433			417
Long-term investments		—			14,153
Related party warrant derivative asset		18,765			—
Restricted cash and other		2,737			1,945
Total assets	$	1,035,661		$	456,094
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	4,554		$	6,237
Accrued liabilities		40,043			41,292
Operating lease liabilities - current		7,891			383
Total current liabilities		52,488			47,912
Operating lease liability		43,717			—
Related party liability		93,765			—
Other long-term liabilities		713			1,908
Total liabilities		190,683			49,820
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding		—			—
Common stock, $0.0001 par value, 150,000,000 shares authorized at September 30, 2020 and December 31, 2019; 53,308,689 and 46,379,073 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		5			5
Additional paid-in capital		1,541,679			884,486
Accumulated other comprehensive income		257			549
Accumulated deficit		(696,963	)		(478,766	)
Total stockholders’ equity		844,978			406,274
Total liabilities and stockholders’ equity	$	1,035,661		$	456,094

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MYOKARDIA, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Operating expenses:
Research and development	$	59,074		$	47,372		$	155,286		$	101,270
Selling, general and administrative		26,329			17,746			66,482			45,153
Repurchase of royalty rights		—			80,000			—			80,000
Total operating expenses		85,403			145,118			221,768			226,423
Loss from operations		(85,403	)		(145,118	)		(221,768	)		(226,423	)
Interest and other income, net		668			3,332			3,592			8,775
Loss before income taxes		(84,735	)		(141,786	)		(218,176	)		(217,648	)
Income tax expense (benefit)		9			16			21			(202	)
Net loss		(84,744	)		(141,802	)		(218,197	)		(217,446	)
Other comprehensive (loss) income		(495	)		(44	)		(292	)		520
Comprehensive loss	$	(85,239	)	$	(141,846	)	$	(218,489	)	$	(216,926	)
Net loss per share, basic and diluted	$	(1.60	)	$	(3.07	)	$	(4.38	)	$	(4.91	)
Weighted average number of shares used to compute net loss per share, basic and diluted		53,101,453			46,133,068			49,860,879			44,255,657

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MYOKARDIA, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share and per share amounts)

(Unaudited)

For the nine months ended September 30,
					Additional		Accumulated other						Total
	Common Stock				Paid-In		comprehensive			Accumulated			Stockholders’
	Shares		Amount		Capital		income			Deficit			Equity
BALANCE—December 31, 2019		46,379,073	$	5	$	884,486	$	549		$	(478,766	)	$	406,274
Issuance of common stock upon the exercise of options and release of stock awards		233,113		—		1,820		—			—			1,820
Stock-based compensation		—		—		10,752		—			—			10,752
Unrealized gains		—		—		—		122			—			122
Net loss		—		—		—		—			(69,868	)		(69,868	)
BALANCE—March 31, 2020		46,612,186	$	5	$	897,058	$	671		$	(548,634	)	$	349,100
Issuance of common stock in connection with the follow-on offering, net of issuance costs of $28,909		6,037,500		—		605,028		—			—			605,028
Issuance of common stock upon the exercise of options and release of stock awards		290,977		—		5,910		—			—			5,910
Issuance of common stock pursuant to employee stock purchase plan		24,370		—		1,229		—			—			1,229
Stock-based compensation		—		—		10,876		—			—			10,876
Unrealized gains, net of tax expense		—		—		—		81			—			81
Net loss		—		—		—		—			(63,585	)		(63,585	)
BALANCE—June 30, 2020		52,965,033	$	5	$	1,520,101	$	752		$	(612,219	)	$	908,639
Issuance of common stock upon the exercise of options and release of stock awards		343,656		—		10,195		—			—			10,195
Stock-based compensation		—		—		11,347		—			—			11,347
Unrealized loss, net of tax benefit		—		—		—		(495	)		—			(495	)
Net loss		—		—		—		—			(84,744	)		(84,744	)
Adjustment for issuance costs		—		—		36		—			—			36
BALANCE—September 30, 2020		53,308,689	$	5	$	1,541,679	$	257		$	(696,963	)	$	844,978

For the nine months ended September 30,
					Additional		Accumulated other						Total
	Common Stock				Paid-In		comprehensive			Accumulated			Stockholders’
	Shares		Amount		Capital		income/ (loss)			Deficit			Equity
BALANCE—December 31, 2018		40,288,949	$	4	$	573,183	$	(67	)	$	(202,553	)	$	370,567
Issuance of common stock in connection with the follow-on offering, net of issuance costs of $17,638		5,663,750		1		271,212		—			—			271,213
Issuance of common stock upon the exercise of options and release of stock awards		49,076		—		280		—			—			280
Vesting of early exercised stock options		—		—		8		—			—			8
Stock-based compensation		—		—		6,981		—			—			6,981
Unrealized gains		—		—		—		363			—			363
Net loss		—		—		—		—			(37,470	)		(37,470	)
BALANCE—March 31, 2019		46,001,775	$	5	$	851,664	$	296		$	(240,023	)	$	611,942
Issuance of common stock upon the exercise of options and release of stock awards		75,326		—		716		—			—			716
Issuance of common stock pursuant to employee stock purchase plan		20,958		—		855		—			—			855
Vesting of early exercised stock options		—		—		7		—			—			7
Stock-based compensation		—		—		8,638		—			—			8,638
Unrealized gains, net of tax expense		—		—		—		201			—			201
Net loss		—		—		—		—			(38,174	)		(38,174	)
BALANCE—June 30, 2019		46,098,059	$	5	$	861,880	$	497		$	(278,197	)	$	584,185
Issuance of common stock upon the exercise of options and release of stock awards		120,866		—		1,739		—			—			1,739
Stock-based compensation		—		—		8,275		—			—			8,275
Unrealized loss, net of tax benefit		—		—		—		(44	)		—			(44	)
Net loss		—		—		—		—			(141,802	)		(141,802	)
BALANCE—September 30, 2019		46,218,925	$	5	$	871,894	$	453		$	(419,999	)	$	452,353

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MYOKARDIA, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Nine Months Ended September 30,
	2020			2019
Cash flow from operating activities:
Net loss	$	(218,197	)	$	(217,446	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		32,975			23,894
Depreciation		2,459			1,441
Amortization of discount on investments		(469	)		(1,034	)
Income tax benefit of unrealized gains on investments		—			(202	)
Loss on disposal of equipment		49			—
Change in operating assets and liabilities:
Prepaid expenses and other current assets		(4,897	)		(2,457	)
Operating lease right-of-use assets		2,573			2,007
Other long-term assets		(370	)		(169	)
Accounts payable		(1,321	)		3,589
Accrued liabilities		7,517			14,702
Prepayment from collaboration partner		—			(12,973	)
Operating lease liabilities		(1,364	)		(2,171	)
Consideration received from related party		40,000			—
Other long-term liabilities		(1,195	)		1,907
Net cash used in operating activities		(142,240	)		(188,912	)
Cash flow from investing activities:
Purchases of investments		(128,892	)		(145,792	)
Sales of investments		4,000			4,000
Maturities of investments		233,575			47,000
Purchases of property and equipment		(15,875	)		(1,978	)
Net cash provided by (used in) investing activities		92,808			(96,770	)
Cash flow from financing activities:
Proceeds from issuance of common stock in follow-on offerings, net of issuance costs		605,064			271,224
Proceeds from exercise of stock options and employee stock purchase plan		18,848			3,573
Net cash provided by financing activities		623,912			274,797
Net increase in cash, cash equivalents and restricted cash		574,480			(10,885	)
Cash, cash equivalents and restricted cash, beginning of period		103,630			248,265
Cash, cash equivalents and restricted cash, end of period	$	678,110		$	237,380
Non-cash investing and financing activities:
Unpaid portion of property and equipment purchases included in period-end accounts payable and accrued liabilities	$	628		$	1,689
Vesting of early exercised options and restricted stock	$	—		$	15
Non-cash exercise of stock options	$	306		$	17

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

MYOKARDIA, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

1. Organization

MyoKardia, Inc. (the Company) is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases. The Company was incorporated in 2012 in Delaware and its corporate headquarters are in Brisbane, California. The Company’s initial focus is on the treatment of cardiomyopathies, a group of diseases of the heart muscle. The Company’s pipeline includes: mavacamten and MYK-224, which are being studied for the treatment of hypertrophic cardiomyopathy; LUS-1, being studied for the treatment of diseases of diastolic dysfunction; and danicamtiv (formerly MYK-491) and ACT-1, being studied for the treatment of diseases of systolic dysfunction.

Liquidity

The Company has incurred significant operating losses since inception and has an accumulated deficit of $697.0 million as of September 30, 2020. The Company has relied on its ability to fund its operations through private and public equity financings and to a lesser extent, through a license and collaboration arrangement with a collaboration partner, Sanofi S.A. (Sanofi) via its subsidiary, Aventis Inc. The collaboration agreement ended on December 31, 2018 and the Company had no revenues relating to its Sanofi collaboration after December 31, 2018, nor has it received reimbursements of research and development expenses after June 30, 2019. In May 2020, the Company completed a follow-on offering and received proceeds totaling approximately $605.0 million from the offering, net of underwriting discounts and commissions and offering expenses. The Company has not yet received regulatory approval to commercialize or sell any product and does not have customers. Management expects operating losses and negative operating cash flows to continue for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities and anticipates the need to raise additional capital to fully implement its business plan. The Company intends to raise such capital through the issuance of additional equity, debt and/or strategic alliances with partner companies. There is no assurance that such financing will be available or that such strategic alliances will be executed on terms acceptable to the Company, or at all.

As of September 30, 2020, the Company had $895.9 million of cash, cash equivalents and investments, which management believes will be sufficient to meet the Company’s anticipated operating and capital expenditure requirements for the twelve months following the date of issuance of these financial statements. Management’s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management’s estimates, the Company may need to seek additional funding. In addition, the Company is closely monitoring ongoing developments in connection with the COVID-19 pandemic, which may negatively impact its financial and operating results.

The Company will continue to assess its operating expenses and cash and cash equivalents and, if circumstances warrant, the Company will make appropriate adjustments to its operating plan.

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited, include the Company’s accounts and those of its wholly owned subsidiaries MyoKardia Australia Pty Ltd and MyoKardia Europe B.V., and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

The condensed consolidated balance sheet at December 31, 2019, presented herein, has been derived from the audited consolidated financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year or any interim period and should be read in conjunction with the audited financial statements for the year ended December 31, 2019 and the notes thereto, which are included in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2019. The significant accounting policies used in preparation of these condensed consolidated financial statements for the periods shown are consistent with those discussed in notes to the consolidated financial statements in the Company’s 2019 Annual Report on Form 10-K and are updated below as necessary.

The Company currently operates in one business segment, which is the identification, development and commercialization of therapies for the treatment of serious cardiovascular diseases and has a single reporting unit and operating segment. These interim statements, in the opinion of management, reflect all normal recurring adjustments necessary for the fair statement of the Company’s financial position and results of operations for the interim periods ended September 30, 2020 and 2019, respectively.

Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Consolidated Statements of Cash Flows

Cash as reported in the consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents and restricted cash as presented on the consolidated balance sheets. Restricted cash at September 30, 2020 and December 31, 2019 represents cash balances held as security in connection with the Company’s facility lease agreements. The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets to the total shown in the consolidated statements of cash flows (in thousands):

	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	675,541	$	101,436
Restricted cash included in prepaid expenses and other current assets		290		337
Restricted cash included in restricted cash and other		2,279		1,857
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	678,110	$	103,630

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trials accrued liabilities, income tax valuation allowance, stock-based compensation and warrant valuation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Recently Adopted Accounting Pronouncements

In November 2018, the Financial Accounting Standards Board (FASB) issued ASU 2018-18 (Topic 808), Clarifying the Interaction Between Topic 808 and Topic 606, which provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The ASU also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. It accomplishes this by allowing organizations to only present units of account in collaborative arrangements that are within the scope of the revenue recognition standard together with revenue accounted for under the revenue recognition standard. The parts of the collaborative arrangement that are not in the scope of the revenue recognition standard should be presented separately from revenue accounted for under the revenue recognition standard. The Company adopted this amendment in the first quarter of 2020 and the adoption did not have a material impact to the Company’s financial statements.

In August 2018, the FASB issued ASU 2018-13 (Topic 820), Fair Value Measurement, which modifies the disclosure requirements in Topic 820 by removing requirements for disclosing (i) amounts of and reasons for transfers between the Level 1 and Level 2 hierarchies, (ii) the policy for timing of transfers between levels and (iii) the valuation processes for Level 3 fair value measurements. The ASU 2018-13 amendment also adds requirements for disclosure of changes in unrealized gains and losses for the period relating to Level 3 fair value measurements and other factors considered in the valuation of Level 3 investments. The Company adopted this amendment in the first quarter of 2020 and the adoption did not have a material impact to the Company’s financial statements.

In June 2016, the FASB issued ASU No. 2016-13 (Topic 326), Financial Instruments –Measurement of Credit Losses on Financial Instruments, which requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The Company adopted this amendment in the first quarter of 2020 and the adoption did not have a material impact to the Company’s financial statements.

3. License and Collaboration Agreements

LianBio

Exclusive License Agreement with LianBio Licensing, LLC

In August 2020, the Company entered into an agreement (the “LianBio Agreement”) with LianBio, a company incorporated in the Cayman Islands, and its wholly owned subsidiary, LianBio Licensing, LLC. Under the LianBio Agreement, the Company granted an exclusive, royalty-bearing right and license to develop, have manufactured, commercialize, use, offer for sale, sell, have sold, and import mavacamten in China and other territories in Asia (the “Territories”). LianBio will initially pursue a registration strategy for mavacamten in China for obstructive HCM, with plans for additional indications to follow. The agreement provides for the supply and shipment of mavacamten by the Company. Due to the nature of the laws and regulatory environment in China that will dictate how the companies will be able to operationalize the agreement, the nature of the relationship between the Company and LianBio cannot be determined until further commercial terms are negotiated. In connection with the LianBio Agreement, the Company’s Chief Executive Officer was appointed to LianBio’s Board of Directors.

Under the LianBio Agreement, the Company received a payment of $40.0 million at closing, with an additional $35.0 million unconditionally due 45 days after the earlier of six months following the date of the LianBio Agreement or a specified financing event for LianBio. The specified financing event occurred on October 29, 2020. The Company also received a warrant to purchase 170,000 ordinary shares of Lian Cardiovascular, a wholly owned subsidiary of LianBio. The warrant is immediately exercisable at $275.00 per share, representing 17% of the ordinary shares of Lian Cardiovascular upon issuance. The warrant was recorded at a fair value of $18.7 million (see Note 4. Fair Value Measurements) on the date of issuance. The Company will be eligible to receive regulatory and sales milestone payments of up to $60.0 million and $87.5 million, respectively, as well as royalties ranging from low to upper teens on the sale of mavacamten in the Territories. The LianBio Agreement does not include a clinical development or commercial supply agreement, which would include pricing and delivery terms; however, it states that the agreements will be negotiated between the Company and LianBio in good faith. The Company and LianBio have also agreed that in the case of China, where a two invoice policy is required, the parties will use commercially reasonable efforts to distribute mavacamten directly or indirectly in China. However, due to the regulatory requirements, such as the two invoice policy, the role LianBio will play in commercializing mavacamten remains to be decided by the parties. The LianBio Agreement provides that the commercial supply agreement will be negotiated within 90 days following the first submission of a new drug application for mavacamten in the Territories, currently anticipated to be no sooner than the fourth quarter of 2021.

The Company assessed the LianBio Agreement and concluded that the LianBio Agreement is incomplete. The parties have yet to determine the supply and distribution terms in the Territories, including the clinical and commercial supply agreements, and therefore the Company has concluded that there are incomplete commercial terms, which if complete, would enable the Company to conclude on the applicable accounting treatment for the arrangement. The Company has deferred the consideration already received from and committed by LianBio until such time information is available that will enable the Company to apply the appropriate accounting framework. Due to the Company’s receipt of a warrant exercisable for 17% of the ordinary shares of Lian Cardiovascular, and the Company’s Chief Executive Officer’s position on the LianBio’s Board of Directors, the Company has concluded that LianBio is a related party. The Company recorded the total consideration of $93.7 million, consisting of the $40.0 million in cash, $35.0 million consideration due from related party and $18.7 million in fair value of the warrant, as a noncurrent related party liability, and recorded the $35.0 million consideration due from related party as a current asset due to its short-term nature. The related party warrant derivative asset was recorded as a non-current asset and changes to its fair value will be recorded in other income (expense) at each reporting period.

Fulcrum Therapeutics, Inc.

Multi-Target Collaboration and License Agreement with Fulcrum Therapeutics, Inc.

In July 2020, the Company entered into a multi-target collaboration and license agreement with Fulcrum Therapeutics, Inc. (“Fulcrum”), to discover, develop and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies (the “Fulcrum Agreement”). Under the Fulcrum Agreement, the Company paid Fulcrum a $10.0 million upfront payment and $2.5 million in prepaid research funding at the close of the transaction. Fulcrum is eligible to receive research, development and commercial milestone payments and additional research reimbursements of up to $302.5 million for a first product to progress through development and commercialization. If the Company chooses to develop and commercialize products directed to more targets under the collaboration, Fulcrum will be eligible for milestone payments of up to $150.0 million for a follow-on target and $298.5 million for an additional cardiomyopathy target. Fulcrum will also be eligible to receive tiered royalties ranging from the mid single digits to low double digits on net sales for any products under the collaboration that are commercialized. The $10.0 million in expense was recorded to research and development expense in the statement of operations when paid, due to its nonrefundable, noncreditable nature, and the Company amortizes the prepaid research funding as research and development expense as incurred by Fulcrum.

Sanofi (Aventis Inc.)

Agreement Overview, Termination and Repurchase of Royalty Rights

Until December 31, 2018 the Company had an exclusive license and collaboration agreement (“Collaboration Agreement”) with Aventis Inc., a wholly owned subsidiary of Sanofi S.A. (Sanofi). On December 31, 2018, Sanofi notified the Company of its intent to terminate the collaboration, specifically, Sanofi elected not to continue with the mavacamten, MYK-224 and danicamtiv programs. As a result, cost sharing and Sanofi’s reimbursement of the Company’s research and development costs for mavacamten and MYK-224 ended in the first half of 2019. At that time Sanofi had continuing rights to royalties in the event of commercialization of the mavacamten and MYK-224 programs. In July 2019, the Company repurchased those rights from Sanofi for $80.0 million. Neither the Company nor Sanofi have any material continuing rights or obligations under the Collaboration Agreement.

4. Fair Value Measurements

The Company’s financial instruments consist primarily of cash and cash equivalents, restricted cash, marketable debt securities, accounts receivable, warrant derivative, accounts payable and accrued liabilities. Cash and cash equivalents, restricted cash, marketable debt securities, and warrant derivative asset are reported at their respective fair values in our consolidated balance sheets. The carrying amount of remaining financial instruments approximate fair value due to their short-term nature.

The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2—Inputs other than quoted market prices included in Level 1 are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

Marketable securities and the warrant derivative asset are stated at their estimated fair values. The counterparties to the agreements relating to the Company’s investment securities consist of the U.S. Treasury, governmental agencies, various major corporations and financial institutions with reputable credit and therefore bear minimal credit risk. The carrying amounts for financial instruments consist of cash and cash equivalents, accounts payable and accrued liabilities and approximate fair value due to their short maturities.

Debt Securities

The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326, Financial Instruments – Credit Losses, as of each reporting date in order to determine if a portion of any decline in fair value below amortized cost basis has resulted from a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other expense, net, which is limited to the difference between the fair value and the amortized cost of the security.

Accrued interest related to the Company's available-for-sale debt securities is presented within other current assets on the Company's condensed consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not recorded any losses from accrued interest receivables associated with its marketable securities.

The following table sets forth the Company’s marketable securities that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

	Fair Value Measurements at September 30, 2020
	Total		Level 1		Level 2		Level 3
Assets
Money market funds	$	674,410	$	674,410	$	—	$	—
U.S. government agency obligations		157,032		—		157,032		—
Corporate securities		63,306		—		63,306		—
Total	$	894,748	$	674,410	$	220,338	$	—

	Fair Value Measurements at December 31, 2019
	Total		Level 1		Level 2		Level 3
Assets
Money market funds	$	100,441	$	100,441	$	—	$	—
U.S. government agency obligations		134,055		—		134,055		—
Corporate securities		194,789		—		194,789		—
Total	$	429,285	$	100,441	$	328,844	$	—

The following table is a summary of amortized cost, unrealized gain and loss, and fair value of the Company’s marketable securities by contractual maturities (in thousands):

	Fair Value Measurements at September 30, 2020
	Amortized Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash equivalents (due within 90 days)	$	674,410	$	—	$	—		$	674,410
Short-term investments (due within one year)		220,076		262		—			220,338
Total	$	894,486	$	262	$	—		$	894,748

	Fair Value Measurements at December 31, 2019
	Amortized Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash equivalents (due within 90 days)	$	100,440	$	1	$	—		$	100,441
Short-term investments (due within one year)		314,181		523		(13	)		314,691
Long-term investments (due between one and two years)		14,110		47		(4	)		14,153
Total	$	428,731	$	571	$	(17	)	$	429,285

As of September 30, 2020, the Company did not have any available-for-sale debt securities in a continuous unrealized position. The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months as of December 31, 2019 (in thousands):

	Less than 12 months					12 months or greater				Total
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss		Fair Value		Unrealized Loss
December 31, 2019
Corporate bonds	$	34,265	$	(15	)	$	—	$	—	$	34,265	$	(15	)
U.S. government agency obligations		34,989		(2	)		—		—		34,989		(2	)
Total	$	69,254	$	(17	)	$	—	$	—	$	69,254	$	(17	)

Warrant Derivative Asset

Pursuant to the LianBio Agreement, on August 11, 2020, the Company received a warrant to purchase 170,000 ordinary shares of Lian Cardiovascular at an exercise price of $275.00 per share. The warrant represented 17% of the then-fully diluted equity of Lian Cardiovascular. The Company accounts for the warrant as a derivative instrument in accordance with ASC 815, Derivatives and Hedging, adjusting the fair value at the end of each reporting period, with changes in fair value recorded as other income (expense), net. The fair value of the warrant was estimated to be $18.7 million at inception; there was no material change in the value of the warrant as of September 30, 2020 and therefore no gain or loss was recorded during the three and nine months ended September 30, 2020.

The Company estimates the fair value of the warrant with a two-step process. On the date acquired, the fair value of the total stockholder’s equity of Lian Cardiovascular was estimated using a discounted cash flow approach. The projected cash flows from Lian Cardiovascular are based on various assumptions, including projected revenues in the territories, the potential development and commercial timeline, regulatory risks, and estimated costs to be incurred by Lian Cardiovascular for clinical trials and selling and marketing expense. The cash flows are discounted at a rate commensurate with the level of risk associated with the projected cash flows. In the second step, the option pricing method is used to estimate the fair value of the warrant.

The Company has determined that the warrant derivative asset should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the two-step process against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification. The significant unobservable inputs used to value the warrant were as follows:

Valuation Technique	Significant Unobservable Inputs	At Inception		September 30, 2020
Option pricing method	Volatility	73.0%		73.0%
	Expected term (in years)		10.0		9.9
	Risk-free rate	0.59%		0.59%
	Dividend yield	0.0%		0.0%

Significant changes in these unobservable inputs could result in a significantly lower or higher fair value measurement.

5. Leases

The Company determines if an arrangement is or contains a lease at inception. Operating lease right-of-use (ROU) assets and liabilities are presented separately on its consolidated balance sheets. The Company does not have any material finance leases.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term beginning at the commencement date. As the Company’s leases do not provide enough information to determine an implicit interest rate, the Company determines its incremental borrowing rate based on the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term in a similar economic environment. The operating lease ROU assets also include any lease payments made and excludes lease incentives and initial direct costs incurred. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

In September 2018, the Company entered into a lease agreement for approximately 129,800 square feet of office and laboratory space at 1000 Sierra Point Parkway, Brisbane, California, which is now the Company’s corporate headquarters. The Company performed an evaluation of the lease and determined it is an operating lease. The lease commencement date was in January 2020 and on the commencement date, the Company recognized a $52.6 million ROU asset and lease liability on its consolidated balance sheet in accordance with ASC 842. The lease grants the Company an option to extend the lease for an additional 10-year period. This optional period was not included in the measurement of the ROU asset or lease liability as it was not reasonably certain that the Company would exercise the option. The lease requires the Company to share in prorated operating expenses and property taxes based upon actual amounts incurred. These expenses were classified as variable lease costs due to the Company’s election to account for each separate lease component and the non-lease components associated with that lease component as a single lease component.

The lease provides for annual base rent of approximately $5.5 million in the first year of the lease term. The annual base rent for the second twelve months will be approximately $8.5 million, which will increase on an annual basis beginning from the 25th month to approximately $11.1 million for the tenth year of the lease.

As of September 30, 2020, the Company has capitalized $10.4 million of leasehold improvements within property and equipment and amortizes the improvements over the lease term.

Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate).

	September 30, 2020			December 31, 2019
Assets
Operating lease right-of-use assets	$	50,433		$	417

Liabilities
Operating lease liabilities - current	$	7,891		$	383
Operating lease liabilities - noncurrent		43,717			—
	$	51,608		$	383

Weighted average remaining lease term (years)		9.3			0.3
Weighted average discount rate		13.5	%		6.0	%

Information related to operating lease activity during the three months ended September 30, 2020 and 2019 was as follows (in thousands):

	Nine Months Ended September 30,
	2020		2019
Operating lease cost	$	7,103	$	2,163
Variable lease cost		1,235		—
Total lease cost	$	8,338	$	2,163

Operating lease right-of-use assets obtained in exchange for lease obligations	$	52,589	$	1,095

Operating lease payments	$	5,888	$	2,330

Future annual payments of operating lease liabilities as of September 30, 2020 are as follows (in thousands):

Year ending December 31:	Amount
2020 (three months remaining)	$	2,045
2021		8,449
2022		8,745
2023		9,051
2024		9,368
Thereafter		52,442
Total future lease payments		90,100
Less: imputed interest		(38,492	)
Total operating lease liabilities	$	51,608

The operating leases require the Company to share in prorated operating expenses and property taxes based upon actual amounts incurred; those amounts are not fixed for future periods and, therefore, are not included in the future commitments listed above.

In June 2020, the Company entered into a noncancellable operating sublease for approximately 34,500 square feet of space at 1200 Sierra Point Parkway, Brisbane, California (the “sublease”). The sublease will become effective upon Landlord’s consent. The date on which the Company will record the ROU asset and lease liability on its balance sheet (the “Commencement Date”) will be the date the premises are ready for occupancy, currently anticipated to be the first quarter of 2021. The sublease expires nine years after the Commencement Date. Future minimum rental payments during the nine year lease term are $19.9 million in the aggregate. The sublease further provides that the Company is obligated to pay its share of certain costs, including taxes and operating expenses.

6. Balance Sheet Components

Property and Equipment

Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from two to five years. Leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations and comprehensive loss.

Property and equipment consist of the following (in thousands):

	September 30, 2020			December 31, 2019
Scientific equipment	$	13,645		$	10,642
Furniture and equipment		3,127			2,572
Capitalized software		360			389
Leasehold improvements		11,925			509
Construction in progress		485			9,568
Total		29,542			23,680
Less: Accumulated depreciation		(9,560	)		(7,937	)
Property and equipment, net	$	19,982		$	15,743

Depreciation expense was $0.9 million and $0.5 million for the three months ended September 30, 2020 and 2019, respectively, and $2.5 million and $1.4 million for the nine months ended September 30, 2020 and 2019, respectively.

Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	September 30, 2020		December 31, 2019
Clinical research and development	$	5,386	$	11,494
Outside services		9,987		6,592
Payroll related liabilities		15,935		11,724
Construction in progress		454		9,139
Other		8,281		2,343
Total accrued liabilities	$	40,043	$	41,292

7. Commitments and Contingencies

Purchase Commitments

The Company conducts product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations; however, these contracts are generally cancelable on 30 days’ notice and the obligations under these contracts are largely based on services performed.

Contingencies

From time to time, the Company may have contingent liabilities that arise in the ordinary course of business activities. The Company accrues for such liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no contingent liabilities requiring accrual or disclosure as of September 30, 2020 or December 31, 2019.

Legal Proceedings Related to the Offer and the Merger

As further described in Note 11, Subsequent Events, on October 3, 2020, the Company entered into an Agreement and Plan of Merger (“Merger Agreement”) by and among the Company, Bristol-Myers Squibb Company, a Delaware corporation (“Bristol-Myers Squibb”), and Gotham Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Bristol-Myers Squibb (“Merger Sub”).

On October 19, 2020, a purported stockholder of the Company filed a complaint in the United States District Court for the Northern District of California, entitled Wang v. MyoKardia, Inc. et al., 3:20-cv-07342, against the Company and each of its directors. On October 26, 2020, a purported stockholder of the Company filed a substantially similar complaint in the United States District Court for the District of Delaware, entitled Adams v. MyoKardia, Inc. et al., 1:20-cv-01445-UNA, against the Company, each of its directors, Bristol Myers Squibb, and Merger Sub. On October 27, 2020, a purported stockholder of the Company filed a substantially similar complaint in the United States District Court for the Eastern District of New York, entitled Gray v. MyoKardia, Inc. et al., 1:20-cv-05176, against the Company and each of its directors. On October 29, 2020, a purported stockholder of the Company filed a substantially similar complaint in the United States District Court for the Southern District of New York, entitled Farina v. MyoKardia, Inc et al.,1:20-cv-09194, against the Company and each of its directors. Each complaint alleges that the defendants violated federal securities laws by misrepresenting and/or omitting material information in the Schedule 14D-9. The complaints seek, among other things, (i) injunctive relief preventing the consummation of the transactions contemplated by the Merger Agreement, (ii) rescissory damages or rescission in the event that the transactions contemplated by the Merger Agreement have already been consummated, (iii) damages and (iv) plaintiff’s attorneys’ and experts’ fees and expenses. The Company believes that the claims asserted in the complaints are without merit. Additional lawsuits may be filed.

Guarantees and Indemnifications

The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to certain of these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these indemnification arrangements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future but have not yet been made.

The Company indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws and agreements providing for indemnification entered into with its officers and directors. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity.

The maximum amount of potential future indemnification of directors and officers is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with its exposure and may enable it to recover a portion of any future amounts paid.

The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

8. Stockholders’ Equity

In May 2020, the Company completed a follow-on offering and issued 6,037,500 shares of common stock at a price of $105.00 per share, which included 787,500 shares sold directly to the underwriters upon exercise of their over-allotment option. The Company received proceeds totaling approximately $605.0 million from the offering, net of underwriting discounts and commissions and offering expenses.

On January 3, 2020, the Company entered into a sales agreement with a sales agent to establish an at-the-market (ATM) offering program, under which the Company is permitted to offer and sell, from time to time, shares of common stock having a maximum aggregate offering price of up to $200.0 million. As of September 30, 2020, no securities have been issued pursuant to the ATM agreement.

In March 2019, the Company completed a follow-on offering and issued 5,663,750 shares of common stock at a price of $51.00 per share, which included 738,750 shares sold directly to the underwriters upon exercise of their over-allotment option. During the nine months ended September 30, 2019, the Company received proceeds totaling approximately $271.2 million from the offering, net of underwriting discounts and commissions and offering expenses.

Common Stock Reserved for Issuance

The Company has reserved shares of common stock for issuance as follows:

	September 30, 2020		December 31, 2019
Options and awards issued and outstanding		5,656,261		5,315,254
Shares available for issuance under 2015 Stock Option and Incentive Plan		1,331,844		685,435
Shares available for issuance under 2015 Employee Stock Purchase Plan		1,579,961		1,140,541
Total		8,568,066		7,141,230

9. Stock-Based Compensation

The Company classifies stock-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss based on the department to which a recipient belongs. The following table sets forth stock-based compensation expense related to equity awards granted to employees and consultants for all periods presented (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development	$	5,621	$	3,644	$	16,152	$	10,402
Selling, general and administrative		5,726		4,631		16,823		13,492
Total	$	11,347	$	8,275	$	32,975	$	23,894

The following summarizes option and other equity award activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan:

	Shares Subject to			Weighted Average
	Outstanding Options			Exercise Price per Share
Balance at December 31, 2019		4,574,158		$	31.81
Options granted		1,064,174		$	74.16
Options exercised		(696,937	)	$	25.72
Options canceled/forfeited		(240,298	)	$	45.70
Balance at September 30, 2020		4,701,097		$	41.59

	Shares Subject to			Weighted Average
	Outstanding Awards			Grant Date Fair Value
Balance at December 31, 2019		741,096		$	46.59
RSUs awarded		450,956		$	74.00
RSUs released		(170,809	)	$	45.09
RSUs forfeited		(66,079	)	$	49.81
Balance at September 30, 2020		955,164		$	59.58

Restricted stock units (“RSUs”) settle into shares of common stock upon vesting and the fair value is the market price on the date of grant.

In relation to stock options and awards that vest upon the achievement of performance criteria, there was $0.3 million and zero in stock-based compensation expense recorded for the three months ended September 30, 2020 and 2019, respectively and $1.0 million and zero was recorded for the nine months ended September 30, 2020 and 2019, respectively. The Company begins to recognize expenses related to these stock options and awards during the period upon concluding that certain performance criteria are considered probable.

10. Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Numerator
Net loss	$	(84,744	)	$	(141,802	)	$	(218,197	)	$	(217,446	)
Denominator
Weighted average shares outstanding		53,101,453			46,133,068			49,860,879			44,258,437
Less: weighted average shares subject to repurchase		—			—			—			(2,780	)
Weighted average shares used to compute basic and diluted net loss per share		53,101,453			46,133,068			49,860,879			44,255,657
Net loss per share, basic and diluted	$	(1.60	)	$	(3.07	)	$	(4.38	)	$	(4.91	)

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

	As of September 30,
	2020		2019
Common stock subject to repurchase		—		—
Options and awards issued and outstanding		5,656,261		5,278,515

As of September 30, 2020, the Company has contributions from plan participants of $1.2 million under the 2015 ESPP, which if converted, would be equivalent to approximately 25,000 shares based on 85% of the stock price at the beginning of the offering period. As of September 30, 2019, the Company had contributions from plan participants of $0.8 million under the 2015 ESPP, which if converted, would have been equivalent to approximately 20,000 shares using the offering price at the beginning of the offering period.

11. Subsequent Events

On October 3, 2020, the Company entered into a Merger Agreement by and among the Company, Bristol-Myers Squibb and Merger Sub. Under the terms of the Merger Agreement, and upon the terms and subject to the conditions thereof, Merger Sub has commenced a cash tender offer to purchase all of the outstanding shares of common stock of the Company for $225.00 per share, in cash, without interest and subject to applicable withholding tax (the “Tender Offer”). Following the completion of the Tender Offer, Merger Sub will be merged into the Company, with the Company surviving as a wholly owned subsidiary of Bristol-Myers Squibb. The acquisition is anticipated to close in the fourth quarter of 2020. If the Merger Agreement is terminated by the Company under specified circumstances, the Company will be required to pay Bristol-Myers Squibb a termination fee of $458.0 million.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following management’s discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated financial statements and notes thereto for the year ended December 31, 2019, included in our Annual Report on Form 10-K for the year ended December 31, 2019, filed with the U.S. Securities and Exchange Commission (SEC) on February 27, 2020 (the “Annual Report”).

Special note regarding forward-looking statements

This report contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in these forward-looking statements. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section titled “Risk Factors” included under Part II, Item 1A below. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Overview

We are a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases. Our goal is to be the world’s leading precision cardiovascular medicine company. Precision medicine involves discovering and developing therapies that integrate clinical and molecular information based on the biological basis of disease. Our strategy is to identify homogenous subgroups of patients with a given cardiovascular disease, understand the causal factors underlying that subgroup’s condition and develop targeted therapies designed to correct the common underlying defect leading to abnormal cardiac contraction or relaxation within each subgroup.

Our lead clinical-stage candidate is mavacamten, a novel, oral, allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). Mavacamten is intended to reduce cardiac muscle contractility by inhibiting the excessive myosin-actin cross-bridge formation that underlies the excessive contractility, left ventricular hypertrophy and reduced compliance characteristic of HCM. In 2016, mavacamten was granted Orphan Drug Designation by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive HCM. In May 2020 we announced positive top-line results from the pivotal Phase 3 EXPLORER-HCM study of mavacamten in patients with symptomatic, obstructive HCM. In July 2020 we announced that mavacamten had been granted Breakthrough Therapy Designation by the FDA. We plan to file a New Drug Application seeking regulatory approval of mavacamten for the treatment of obstructive HCM in the first quarter of 2021.

In addition to the EXPLORER-HCM study of mavacamten, we are conducting a MAVA long-term extension (LTE) study of mavacamten, which will include patients from our Phase 3 EXPLORER-HCM study and the Phase 2 MAVERICK-HCM in non-obstructive HCM. In March 2020, in order to protect the safety of study participants, investigators and staff, and to ensure consistent and appropriate clinical trial conduct in light of the COVID-19 pandemic, we temporarily suspended new patient enrollment in the MAVA-LTE study but enrollment resumed in the second quarter of 2020.

MAVERICK-HCM is a Phase 2 clinical trial initiated in 2018 for the potential treatment of symptomatic non-obstructive HCM. In November 2019, we reported positive top-line results and established safety and tolerability of mavacamten in non-obstructive HCM over a treatment period of 16 weeks. Additional data were reported in March 2020. Meaningful reductions in biomarkers of cardiac stress were observed in patients receiving mavacamten versus those in the placebo cohort and clear signals of clinical benefit were noted in a subgroup with elevated cardiac filling pressures and in a pre-specified group of patients at higher risk for morbidity and mortality. Based on the safety and pharmacologic benefits observed in the MAVERICK-HCM study, we plan to advance mavacamten into additional studies in defined groups of patients with non-obstructive HCM and heart failure with preserved ejection fraction (HFpEF).

In August 2020, we announced the initiation of our Phase 3 VALOR-HCM clinical trial designed to evaluate mavacamten as a potential alternative to septal reduction therapy (SRT) in obstructive HCM patients. SRT is a highly invasive procedure consisting of a surgical or catheter-based therapy that eliminates or reduces the left ventricular outflow tract obstruction. The Phase 3 VALOR-HCM trial is a double-blind, placebo-controlled, multicenter study that will enroll approximately 100 individuals randomized 1:1 for a 16-week placebo-controlled period, with an interim analysis planned after 50 subjects have completed treatment through Week 16.

We are also conducting PIONEER-OLE, an open label extension study of obstructive HCM patients from our Phase 2 PIONEER study. Data for twelve patients at 48 weeks of treatment with mavacamten were consistent with prior safety and efficacy observations at the 12, 24, and 36-week readouts. Highlights of the data included continued safety and tolerability and sustained clinical benefits, including reductions in left ventricular outflow tract (LVOT) gradient, improvements in New York Heart Association functional class and improvement of multiple biomarkers toward normal ranges. A reduction in septal wall thickness, a defining characteristic of HCM, as well as an improvement in patient reported quality of life, as measured by the Kansas City Cardiomyopathy Questionnaire were also reported.

Our second clinical-stage candidate is danicamtiv, designed to increase the contractility of the heart (systolic function) with minimal or no effect on myocardial relaxation and compliance (diastolic function) by acting directly on the proteins in the heart muscle responsible for contraction.

In September 2020, we announced that the first patient had been dosed in our Phase 2 clinical trial of danicamtiv in people with primary dilated cardiomyopathy (DCM), thought to be caused by genetic mutations of the sarcomere. Topline data are anticipated in the second half of 2021, assuming conditions related to the COVID-19 pandemic continue to allow for enrollment and study conduct in line with current expectations. In June 2020, we announced interim results from a Phase 2a multiple-ascending dose clinical trial of danicamtiv in patients with stable heart failure. This trial follows the completion of two single-ascending dose Phase 1 studies in healthy volunteers and in patients with dilated cardiomyopathy, a disease of systolic dysfunction that can result in heart failure. In the Phase 2a study, danicamtiv was generally well-tolerated, and was associated with clinically meaningful improvements in left ventricular (LV) contractility, including statistically significant increases in LV stroke volume without impairing diastolic function (the heart’s ability to relax and fill). Danicamtiv treatment also improved left atrial volume and function, a new and potentially important finding given that left atrial size is a well-established prognostic factor for atrial fibrillation. We expect to initiate a Phase 2 study in patients with systolic heart failure and paroxysmal or persistent atrial fibrillation in the first half of 2021.

In August 2019, we commenced dosing healthy volunteers in a Phase 1 study of small molecule MYK-224. In March 2020, in response to the coronavirus pandemic, we paused new patient enrollment in the Phase 1 healthy volunteer study of MYK-224. We have since resumed patient enrollment in the study.

The ultimate impacts of COVID-19 on our business are currently unknown. We will continue to actively monitor the situation and may take further precautionary and preemptive actions as may be required by federal, state or local authorities or that we determine are in the best interests of public health and safety and that of our patient community, employees, partners, suppliers and stockholders. We cannot predict the effects that such actions, or the impact of COVID-19 on global business operations and economic conditions may have on our business or strategy, including the effects on our ongoing and planned clinical development activities and prospects, or on our financial and operating results.

Financial Overview

We have not generated net income from operations and, as of September 30, 2020, had an accumulated deficit of $845.0 million, primarily as a result of research and development and selling, general and administrative expenses. We have not generated any revenue from product sales since our inception and have funded our operations primarily through the issuance of equity securities, payments from Sanofi pursuant to a Collaboration Agreement with Sanofi that was terminated in December 2018 and payments from LianBio pursuant to an exclusive license agreement executed in August 2020. We expect to incur significant and increasing losses from operations for the foreseeable future and we can provide no assurance that we will ever generate significant revenue or profits. As of September 30, 2020, we have cash, cash equivalents and investments totaling $895.9 million.

Merger with Bristol-Myers Squibb

On October 3, 2020, we entered into an Agreement and Plan of Merger (“Merger Agreement”) with Bristol-Myers Squibb Company, a Delaware corporation (“Bristol-Myers Squibb”), and Gotham Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Bristol-Myers Squibb (“Merger Sub”). Under the terms of the Merger Agreement, and upon the terms and subject to the conditions thereof, Merger Sub has commenced a cash tender offer (“Tender Offer”) to purchase all of the outstanding shares of our common stock for $225.00 per share, in cash, without interest and subject to applicable withholding tax. Following the completion of the Tender Offer, Merger Sub will be merged into our company, with our company surviving as a wholly owned subsidiary of

Bristol-Myers Squibb. The acquisition is anticipated to close in the fourth quarter of 2020. If the Merger Agreement is terminated by us under specified circumstances, we will be required to pay Bristol-Myers Squibb a termination fee of $458.0 million.

LianBio

In August 2020, we entered into an agreement (the “LianBio Agreement”) with LianBio, a company incorporated in the Cayman Islands, and its wholly owned subsidiary, LianBio Licensing, LLC. Under the LianBio Agreement, we granted an exclusive, royalty-bearing right and license to develop, have manufactured, commercialize, use, offer for sale, sell, have sold, and import mavacamten in China and other territories in Asia (the “Territories”). LianBio will initially pursue a registration strategy for mavacamten in China for obstructive HCM, with plans for additional indications to follow. The agreement provides for the supply and shipment of mavacamten by us. Due to the nature of the laws and regulatory environment in China that will dictate how the companies will be able to operationalize the agreement, the nature of the relationship between LianBio and us cannot be determined until further commercial terms are negotiated. In connection with the LianBio Agreement, our Chief Executive Officer was appointed to LianBio’s Board of Directors.

Under the LianBio Agreement, we received a payment of $40.0 million at closing, with an additional $35.0 million unconditionally due 45 days after the earlier of six months following the date of the LianBio Agreement or a specified financing event for LianBio. The specified financing event occurred on October 29, 2020. We also received a warrant to purchase 170,000 ordinary shares of Lian Cardiovascular, a wholly owned subsidiary of LianBio. The warrant is immediately exercisable at $275.00 per share, representing 17% of the ordinary shares of Lian Cardiovascular upon issuance. The warrant was recorded at a fair value of $18.7 million (see Note 4. Fair Value Measurements) on the date of issuance. We will be eligible to receive regulatory and sales milestone payments of up to $60.0 million and $87.5 million, respectively, as well as royalties ranging from low to upper teens on the sale of mavacamten in the Territories. The LianBio Agreement does not include a clinical development or commercial supply agreement, which would include pricing and delivery terms; however, it states that the agreements will be negotiated between the parties in good faith. The parties have also agreed that in the case of China, where a two invoice policy is required, we will use commercially reasonable efforts to distribute mavacamten directly or indirectly in China. However, due to the regulatory requirements, such as the two invoice policy, the role LianBio will play in commercializing mavacamten remains to be decided by the parties. The LianBio Agreement provides that the commercial supply agreement will be negotiated within 90 days following the first submission of a new drug application for mavacamten in the Territories, currently anticipated to be no sooner than the fourth quarter of 2021.

Termination of Sanofi Collaboration

Until December 31, 2018 we had an exclusive Collaboration Agreement with Sanofi. On December 31, 2018, Sanofi notified us of its intent to terminate our collaboration, specifically, Sanofi elected not to continue with the mavacamten, MYK-224 and danicamtiv programs. As a result, cost sharing and Sanofi’s reimbursement of our research and development costs for mavacamten and MYK-224 ended in the first half of 2019. At that time Sanofi had continuing rights to royalties in the event of commercialization of the mavacamten and MYK-224 programs. In July 2019, we repurchased those rights from Sanofi for $80.0 million. Neither we nor Sanofi have any material continuing rights or obligations under the Collaboration Agreement.

Financings

In May 2020, we completed a follow-on offering and issued 6,037,500 shares of common stock at a price of $105.00 per share, which included 787,500 shares sold directly to the underwriters upon exercise of their over-allotment option. We received proceeds totaling approximately $605.0 million from the offering, net of underwriting discounts, commissions and offering expenses.

On January 3, 2020, we entered into a sales agreement with a sales agent to establish an at-the-market (ATM) offering program, under which we are permitted to offer and sell, from time to time, shares of common stock having a maximum aggregate offering price of up to $200.0 million. As of September 30, 2020, no securities have been issued pursuant to the ATM agreement.

Components of Operating Results

Operating Expense

Research and Development Expenses

Research and development expenses consist of salaries and benefits, including stock-based compensation, lab supplies and facility costs and fees paid to contract manufacturing organizations (CMOs) and clinical research organizations (CROs) to conduct certain research and development activities on our behalf. Research and development expenses are shown net of amounts that Sanofi agreed to reimburse us under the cost sharing program for research and development activities. Payments made prior to the receipt of goods or services are capitalized until the goods or services are received.

Research and development expenses incurred in the development and potential commercialization of mavacamten, danicamtiv and other product candidates are shown net of zero and $8.6 million in reductions in expense due to Sanofi research and development reimbursements during the three months ended September 30, 2020 and 2019, respectively, and zero and $18.5 million during the nine months ended September 30, 2020 and 2019, respectively, as follows (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Mavacamten	$	25,207	$	24,987	$	78,132	$	47,084
Danicamtiv		3,727		8,871		10,419		18,517
Stock-based compensation		5,621		3,644		16,152		10,402
Other		24,519		9,870		50,583		25,267
Total research and development expenses	$	59,074	$	47,372	$	155,286	$	101,270

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist principally of salaries and benefits, including stock-based compensation, professional fees for legal, consulting, audit and tax services, market research, rent and other general operating expenses not otherwise classified as research and development expenses.

Interest and Other Income, Net

Interest and other income, net consists primarily of interest income earned on our cash and cash equivalents, short-term investments and long-term investments.

Critical Accounting Estimates

See Part I, Item 7, “Critical Accounting Estimates” in our Annual Report. There have been no material changes to our critical accounting estimates disclosed in our Annual Report, except for the following.

Fair Value Measurement of Warrant Derivative Asset

We estimate the fair value of the warrant with a two-step process. On the date acquired, the fair value of the total stockholder’s equity of Lian Cardiovascular was estimated using a discounted cash flow approach. The projected cash flows from Lian Cardiovascular are based on various assumptions, including projected revenues in the territories, potential development and commercial timeline, regulatory risks, and estimated costs to be incurred by Lian Cardiovascular for clinical trials, and selling and marketing expense. The cash flows are discounted at a rate commensurate with the level of risk associated with the projected cash flows. In the second step, the option pricing method was used to estimate the fair value of the warrant. Significant unobservable inputs include the risk-free rate of interest, volatility and estimated term of the warrant. Changes in these unobservable inputs and assumptions can materially affect the fair value. These inputs are subjective and generally require significant analysis and judgement to develop.

Results of Operations

Comparison of the Three Months Ended September 30, 2020 and 2019

The following table compares the operating results (in thousands):

	Three Months Ended September 30,						Change
	2020			2019			$			%
Operating expenses:
Research and development	$	59,074		$	47,372		$	11,702			25	%
Selling, general and administrative		26,329			17,746			8,583			48	%
Repurchase of royalty rights		—			80,000			(80,000	)		-100	%
Total operating expenses		85,403			145,118			(59,715	)		-41	%
Loss from operations		(85,403	)		(145,118	)		59,715			-41	%
Interest and other income, net		668			3,332			(2,664	)		-80	%
Income tax expense		9			16			(7	)		-44	%
Net loss	$	(84,744	)	$	(141,802	)	$	57,058			-40	%

Research and Development Expenses

Research and development expenses increased $11.7 million, or 25%, from $47.4 million for the three months ended September 30, 2019 to $59.1 million for the three months ended September 30, 2020. The increase in research and development expenses was primarily due to the following:

•

a $10.1 million increase in collaboration partner expenses relating to our partnership with Fulcrum;

•

a $4.1 million increase in personnel expenses due to a higher employee headcount;

•

a $2.5 million increase in facility and information technology expenses;

•

a $2.0 million increase in stock compensation expense;

•

a $1.7 million increase in contract research;

•

a $1.5 million increase in professional and consultant fees;

•

a $0.7 million increase in medical affairs;

•

offset by a $6.7 million decrease in clinical expenses due to completion of the EXPLORER clinical trial and reduced activity due to the COVID-19 pandemic;

•

a $2.9 million decrease in contract manufacturing;

•

a $0.8 million decrease in preclinical and laboratory supplies; and

•

a $0.5 million decrease in travel and other expenses.

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased $8.6 million, or 48%, from $17.7 million for the three months ended September 30, 2019 to $26.3 million for the three months ended September 30, 2020. The increase in selling, general and administrative expenses was primarily due to the following:

•

a $5.2 million increase in professional fees;

•

a $2.9 million increase in personnel expenses due to a higher employee headcount;

•

a $2.2 million increase in marketing expenses;

•

a $1.1 million increase in stock compensation expense; and

•

a $0.4 million increase in software, facilities and other;

•

offset by a $3.1 million decrease in sponsorship of cardiovascular research and education.

Interest and Other Income, Net

Interest and other income decreased $2.7 million, or 80%, from $3.3 million for the three months ended September 30, 2019 to $0.7 million for the three months ended September 30, 2020. The decrease in interest income was primarily due to reduced interest rates on invested balances.

Comparison of the Nine Months Ended September 30, 2020 and 2019

The following table compares the operating results (in thousands):

	Nine Months Ended September 30,						Change
	2020			2019			$			%
Operating expenses:
Research and development	$	155,286		$	101,270		$	54,016			53	%
Selling, general and administrative		66,482			45,153			21,329			47	%
Repurchase of royalty rights		—			80,000			(80,000	)		-100	%
Total operating expenses		221,768			226,423			(4,655	)		-2	%
Loss from operations		(221,768	)		(226,423	)		4,655			-2	%
Interest and other income, net		3,592			8,775			(5,183	)		-59	%
Income tax expense (benefit)		21			(202	)		223			-110	%
Net loss	$	(218,197	)	$	(217,446	)	$	(751	)		0	%

Research and Development Expenses

Research and development expenses increased $54.0 million, or 53%, from $101.3 million for the nine months ended September 30, 2019 to $155.3 million for the nine months ended September 30, 2020. The increase in research and development expenses was primarily due to the following:

•

a $18.5 million decrease in research and development reimbursements from Sanofi;

•

a $10.1 million increase in collaboration partner expenses relating to our partnership with Fulcrum;

•

a $11.1 million increase in personnel expenses due to a higher employee headcount;

•

a $8.3 million increase in facility and information technology expenses;

•

a $6.3 million increase in professional and consultant fees;

•

a $5.7 million increase in stock compensation expense;

•

a $1.3 million increase in medical affairs expense; and

•

a $1.3 million increase in contract research;

•

offset by a $5.3 million decrease in clinical expenses due to completion of the EXPLORER clinical trial and reduced activity due to the COVID-19 pandemic; and

•

a $1.2 million decrease in contract manufacturing;

•

a $1.1 million decrease in lab supplies and other office expenses; and

•

a $1.0 million decrease in travel and other expenses.

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased $21.3 million, or 47%, from $45.2 million for the nine months ended September 30, 2019 to $66.5 million for the nine months ended September 30, 2020. The increase in selling, general and administrative expenses was primarily due to the following:

•

a $7.8 million increase in professional fees;

•

a $7.2 million increase in personnel expenses due to a higher employee headcount;

•

a $4.5 million increase in marketing expenses;

•

a $3.3 million increase in stock compensation expense; and

•

a $1.6 million increase in software, facilities and other;

•

offset by a $3.1 million decrease in sponsorship of cardiovascular research and education.

Repurchase of Royalty Rights

In July 2019, Sanofi’s continuing rights to royalties in the event of commercialization of the HCM-1 programs were terminated when we repurchased those rights for $80.0 million.

Interest and Other Income, Net

Interest and other income decreased $5.2 million, or 59%, from $8.8 million for the nine months ended September 30, 2019 to $3.6 million for the nine months ended September 30, 2020. The decrease in interest income was primarily due to reduced interest rates on invested balances.

Liquidity and Capital Resources

We consider the following when assessing our liquidity and capital resources (in thousands):

	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	675,541	$	101,436
Short-term investments	$	220,338	$	314,691
Long-term investments	$	—	$	14,153

Since inception, we have funded our operations primarily through the issuance of our equity securities and payments from Sanofi pursuant to the Collaboration Agreement, which was terminated in December 2018. All our investments are in investment-grade securities.

In March 2019, we completed a follow-on offering in which we issued 5,663,750 shares of our common stock at a price of $51.00 per share, including 738,750 shares sold directly to the underwriters upon exercise of their option to purchase up to 738,750 shares of our common stock within 30 days of the offering. We received proceeds totaling approximately $271.2 million from the offering, net of underwriting discounts, commissions and offering expenses.

We believe we have sufficient financial resources to meet our business requirements for the 12 months following the date of this Quarterly Report on Form 10-Q without giving effect to our potential acquisition by Bristol-Myers Squibb and assuming we remain a standalone entity. If the potential acquisition by Bristol-Myers Squibb is not completed, we expect to incur substantial expenditures in the foreseeable future for the advancement of our precision medicine platform, the development and potential commercialization of our product candidates and the discovery, development and potential commercialization of any additional product candidates we may pursue. Furthermore, if our clinical trials for mavacamten are successful, or our other product candidates, including danicamtiv, enter into late-stage clinical trials or more advanced discovery and development stages, we may need to raise additional capital in order to further advance our product candidates towards regulatory approval. If the potential acquisition by Bristol-Myers Squibb is not completed within the timeframe we currently expect, we will continue to seek additional financing to develop our product candidates and fund operations for the foreseeable future through equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to other technologies, product candidates or programs that we would prefer to develop and commercialize ourselves.

Cash Flows

The following table sets forth the primary sources and uses of cash for each of the periods presented below (in thousands):

	Nine Months Ended September 30,
	2020			2019
Net cash (used in) provided by:
Operating activities	$	(142,240	)	$	(188,912	)
Investing activities		92,808			(96,770	)
Financing activities		623,912			274,797
Net increase in cash, cash equivalents and restricted cash	$	574,480		$	(10,885	)

Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2020 was $142.2 million. Net cash used in operating activities primarily consisted of payroll and benefits of $50.4 million, payments for accounts payable, accrued liabilities and other of $135.1 million, and a $12.5 million payment to Fulcrum under our collaboration agreement, offset by a receipt of $40.0 million, net from LianBio under our license agreement.

Net cash used in operating activities for the nine months ended September 30, 2019 was $188.9 million and was primarily due to the net loss for the period of $217.4 million, adjusted for non-cash stock-based compensation expense of $23.9 million and depreciation of $1.4 million less a $1.0 million amortization of discount on investments. Changes in working capital primarily consisted of an increase in accrued liabilities of $14.7 million, a $3.6 million increase in accounts payable, a $1.9 million increase in other long-term liabilities, and a $2.0 million decrease in operating lease right-of-use assets, offset by a reduction in prepayments from our collaboration partner of $13.0 million, a $2.5 million increase in prepaid expenses and other current assets, and a decrease in operating lease liabilities of $2.2 million.

Investing Activities

Cash provided by investing activities for the nine months ended September 30, 2020 was $92.8 million and consisted of sales and maturities of investments of $4.0 million and $233.6 million, respectively, offset by cash outflows of $128.9 million in purchases of short-term investments and $15.9 million for leasehold improvements and purchases of equipment, which was related to the occupancy of our new corporate headquarters in Brisbane, California in January 2020.

Cash used in investing activities for the nine months ended September 30, 2019 consisted primarily of purchases of investments of $145.8 million and purchases of equipment of $2.0 million, offset by sales and maturities of investments of $4.0 million and $47.0 million, respectively.

Financing Activities

Cash provided by financing activities for the nine months ended September 30, 2020 was $623.9 million and consisted of $605.1 million in cash from the issuance of common stock in our May 2020 equity offering and $18.8 million received from stock option exercises.

Cash provided by financing activities for the nine months ended September 30, 2019 consisted primarily of proceeds from the issuance of common stock in connection with a follow-on offering of $271.2 million, net of underwriting discounts, commissions and offering costs, as well as proceeds from the issuance of common stock in connection with purchases pursuant to the Amended and Restated 2015 Employee Stock Purchase Plan and funds received as a result of common stock option exercises of $3.6 million.

Contractual Obligations and Commitments

In June 2020, we entered into a noncancelable operating sublease for approximately 34,500 square feet of office space at 1200 Sierra Point Parkway, Brisbane, California. The sublease will become effective upon Landlord’s consent. We will become responsible for paying rent when the premises are ready for occupancy, currently anticipated to be in the first quarter of 2021. Future minimum rental payments during the nine-year lease term are $19.9 million in the aggregate. The sublease further provides that we are obligated to pay our share of certain costs, including taxes and operating expenses.

As more fully disclosed in Note 3 to the footnotes to the condensed consolidated financial statements, in July 2020, we entered into a license and collaboration agreement with Fulcrum Therapeutics, or Fulcrum, to discover, develop and commercialize novel

targeted therapies for the treatment of genetic cardiomyopathy. We have made an upfront payment of $12.5 million to Fulcrum. We may pay specified research, development and commercial milestone payments and additional research reimbursements of up to $302.5 million for the first product to progress through development and commercialization.

Except for the sublease and license and collaboration agreement discussed above, there have been no material changes to our contractual obligations during the nine months ended September 30, 2020, as compared to those disclosed in our Annual Report.

Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

The market risk inherent in our financial instruments represents the potential loss arising from adverse changes in interest rates or exchange rates. As of September 30, 2020, we had cash, cash equivalents and investments of $895.9 million, consisting of interest-bearing money market accounts and money market funds, which would be affected by changes in the general level of United States interest rates. However, due to the short-term maturities of our cash and cash equivalents and the low- risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair value of our cash, cash equivalents or investments.

In addition, we are also exposed to foreign currency exchange rate risk inherent in our contracts with research institutions and contract research organizations as certain services are performed by them outside the United States. We have immaterial payments due in Australian dollars and Euros. A hypothetical 10% adverse movement in those currencies would not have had a material impact on our consolidated financial statements.

We do not believe that inflation, interest rate changes or exchange rate fluctuations had a significant impact on our results of operations for any periods presented.

Item 4.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), refers to controls and procedures that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2020, the end of the period covered by this Quarterly Report on Form 10-Q. Based upon such evaluation, our Chief Executive Officer and Principal Financial and Accounting Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

For a description of our pending legal proceedings, please see Note 7 “Commitments and Contingencies” of the Notes to Condensed Consolidated Financial Statements included in Part I, Item I of this Quarterly Report on Form 10-Q.

Item 1A.

RISK FACTORS

You should consider carefully the following risk factors, together with all the other information in this report, including our consolidated financial statements and notes thereto, and in our other public filings with the SEC. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business.

Risk Factor Summary

Risks Related to the Pending Transaction with Bristol-Myers Squibb

•

We may not complete the pending transaction with Bristol-Myers Squibb within the time frame we anticipate, or at all, which could have an adverse effect on our business and financial results.

•

While the Merger Agreement is in effect, we are subject to restrictions on our business activities, and in certain instances, the Merger Agreement requires us to pay a termination fee to Bristol-Myers Squibb, which could require us to use available cash that would have otherwise been available for general corporate purposes.

Risks Related to Our Precision Medicine Platform and the Discovery and Development of Our Product Candidates

•

Our product candidates consist of mavacamten, danicamtiv and MYK-224, and all of our other programs are in discovery or preclinical development, which is a lengthy and expensive process.

•

We may find it difficult to enroll patients and encounter delays, negative clinical results or unfavorable regulatory decisions, and may not obtain regulatory approval to commercialize any products.

•

Historically, cardiovascular drugs have had a lower probability of moving from Phase 2 to Phase 3 trials.

Risks Related to Commercialization and the Market for Our Product Candidates

•

Our focus on the research and development of new drug candidates presents risks of a lack of market opportunities, inadequate market acceptance, and lack of collaboration partners willing to sell and market our drugs, as well as the risk of patients being unable to obtain insurance coverage for any of our products, if approved.

•

If we participate in but fail to comply with our reporting and payment obligations under governmental pricing programs in the United States, we could be subject to additional reimbursement requirements or penalties.

Risks Related to Our Reliance on Third Parties

•

We may enter into collaborations that place the development and commercialization of our product candidates outside our control, require us to relinquish important rights or may otherwise be on terms unfavorable to us, and if our collaborations are not successful, our product candidates may not reach their full market potential.

•

We expect to rely on third parties to conduct some or all aspects of our clinical trials and other research and development activities, and these third parties may not perform satisfactorily.

•

We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or medicines or that such supply will not be available to us at an acceptable cost, which could prevent or impair our development or commercialization efforts.

Risks Related to Our Intellectual Property

•

Our business and competitive position would be harmed if we are unable to maintain and protect our trade secrets and patent rights for our medicines and technology whether domestically or internationally.

•

They may also be found to be invalid or unenforceable if challenged in court and such lawsuits could prove to be distracting, expensive and unsuccessful.

Risks Related to Government Regulation

•

We currently do not have regulatory approval to market any of our product candidates in any jurisdiction worldwide.

•

Our ability to obtain approval for any indication is dependent upon the domestic and international regulatory environments, which may change without notice and such changes could impact our ability to obtain approval.

•

Although the FDA provided feedback on the Phase 3 clinical trial for mavacamten, the FDA may raise questions regarding mavacamten's safety data, which may delay or prevent U.S. approval of mavacamten.

•

While we have partnered with a third party, LianBio, to sell mavacamten in the PRC, Macau, Thailand, Taiwan, Hong Kong and Taiwan, approval to market the drug may not be obtained.

Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements

•

Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.

•

We have never generated any revenue from product sales and may never be profitable, and have a history of significant losses and anticipate that we will continue to incur losses for the near future and may not achieve or sustain profitability.

Risks Related to Our Business and Industry

•

We face significant competition in the field of cardiovascular medicine.

•

Our future success depends on growing our company, which we may not be able to manage successfully.

Risks Related to Our Common Stock

•

The market price of our common stock has been and may continue to be highly volatile.

•

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

•

Our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.

•

Certain provisions in our articles of incorporation and Delaware law make it difficult or costly for a third party to acquire us.

General Risk Factors

•

Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States.

•

Future sales of our common stock will result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

•

Our future success depends on our ability to retain our key executives, employees and consultants and to attract, retain and motivate qualified personnel.

•

We and the third parties with which we depend are subject to domestic and international economic conditions, natural disasters, regulation and enforcement.

•

Our operating as a public company causes us to incur significant costs and subjects us to the risk of securities class action litigation.

Risks related to the pending transaction with Bristol-Myers Squibb

We may not complete the pending transaction with Bristol-Myers Squibb within the time frame we anticipate, or at all, which could have an adverse effect on our business, financial results and/or operations.

On October 3, 2020, we entered into an Agreement and Plan of Merger, dated as of October 3, 2020, with Bristol-Myers Squibb Company, a Delaware corporation (“Bristol-Myers Squibb”), and Gotham Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Bristol-Myers Squibb (“Merger Sub”) (“Merger Agreement”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, the Merger Sub has commenced a cash tender offer (“Tender Offer”) to acquire all of the issued and outstanding shares of our common stock at a price per share of $225.00, net to the seller in cash, without interest, subject to any withholding of taxes required by applicable law. Following the completion of the Tender Offer, the Merger Sub will merge with and into our company, with our company surviving as a wholly owned subsidiary of Bristol-Myers Squibb, and each outstanding share of our common stock (other than shares of common stock held by us as treasury stock, or owned by Bristol-Myers Squibb or the Merger Sub or held by stockholders who are entitled to demand, and who properly demand, appraisal rights under Delaware law) will be converted into the right to receive $225.00 per share in cash, without interest, subject to any withholding of taxes required by applicable law.

The completion of the transaction will be conditioned on (1) at least a majority of the shares of our outstanding common stock having been validly tendered into and not withdrawn from the tender offer, (2) receipt of certain regulatory approvals, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, (3) there being no restraint enjoining, making illegal or otherwise prohibiting the transaction, (4) the accuracy of certain representations and warranties that we made and compliance by us with certain covenants contained in the Merger Agreement, subject to customary qualifications, (5) there not having been a “Material Adverse Effect” (as defined in the Merger Agreement) with respect to us and (6) other customary conditions. In addition, the Merger Agreement may be terminated under certain specified circumstances, including, but not limited to, a change in the recommendation of our Board of Directors or a termination of the Merger Agreement by us to enter into an agreement for a “Superior Proposal,” as defined in the Merger Agreement. As a result, we cannot assure you that the transaction with Bristol-Myers Squibb will be completed, or that, if completed, it will be exactly on the terms set forth in the Merger Agreement or within the expected time frame. As a result, we cannot assure you that the transaction with Bristol-Myers Squibb will be completed, or that, if completed, it will be exactly on the terms set forth in the Merger Agreement or within the expected time frame.

If the transaction is not completed within the expected time frame or at all, we may be subject to a number of material risks. The price of our common stock may decline to the extent that current market prices reflect a market assumption that the transaction will be completed. We could be required to pay Bristol-Myers Squibb a termination fee of $458.0 million if the Merger Agreement is terminated under specific circumstances described in the Merger Agreement. The failure to complete the transaction also may result in negative publicity and negatively affect our relationship with our stockholders, employees, collaborators, vendors, suppliers, regulators and other business partners. We may also be required to devote significant time and resources to litigation related to any failure to complete the merger or related to any enforcement proceeding commenced against us to perform our obligations under the Merger Agreement.

The announcement and pendency of the transaction with Bristol-Myers Squibb could adversely affect our business, financial results and/or operations.

Our efforts to complete the transaction could cause substantial disruptions in, and create uncertainty surrounding, our business, which may materially adversely affect our results of operation and our business. Uncertainty as to whether the transaction will be completed may affect our ability to recruit prospective employees or to retain and motivate existing employees. Employee retention may be particularly challenging while the transaction is pending because employees may experience uncertainty about their roles following the transaction. A substantial amount of our management’s and employees’ attention is being directed toward the completion of the transaction and thus is being diverted from our day-to-day operations. Uncertainty as to our future could adversely affect our business and our relationship with collaborators, vendors, suppliers, regulators and other business partners. For example, vendors, suppliers, collaborators and other counterparties may defer decisions concerning working with us, or seek to change existing business relationships with us. Changes to or termination of existing business relationships could adversely affect our results of operations and financial condition, as well as the market price of our common stock. The adverse effects of the pendency of the transaction could be exacerbated by any delays in completion of the transaction or termination of the Merger Agreement.

While the Merger Agreement is in effect, we are subject to restrictions on our business activities.

While the Merger Agreement is in effect, we are subject to restrictions on our business activities, generally requiring us to conduct our business in the ordinary course, consistent with past practice, and subjecting us to a variety of specified limitations absent Bristol-Myers Squibb’s prior consent. These limitations include, among other things, restrictions on our ability to acquire other businesses and assets, dispose of our assets, make investments, enter into certain contracts, repurchase or issue securities, pay dividends, make capital expenditures, take certain actions relating to intellectual property, amend our organizational documents and incur indebtedness. These restrictions could prevent us from pursuing strategic business opportunities, taking actions with respect to our business that we may consider advantageous and responding effectively and/or timely to competitive pressures and industry developments, and may as a result materially and adversely affect our business, results of operations and financial condition.

In certain instances, the Merger Agreement requires us to pay a termination fee to Bristol-Myers Squibb, which could require us to use available cash that would have otherwise been available for general corporate purposes.

Under the terms of the Merger Agreement, we may be required to pay Bristol-Myers Squibb a termination fee of $458.0 million if the Merger Agreement is terminated under specific circumstances described in the Merger Agreement. If the Merger Agreement is terminated under such circumstances, the termination fee we may be required to pay under the Merger Agreement may require us to use available cash that would have otherwise been available for general corporate purposes and other uses. For these and other reasons, termination of the Merger Agreement could materially and adversely affect our business operations and financial condition, which in turn would materially and adversely affect the price of our common stock.

We have incurred, and will continue to incur, direct and indirect costs as a result of the pending transaction with Bristol-Myers Squibb.

We have incurred, and will continue to incur, significant costs and expenses, including fees for professional services and other transaction costs, in connection with the pending transaction. We must pay a material portion of these costs and expenses whether or not the transaction is completed. There are a number of factors beyond our control that could affect the total amount or the timing of these costs and expenses, any of which could materially and adversely affect our business, prospects, financial condition and results of operations.

The following risk factors assume that we remain a stand-alone company except as otherwise noted.

Risks Related to Our Precision Medicine Platform and the Discovery and Development of Our Product Candidates

The precision medicine approach we are taking to discover and develop drugs for serious diseases of systolic or diastolic dysfunction is novel and may never lead to marketable products.

We have concentrated our therapeutic product research and development efforts on the application of precision medicine to the treatment of cardiovascular diseases, and our future success depends on the successful development of products based on our precision medicine platform and the continued development of this platform. We believe we are the first company to apply precision medicine to the treatment of cardiovascular disease, and neither we nor any other company has received regulatory approval to market therapeutics specifically targeting the underlying cause of cardiomyopathy. The scientific discoveries that form the basis for our efforts to discover and develop product candidates are novel, and the scientific evidence to support the feasibility of developing product candidates based on these discoveries is both preliminary and limited. If we do not successfully develop and commercialize product candidates based upon our technological approach, we will not become profitable and the value of our common stock may decline.

Further, our focus, which has been solely on precision medicine for the development of drugs for diseases of cardiac muscle contraction as opposed to multiple, more proven technologies for drug development, increases the risks associated with the ownership of our common stock. If we are not successful in developing any product candidates using our precision medicine platform, we may be required to change the scope and direction of our product development activities. In that case, we may not be able to identify and implement successfully an alternative product development strategy, which would materially and adversely affect our business, financial condition and results of operations.

We depend heavily on the success of mavacamten, danicamtiv and MYK-224, our initial product candidates. Other than mavacamten, danicamtiv and MYK-224, all of our other programs are in discovery or preclinical development. Clinical trials and preclinical studies of our product candidates may not be successful. If we are unable to successfully develop and commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.

We have invested a significant portion of our efforts and financial resources in the identification and development of our initial product candidates, mavacamten and MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM) and danicamtiv for the treatment of dilated cardiomyopathy (DCM). We are currently evaluating mavacamten, danicamtiv and MYK-224 in clinical trials, and if these product candidates fail to demonstrate safety or efficacy in their respective target indications to the satisfaction of the U.S. Food and Drug Administration (FDA) or other comparable regulatory authorities, we will need to identify and rely on other product candidates or target indications, or both, for clinical development. All of our other programs are still in discovery or preclinical development. Our ability to generate revenue from product sales, which we do not expect will occur for years, if ever, will depend heavily on the successful development and eventual commercialization of mavacamten, danicamtiv, MYK-224 or other product candidates that we may identify from our precision medicine platform.

The success of mavacamten, danicamtiv, MYK-224 and any other product candidates that we discover and develop will depend on many factors, including the following:

•

timely and successful initiation of, enrollment in, and completion of, clinical trials, including our Phase 3 VALOR-HCM clinical trial of mavacamten, our Phase 2 clinical trial of danicamtiv in genetic DCM, our Phase 1 clinical trial of MYK-224 and any additional clinical trials of these product candidates;

•

achieving positive safety and efficacy data and desirable medicinal properties for our product candidates for the intended indications;

•

our ability to receive, and the timing of our receipt of, any marketing approvals from applicable regulatory authorities;

•

establishing and maintaining manufacturing capabilities or making arrangements with third-party manufacturers for the manufacture of our product candidates for clinical trials and, if approved, for commercialization;

•

obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates;

•

launching commercial sales of our products, if and when approved, whether alone or in collaboration with others;

•

acceptance of our products, if and when approved, by patients, the medical community and third-party payors;

•

effectively competing with other therapies;

•

a continued acceptable safety profile of our products following approval; and

•

enforcing and defending intellectual property rights and claims.

If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business.

Preclinical and clinical drug development involves a lengthy and expensive process with an uncertain outcome, and observations and results from earlier studies and trials may not be applicable or predictive in future clinical trials.

Preclinical and clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical development or clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Our precision medicine platform is based on a translational medicine approach. Translational medicine, or the application of basic scientific findings to develop therapeutics that promote human health, is subject to a number of inherent risks. In particular, scientific hypotheses formed from preclinical or early clinical observations may prove to be incorrect, and the data generated in animal models or observed in limited patient populations may be of limited value and may not be applicable in clinical trials conducted under the controlled conditions required by applicable regulatory requirements and our protocols. The initial clinical data from our Phase 1, Phase 2 and Phase 3 clinical trials of mavacamten, as well as our Phase 1 and 2 clinical trials of danicamtiv, are preliminary in nature, and the clinical development of mavacamten and danicamtiv is not complete. Early positive data may not be repeated or observed in ongoing or future trials involving our product candidates. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. There is a high failure rate for drugs and biologics proceeding through clinical trials, particularly in the field of cardiovascular medicine. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in

earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results.

We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.

Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive, time-consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. We may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Additionally, although we believe that our precision medicine approach should eliminate the need for mavacamten to undergo the large outcomes-based studies that are often required for cardiovascular drugs as a condition to regulatory approval by the FDA or other regulatory authorities, regulatory authorities may nevertheless require us to conduct additional trials or generate additional data, including potential trials studying the interaction of our product candidates with other therapeutics commonly administered in the patient populations we are seeking to treat, which would increase the time and cost of our clinical development process. Furthermore, we will need to conduct larger clinical trials, and the FDA may subsequently require us to evaluate a larger number of patients than we presently anticipate, or to assess other endpoints besides those presently contemplated, in order to support regulatory approval.

Clinical trials can be delayed for a variety of reasons, including:

•

delays in reaching a consensus with regulatory agencies on trial design;

•

delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;

•

delays in obtaining required Institutional Review Board (IRB) approval at each clinical trial site;

•

delays in recruiting suitable patients to participate in our clinical trials;

•

imposition of a clinical hold by regulatory agencies, including after an inspection of our clinical trial operations or trial sites;

•

failure by our CROs, other third parties or us to adhere to clinical trial requirements;

•

failure by us, our CROs or other third-party contractors to perform clinical trials in accordance with the FDA’s good clinical practice (GCP) requirements or applicable regulatory guidelines in other countries;

•

delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites;

•

delays in having patients complete participation in a study or return for post-treatment follow-up;

•

clinical trial sites deviating from a trial protocol or dropping out of a trial;

•

clinical trial subjects failing to comply with the trial regimen or dropping out of a trial;

•

adding new clinical trial sites;

•

failure to manufacture or supply sufficient quantities of product candidates for use in clinical trials;

•

occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits; or

•

changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.

We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, or suspension or termination is recommended by the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or other regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.

Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenues from product sales, and, if applicable under any collaboration or similar agreement, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

If the results of our clinical trials are inconclusive or if there are safety concerns or adverse events associated with our product candidates, we may:

•

be delayed in obtaining marketing approval for our product candidates, if at all;

•

obtain approval for indications or patient populations that are not as broad as intended or desired;

•

obtain approval with labeling that includes significant restrictions on use or distribution of the drug;

•

require safety warnings in the label and/or require risk management plan post-approval;

•

be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;

•

have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy (REMS);

•

be subject to the addition of labeling statements, such as warnings or contraindications;

•

be sued; or

•

experience damage to our reputation.

We may find it difficult to enroll patients in our clinical trials, which could delay or prevent clinical trials of our product candidates.

Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing to commence and complete our clinical trials depends on the speed at which we can recruit patients to participate in testing our product candidates. If patients are unwilling to participate in our clinical trials because of a lack of familiarity with our approach to the treatment of cardiovascular diseases, negative publicity from adverse events in biotechnology or the fields of precision medicine or cardiovascular disease or for other reasons, including competitive clinical trials for similar patient populations, our timelines for recruiting patients, conducting clinical trials and obtaining regulatory approval of potential products may be delayed. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our product candidates or termination of our clinical trials altogether.

We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a study, to complete our clinical trials in a timely manner. Patient enrollment is affected by factors including:

•

severity of the disease under investigation;

•

design of the clinical trial protocol;

•

size and nature of the patient population;

•

eligibility criteria for the clinical trial in question;

•

perceived risks and benefits of the product candidate under study in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;

•

proximity and availability of clinical trial sites for prospective patients;

•

availability of competing therapies and clinical trials;

•

efforts to facilitate timely enrollment in clinical trials;

•

patient referral practices of physicians; and

•

ability to monitor patients adequately during and after treatment.

In particular, each of the conditions in which we are evaluating or plan to evaluate our product candidates are rare genetic disorders or involve segmented patient populations with limited patient pools from which to draw for clinical trials. To date, the HCM and DCM patient populations have not been extensively evaluated in clinical trials. As a result, enrollment in our ongoing and planned clinical trials is difficult to predict and may take longer or cost more than we anticipate.

We plan to seek initial marketing approval in the United States. We may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or other regulatory agencies. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:

•

difficulty in establishing or managing relationships with CROs and physicians;

•

different standards for the conduct of clinical trials;

•

our inability to locate qualified local consultants, physicians and partners; and

•

the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment.

If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business.

We may not be successful in our efforts to identify or discover potential product candidates.

The success of our business depends primarily upon our ability to identify, develop and commercialize therapeutics for the treatment of cardiovascular diseases based on our precision medicine approach. A key element of our initial strategy is to use our precision medicine platform to identify and study compounds that can be used to correct or offset the abnormal contraction caused by HCM and DCM. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:

•

the research methodology used may not be successful in identifying appropriate biomarkers or potential product candidates;

•

our initial hypotheses based on our preclinical or early clinical observations may not be supported by later clinical results;

•

potential product candidates may, on further study, be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; or

•

research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful.

If we are unable to identify suitable compounds for preclinical and clinical development, we may be forced to abandon our development efforts for a research program or programs and we will not be able to obtain product revenues in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price.

Any of our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval, limit the scope of any approved label or market acceptance or result in other significant negative consequences following marketing approval, if any.

Adverse events or other unintended side effects or safety signals caused by our product candidates could cause us, IRBs or ethics committees, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of

regulatory approval. For example, through additional studies, we may determine that although mavacamten has been shown to be specific to striated muscle, which includes both skeletal and cardiac muscle, and selective for cardiac muscle, it may target myosin in skeletal muscle, which could result in unintended adverse effects.

We have observed adverse events in our clinical trials of mavacamten. Results of our ongoing and planned trials could reveal a high and unacceptable severity and prevalence of these or other adverse events in subjects treated with our product candidates. Additionally, if the adverse events we have observed are deemed to be unacceptable or other unacceptable side effects or safety signals are observed in any ongoing or subsequent preclinical studies or clinical trials of our product candidates, our trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Any adverse effects encountered in our preclinical studies or clinical trials, whether or not drug-related, could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Additionally, adverse effects may represent safety signals that could influence the benefit-risk assessment for further development or commercialization of a product candidate and may warrant further clinical or nonclinical investigation, consultation with health authorities, changes to product labeling or guidelines for its safe use, or other scientific or regulatory actions. Any of these occurrences may harm our business, financial condition and prospects significantly.

Further, if any of our future products, if and when approved for commercial sale, cause serious or unexpected adverse events, a number of potentially significant negative consequences could result, including:

•

regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a REMS or provide a medication guide outlining the risks of such side effects for distribution to patients;

•

regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;

•

we may be required to change the way the product is administered or conduct additional clinical trials;

•

we could be sued and held liable for harm caused to patients; or

•

our reputation may suffer.

Any of these events could prevent us or our partners from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our future products and impair our ability to generate revenues from the commercialization of these products.

We may choose not to develop a potential drug candidate, or we may suspend, deprioritize or terminate one or more discovery programs or pre-clinical drug candidates or programs.

At any time and for any reason, we may determine that one or more of our discovery or development programs or preclinical or clinical product candidates or programs, including any program subject to a third-party collaboration agreement, such as our strategic collaboration and license agreement with Fulcrum Therapeutics, Inc., does not have sufficient potential to warrant the allocation of resources toward such program or drug candidate. Accordingly, we may choose not to develop a potential drug candidate or elect to suspend, deprioritize or terminate one or more of our discovery or development programs or preclinical drug candidates or programs. If we suspend, deprioritize or terminate a program or drug candidate in which we have invested significant resources, we will have expended resources on a program that will not provide a full return on our investment and may have missed the opportunity to have allocated those resources to potentially more productive uses, including existing or future programs or drug candidates. In addition, for any discontinued program or product candidate subject to a third-party collaboration, we may lose rights under, or otherwise fail to realize the anticipated benefits of, the collaboration.

Risks Related to Government Regulation

We currently do not have regulatory approval to market any of our product candidates. The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

The time required to obtain approval by the FDA, the European Medicines Agency (EMA) and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.

Our product candidates could fail to receive regulatory approval for many reasons, including the following:

•

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;

•

we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;

•

the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;

•

we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

•

the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

•

the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application (NDA) or other submission or to obtain regulatory approval in the United States or elsewhere;

•

the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; or

•

the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market mavacamten, danicamtiv or any other product candidate we may develop, which would significantly harm our business, results of operations and prospects.

In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

Although the FDA provided feedback on the Phase 3 clinical trial for mavacamten, the FDA may raise questions regarding mavacamten’s safety data, which may delay or prevent the approval of mavacamten or adversely affect our ability to commercialize mavacamten on the timelines we have announced.

The size of a safety database when submitting an NDA is usually between 3,000 to 5,000 patients. When we sought feedback on EXPLORER-HCM, our Phase 3 clinical trial for mavacamten, we estimated that at the time of submitting our NDA, our safety database would have 250 patient-years of exposure, as we are treating an orphan disease. When we submit our NDA, we anticipate that we will have approximately 200 patient-years in the safety database and at the time of submission of the 120-day safety update, it will have increased to 300-350 patient-years. While we plan to conduct a prospective registry study to demonstrate our commitment to post-approval product characterization, and the FDA has accepted a lesser number of patients for a safety database in the past, the FDA may request additional clinical data, which may delay or prevent the approval and commercialization of mavacamten and could have a negative impact on our business.

Even if we complete the necessary preclinical studies and clinical trials, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate or the approval may be for a more limited indication than we expect.

We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical trials and the review process. Regulatory agencies also may approve a treatment candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our treatment candidates. If we are unable to obtain regulatory approval for our product candidates for use in the treatment of cardiomyopathies, our business may suffer.

Failure to obtain marketing approval in international jurisdictions would prevent our products from being marketed in such jurisdictions.

In order to market and sell our products in the European Union, China and other jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. Additionally, we may be dependent on third-party collaborators to develop and commercialize our product candidates in certain international jurisdictions, such as in the case of our exclusive license agreement with LianBio for the development and commercialization of mavacamten in China. In the agreement with LianBio, while we have agreed that in the case of China, where a two invoice policy is required, the parties will use commercially reasonable efforts to distribute mavacamten directly or indirectly in China, due to the regulatory requirements such as the two invoice policy, the role LianBio will play in commercializing mavacamten remains to be decided by the parties. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval in other jurisdictions. We and our third-party collaborators may not be able to file for marketing approvals, and even if we do, we may not obtain necessary approvals to commercialize our medicines in any market.

Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.

Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to extensive and ongoing regulatory requirements and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, current Good Manufacturing Practice (cGMP) requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. For example, the holder of an approved NDA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process.

In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP and adherence to commitments made in the NDA and other marketing authorizations.

Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine.

The FDA closely regulates the post-approval marketing and promotion of medicines to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use and if we do not market our medicines for their approved indications, we may be subject to enforcement action for off-label marketing.

In addition, later discovery of previously unknown problems with our medicines, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in various negative consequences, including:

•

restrictions on the labeling, marketing or manufacturing of the product;

•

restrictions on distribution or use of the product;

•

requirements to conduct post-marketing clinical trials or holds on ongoing or planned clinical trials;

•

warning or untitled letters;

•

withdrawal of the medicines from the market;

•

refusal by the FDA or comparable foreign regulatory authorities to approve pending applications or supplements to approved applications that we submit;

•

mandatory or voluntary recalls;

•

fines, restitution or disgorgement of profits or revenue;

•

suspension or withdrawal of marketing approvals;

•

refusal to permit the import or export of our medicines;

•

product seizure or detention; and

•

injunctions or the imposition of civil or criminal penalties.

The FDA’s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues.

We may seek one or more additional special designations from regulatory authorities to expedite the review and approval process for our product candidates, including Breakthrough Therapy Designation or Fast Track Designation. These designations may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.

We have been granted Breakthrough Therapy Designation for mavacamten by the FDA and may seek additional special designations from regulatory authorities to expedite the review and approval process for our product candidates, including Fast Track Designation.

A breakthrough therapy is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically important endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough therapies by the FDA can also be eligible for accelerated approval. If a product is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for Fast Track Designation.

The FDA has broad discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for a particular designation, we cannot assure you that the FDA would decide to grant it. Accordingly, even if we believe one of our product candidates meets the criteria for a designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a particular designation for a product candidate may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the products no longer meet the conditions for qualification and rescind the breakthrough designation. Further, the FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from a clinical development program.

If we are unable to maintain any existing Breakthrough Therapy Designation or Fast Track Designation or fail to secure such designation for any additional product candidates, this would have an adverse impact on our development timelines and our ability to obtain approval for and commercialize our product candidates.

Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements

Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.

We were incorporated and commenced operations in June 2012. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, creating and expanding on our precision medicine platform, identifying potential product candidates, undertaking preclinical studies for our programs, completing our ongoing clinical trials for our most advanced product candidate, mavacamten, planning further clinical development of mavacamten and completing our ongoing clinical development of our second product candidate, danicamtiv, and beginning clinical development of our third product candidate, MYK-224. We have not yet demonstrated our ability to successfully complete the clinical development of a product candidate, including the completion of any clinical trials designed to support the registration of a product candidate, obtain marketing approvals, manufacture a commercial scale medicine, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes many years to develop a new medicine from the time it is discovered to when it is available for treating patients. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history.

In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a research and development focus to a company capable of supporting pre-commercial and commercial activities. If we are not successful in such a transition, our business, results and financial condition will be harmed.

We have a history of significant losses and anticipate that we will continue to incur losses for the near future and may not achieve or sustain profitability and, as a result, you may lose all or part of your investment.

Our initial product candidates, mavacamten, danicamtiv and MYK-224, are in various stages of clinical testing and we must successfully complete our ongoing clinical trials of mavacamten and conduct significant additional clinical trials for danicamtiv and MYK-224 before we can seek the regulatory approvals necessary to begin commercial sales of these or any other product candidates we may develop. We have incurred operating losses in each year since our inception due to costs incurred in connection with our research and development activities and selling, general and administrative costs associated with our operations. Our net loss for the quarter ended September 30, 2020 was $84.7 million and as of September 30, 2020, we had an accumulated deficit of $697.0 million. We expect to incur increasing losses for several years as we continue our research activities and conduct development of, and seek regulatory approvals for, our initial product candidates, and commercialize any approved drugs. If our product candidates fail in clinical trials or do not gain regulatory approval, or if our product candidates do not achieve market acceptance, we will not be profitable. If we fail to become and remain profitable, or if we are unable to fund our continuing losses, you could lose all or part of your investment.

We have never generated any revenue from product sales and may never be profitable.

Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We do not anticipate generating revenues from product sales in the near future, if ever. Our ability to generate future revenue from product sales depends heavily on our success in:

•

completing research and preclinical and clinical development of our product candidates;

•

seeking and obtaining regulatory approvals to market product candidates for which we complete clinical trials;

•

developing a sustainable, scalable, reproducible and transferable manufacturing process for our product candidates;

•

establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products and services to support clinical development and the market demand, if any, for our product candidates, if approved;

•

launching and commercializing product candidates for which we obtain regulatory approval, either through a collaboration or, if launched independently, by establishing a sales force, marketing and distribution infrastructure;

•

obtaining market acceptance of our product candidates and the use of precision medicine as a viable treatment option for cardiovascular diseases;

•

addressing any competing technological and market developments;

•

implementing additional internal systems and infrastructure, as needed;

•

identifying and validating new product candidates from our platform;

•

maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and

•

attracting, hiring and retaining qualified personnel who are suitable to our culture and mission.

Even if one or more of the product candidates that we are developing is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond our expectations if we are required by the FDA, EMA or other regulatory agencies, domestic or foreign, to perform clinical trials and other studies in addition to those that we currently anticipate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.

We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.

We are currently advancing mavacamten, danicamtiv and MYK-224, our initial product candidates, through clinical development, and conducting preclinical discovery and development activities in our other programs. Drug development is expensive, and we expect our research and development expenses to increase substantially in connection with our ongoing activities, particularly as we continue to advance our product candidates in clinical trials and identify additional product candidates from our pipeline for clinical development.

As of September 30, 2020, our cash, cash equivalents and investments totaled $895.9 million. We intend to use our cash, cash equivalents and investments to support the regulatory approval process and potential commercial launch of mavacamten for the treatment of obstructive HCM, if approved; to fund ongoing and potential later-stage clinical studies of mavacamten in non-obstructive HCM and targeted heart failure with preserved ejection fraction (HFpEF), danicamtiv in targeted segments of systolic heart failure and MYK-224; to advance ACT-1 and LUS-1 into clinical development; to fund ongoing preclinical, discovery and research programs; and for working capital, business development and other general corporate purposes. However, our operating plan may change as a result of many factors currently unknown to us, including the effects of the COVID-19 pandemic on our research and development activities and our commercial launch activities for mavacamten, if approved, and we may need to seek additional funds sooner than planned, through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic and licensing arrangements or a combination of these approaches. In any event, we may require additional capital to obtain regulatory approval for, and to commercialize, mavacamten, danicamtiv, MYK-224 or any other product candidates we may identify and develop. Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations.

Our funding requirements and the timing of our need for additional capital are subject to change based on a number of factors, including:

•

the rate of progress and the cost of our ongoing and planned clinical trials of mavacamten, danicamtiv and MYK-224;

•

the number of product candidates that we intend to develop using our precision medicine platform;

•

the costs of research and preclinical studies to support the advancement of other product candidates into clinical development;

•

the timing of, and costs involved in, seeking and obtaining approvals from the FDA and comparable foreign regulatory authorities, including the potential by the FDA or comparable regulatory authorities to require that we perform more studies than those that we currently expect;

•

the costs of preparing to manufacture mavacamten on a commercial scale, and to manufacture danicamtiv and MYK-224 for further clinical development;

•

the costs of commercialization activities if mavacamten or any future product candidate is approved, including the formation of a sales force;

•

the degree and rate of market acceptance of any products launched by us or our partners, if any;

•

the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;

•

our need and ability to hire additional personnel;

•

our ability to enter into and maintain collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements; and

•

the emergence of competing technologies or other adverse market developments.

Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise at a different stage than otherwise would be desirable and we may be required to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.

If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially and adversely affect our business, financial condition and results of operations.

Risks Related to Our Reliance on Third Parties

We have entered into, and may enter into collaborations that place the development and commercialization of our product candidates outside our control, require us to relinquish important rights or may otherwise be on terms unfavorable to us, and if our collaborations are not successful, our product candidates may not reach their full market potential.

Our drug development programs and the potential commercialization of our drug candidates will require substantial additional cash to fund expenses. For some of our drug candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies for the development and potential commercialization of those drug candidates in selected geographic territories or for selected patient populations. For example, in August 2020, we entered into a strategic collaboration with LianBio to develop and commercialize mavacamten in China. We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration or successfully maintain a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed or existing collaboration and the proposed or existing collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject drug candidate, the costs and complexities of manufacturing and delivering such drug candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative drug candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our drug candidate. The terms of any existing or additional collaborations or other arrangements that we may establish may not be favorable to us.

Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.

We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If we are unable to do so, we may have to curtail the development of the drug candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our drug candidates or bring them to market and generate drug revenue. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process or commercializing the applicable drug candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party.

We expect to rely on third parties to conduct some or all aspects of our clinical trials, protocol development and research and development activities, and these third parties may not perform satisfactorily.

We currently rely on third parties to conduct our clinical trials and expect to continue to rely on third parties with respect to some or all aspects of our clinical trials, protocol development and research and development activities.

Any of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the study plan and protocols. We and our third-party contractors and CROs are required to comply with GCP regulations, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area (EEA), and comparable foreign regulatory authorities for all products in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors or CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process.

If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will be delayed in completing, or may not be able to complete, the preclinical and clinical studies required to support future Investigational New Drug Application (IND) submissions and approval of our product candidates. Any of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize future products. Some of these events could be the basis for FDA action, including injunction, request for voluntary recall, seizure or total or partial suspension of production.

We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or medicines or that such supply will not be available to us at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

We do not have, nor do we plan to acquire, any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our product candidates for preclinical and clinical testing and for the commercial supply of any of these product candidates for which we may obtain marketing approval.

Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:

•

the inability to negotiate or maintain manufacturing agreements with third parties under commercially reasonable terms;

•

reduced control as a result of using third-party manufacturers for all aspects of manufacturing activities;

•

reliance on the third party for regulatory compliance, quality assurance, and safety and pharmacovigilance reporting;

•

the possible breach of the manufacturing agreement by the third party;

•

the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and

•

disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier.

The facilities used by our contract manufacturers to manufacture any of our future products must be evaluated by the FDA pursuant to inspections that will be conducted after we submit an NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the cGMP regulation for manufacture of both active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities or our marketing applications will not be approved. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the

manufacture of our product candidates or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or voluntary recalls of product candidates or medicines, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our medicines and harm our business and results of operations.

Any products that we may develop may compete with our other product candidates and products and the products of third parties for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.

Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for a redundant supply of bulk drug substances. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement.

Our current and anticipated future dependence upon others for the manufacture of our product candidates or medicines may adversely affect our future profit margins and our ability to commercialize any medicines that receive marketing approval on a timely and competitive basis.

Risks Related to Our Intellectual Property

If we are unable to obtain and maintain patent protection for our medicines and technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize medicines and technology similar or identical to ours, and our ability to successfully commercialize our medicines and technology may be adversely affected.

Our commercial success will depend, in part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our proprietary products and technology. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and medicines that are important to our business, by pursuing the grant of patents from those applications around the world, and by taking steps to defend those patents if challenged by third parties. It is not uncommon in the pharmaceutical industry for patents covering successful drugs to be challenged for invalidity by third parties before or after the grant of such patents by a patent office (e.g., by a pre- or post-grant proceeding in a patent office or a court action). Currently we own five issued U.S. patents, several foreign patents and multiple pending applications worldwide that relate to our proprietary technology or product candidates. We cannot be certain that we will secure any additional rights to any issued patents with claims that cover any of our proprietary technology or product candidates.

The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection on or due to the public disclosures of others or ourselves. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for some of our technology and medicines, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. With respect to our proprietary scientific insights, screening assays and manufacturing processes, we consider trade secrets and know-how to be our primary intellectual property. Trade secrets and know-how can be difficult to protect. In particular, we anticipate that with respect to our precision medicine platform, these trade secrets and know-how will over time be acquired within the industry through independent development, the publication of journal articles describing methodologies and insights, and the movement of personnel skilled in the art into the pharmaceutical and biotechnology industry.

We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers,

consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets, and discovery processes to aid in proving trade secret misappropriation may be limited in many foreign countries. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we may have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position could be harmed.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including court actions for patent infringement or nullification, pre- and post-grant proceedings before the U.S. Patent and Trademark Office (USPTO), and corresponding proceedings in foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block or delay our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.

Parties making claims against us may also obtain injunctive or other equitable relief, which could effectively block or delay our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and could be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may be required to take a number of steps, including but not limited to, paying substantial damages, including treble damages and attorneys’ fees for willful infringement, paying lost profits or royalties, redesigning our infringing products or manufacturing process, obtaining one or more licenses from third parties for activities going forward, which may be impossible or require substantial time and monetary expenditure.

Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue for many reasons, including but not limited to, a determination that our patents do not cover the technology in question. Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors or collaborators. An adverse result in any litigation or patent office proceeding could put one or more of our patents at risk, for example, of being invalidated, deemed unenforceable or interpreted narrowly or could put our patent applications at risk of not issuing.

An unfavorable outcome could require us to cease using a technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of our patents and patent applications may fail and, even if successful, may result in substantial costs and distract our management and other

employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, these perceptions could have a material adverse effect on the price of our common stock.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We may also be subject to claims that third parties, including but not limited to, former employees and collaborators, have an ownership interest in our patents or other intellectual property. In the future, we may have ownership disputes arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as the exclusive ownership of, or the right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation or arbitration could result in substantial costs and be a distraction to management and other employees.

Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court.

If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one of our product candidates or the use or manufacture thereof, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including utility, written description, novelty, non-obviousness or enablement. Additionally, in the United States, a patent can be deemed unenforceable if someone connected with the prosecution of a patent application intentionally withheld materially relevant information from the USPTO, or intentionally mislead the USPTO during prosecution. Third-party challenges to the validity and/or enforceability of a patent can occur in courts in the United States or abroad, or in pre- or post-grant proceedings in some foreign patent offices (e.g., but not limited to re-examination, post grant review, inter parties review, or opposition proceedings). Such proceedings could result in the revocation of, or amendment to, our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability of one of our patents for a product candidate, this could substantially affect our ability to protect that product candidate in the country in which the patent was issued. Such a loss of patent protection could have a material adverse impact on our business.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

As is common in the biotechnology and pharmaceutical industry, we employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee’s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages and suffering reputational harm, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all

countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with any products that we may develop and commercialize, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from these intellectual property rights.

Risks Related to Commercialization and the Market for Our Product Candidates

If the market opportunities for our product candidates are smaller than we believe they are or if we are unable to market our products to expanded patient populations, our revenues may be adversely affected, and our business may suffer.

We focus our research and product development efforts on treatments for cardiac muscle contraction and our targeted indications affect relatively small populations. In particular, we estimate that approximately 630,000 people in the United States have a form of HCM, and that approximately 360,000 people in the United States have a form of genetic DCM. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates derived from primary research with physicians and payors, analysis of medical journals and peer-reviewed literature, the work of third-party consultants and other publicly- or non-publicly-available data sources. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of our targeted disease indications. The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our products, and new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.

Additionally, because the target patient populations of our product candidates are small, we must be able to successfully identify patients and achieve a significant market share to achieve or maintain profitability and growth.

Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.

If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, current cardiovascular disease treatments such as beta blockers, non-dihydropyridine calcium channel blockers and disopyramide are well-established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:

•

efficacy and potential advantages compared to alternative treatments;

•

the ability to offer our medicines for sale at competitive prices;

•

convenience and ease of administration compared to alternative treatments;

•

the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;

•

the strength of marketing and distribution support;

•

sufficient third-party coverage or reimbursement; and

•

the prevalence and severity of any side effects.

Any failure to achieve or maintain sufficient market acceptance of mavacamten, danicamtiv or any of our other product candidates, if approved, could significantly harm our business, prospects, financial condition and results of operations.

We are currently establishing a sales and marketing organization; however, if we are unable to enter into agreements with third parties to sell and market our drug candidates, we may not be successful in commercializing our drug candidates if and when they are approved, and we may not be able to generate any revenue.

We have limited experience in the sale, marketing or distribution of drugs. To achieve commercial success for any approved drug candidate for which we retain sales and marketing responsibilities, we must build our sales, marketing, managerial, and other non‑technical capabilities or make arrangements with third parties to perform these services. In the future, we may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for some of our drug candidates if and when they are approved.

There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time-consuming and could delay any drug launch. If the commercial launch of a drug candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost.

Factors that may inhibit our efforts to commercialize our drug candidates on our own include:

•

our inability to recruit and retain adequate numbers of effective sales and marketing personnel;

•

the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future drugs;

•

the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and

•

unforeseen costs and expenses associated with creating an independent sales and marketing organization

If we enter into arrangements with third parties to perform sales, marketing and distribution services, our drug revenues or the profitability of these drug revenues to us are likely to be lower than if we were to market and sell any drug candidates that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our drug candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our drug candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our drug candidates. Further, our business, results of operations, financial condition and prospects will be materially adversely affected.

The insurance coverage and reimbursement status of newly-approved products targeting small patient populations is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.

The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments, such as endothelin receptor antagonists used in the treatment of certain cardiovascular diseases. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. Additionally, therapies directed at small patient populations, such as our product candidates, may be more expensive, and reimbursement options for these therapies may be more limited. If reimbursement or coverage is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products and for products whose targeted patient populations are small. In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare & Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. It is difficult to predict what CMS or third-party payors will decide with respect to reimbursement and coverage for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Reimbursement agencies in Europe may be more conservative than CMS.

Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries may put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.

Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.

While we have received orphan drug designation for our most advanced drug candidate, mavacamten, for the treatment of symptomatic obstructive HCM, we may seek orphan drug designation for some of our other drug candidates. However, we may be unsuccessful in obtaining or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity.

The FDA has granted orphan drug designation to mavacamten for the treatment of symptomatic obstructive HCM. As part of our business strategy, we may seek orphan drug designation for some of our other drug candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user‑fee waivers.

Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug and indication for that time period, except in limited circumstances. The applicable period is seven years in the United States. Even if we obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the designated drug from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In addition, a designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Moreover, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. While we might seek orphan drug designation for our other drug candidates in addition to mavacamten for the treatment of symptomatic oHCM, we may never receive such designations. Even if we receive orphan drug designation for any of our drug candidates, there is no guarantee that we will enjoy the benefits of those designations.

If we participate in and then fail to comply with our reporting and payment obligations under governmental pricing programs in the United States, we could be subject to additional reimbursement requirements, penalties, sanctions and fines which could have a material adverse effect on our business financial condition, results of operations and growth prospects.

With the approval of any product candidate, we anticipate that we may participate in a number of federal and state government pricing programs in the United States in order to obtain coverage for the product by certain government healthcare programs. These programs would generally require us to pay rebates or provide discounts to certain private purchasers or government payers in connection with our products when dispensed to beneficiaries of these programs. In some cases, such as with the Medicaid Drug Rebate Program, the rebates are based on pricing and rebate calculations that we report on a monthly and quarterly basis to the government agencies that administer the programs. The terms, scope and complexity of these government pricing programs change frequently. We may also have reimbursement obligations or be subject to penalties if we fail to provide timely and accurate information to the government, pay

the correct rebates or offer the correct discounted pricing. Changes to the price reporting or rebate requirements of these programs would affect our obligations to pay rebates or offer discounts. Responding to current and future changes may increase our costs and the complexity of compliance, will be time-consuming, and could have a material adverse effect on our results of operations.

Risks Related to Our Business and Industry

The outbreak of the novel strain of coronavirus, SARS-CoV-2, which causes COVID-19, could adversely impact our business.

The outbreak of the novel strain of coronavirus, SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19) has evolved into a global pandemic. In response to the spread of COVID-19, we have closed our executive offices with our administrative employees continuing their work outside of our offices, and restricted on-site staff to only those required to maintain the facilities and equipment, perform and support research activities and support financial and IT activities.

As a result of the COVID-19 outbreak, or similar pandemics, we have and may in the future experience disruptions that could severely impact our business, research and clinical development activities, including:

•

delays or difficulties in enrolling patients in our clinical trials;

•

delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;

•

delays or disruptions in non-clinical studies due to the inability of our research and development personnel to perform their regular duties or unforeseen circumstances at contract research organizations and vendors along their supply chain;

•

increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19, being forced to quarantine, or not accepting home health visits;

•

diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;

•

interruption of key clinical trial activities, such as clinical trial site data monitoring and site inspections, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed non-essential), which may impact the integrity of subject data and clinical trial endpoints;

•

interruption or delays in the operations of the FDA and comparable foreign regulatory agencies, which may impact review, inspection and approval timelines;

•

interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; and

•

limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions.

In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through equity or debt financings, or such financing transactions may be on unfavorable terms.

The COVID-19 outbreak continues to rapidly evolve, and it is unknown how long disruptions to our research, clinical development and other business operations resulting from the COVID-19 pandemic, including any disruptions relating to the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and actions by businesses and governmental authorities to contain the outbreak, such as quarantines or “stay at home” orders and business closures, will continue. However, any prolonged disruption could have a material adverse impact our business, financial condition and results of operations, and we will continue to monitor the situation closely.

To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this ‘‘Risk Factors’’ section, such as those relating to our clinical development operations, the supply chain for our ongoing and planned clinical trials, and our need to raise additional capital to support our operations.

We may be subject to healthcare, health information privacy and security laws, regulation and enforcement, and our failure to comply with these laws could harm our results of operations and financial conditions.

Although we do not currently have any products on the market, if we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be directly, or indirectly through our customers and third-party payors, subject to various U.S. federal and state fraud and abuse, patient privacy and other healthcare regulatory laws, and to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. Healthcare providers, physicians and other healthcare market participants play a primary role in the recommendation and prescription of any product for which we obtain marketing approval. These laws may impact, among other things, our proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. There are ambiguities as to what is required to comply with these requirements, and if we fail to comply with any applicable federal, state or foreign legal requirement, we could be subject to penalties.

Regulators globally are also imposing greater monetary fines for privacy violations. For example, in 2016, the European Union adopted a new regulation governing data practices and privacy called the General Data Protection Regulation (GDPR) which became effective on May 25, 2018. The GDPR applies to any company established in the European Union as well as to those outside the European Union if they collect and use personal data in connection with the offering goods or services to individuals in the European Union or the monitoring of their behavior. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, special protections for “sensitive information” such as health and genetic information, expanded disclosures about how personal information is to be used, limitations on retention of information, mandatory data breach notification requirements and onerous new obligations on service providers. Non-compliance with the GDPR may result in monetary penalties of up to €20 million or 4% of worldwide revenue, whichever is higher. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of personal data, such as healthcare data or other sensitive information, could greatly increase our cost of developing or commercializing our product candidates or impair our ability to collect data from patients resident in the European Union, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries.

Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations.

We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.

Our competitors may develop drugs that are less expensive, safer, or more effective, which may diminish or eliminate the commercial success of any drugs that we may commercialize.

Our competitors may:

•

develop drug candidates and market drugs that are less expensive or more effective than our future drugs;

•

commercialize competing drugs before we or our partners, if any, can launch any drugs developed from our drug candidates;

•

initiate or withstand substantial price competition more successfully than we can;

•

have greater success in recruiting skilled scientific workers from the limited pool of available talent;

•

more effectively negotiate third-party licenses and strategic collaborations; and

•

take advantage of acquisition or other opportunities more readily than we can.

We will compete for market share against large pharmaceutical and biotechnology companies and smaller companies that are collaborating with larger pharmaceutical companies, new companies, academic institutions, government agencies and other public and

private research organizations. Many of these competitors, either alone or together with their partners, may develop new drug candidates that will compete with ours, as these competitors may, and in certain cases do, operate larger research and development programs or have substantially greater financial resources than we do. Our competitors may also have significantly greater experience in:

•

developing product candidates;

•

undertaking preclinical testing and clinical trials;

•

building relationships with key customers and opinion-leading physicians;

•

obtaining and maintaining FDA and other regulatory approvals of product candidates;

•

formulating and manufacturing drugs; and

•

launching, marketing and selling drugs.

If our competitors market drugs that are less expensive, safer or more effective than our potential drugs, or that reach the market sooner than our potential drugs, we may not achieve commercial success. In addition, the life sciences industry is characterized by rapid technological change. Because our research approach integrates many technologies, it may be difficult for us to stay abreast of the rapid changes in each technology. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Our competitors may render our technologies obsolete by advances in existing technological approaches or the development of new or different approaches, potentially eliminating the advantages in our drug discovery process that we believe we derive from our research approach and proprietary technologies.

In the field of heart failure drug development, our principal competitors include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, Novartis AG and Takeda Pharmaceutical Company Limited. Specific to our initial drug discovery and development focus areas, we believe that Cytokinetics, Inc., Takeda Pharmaceutical Company Limited, Novartis AG and Biomarin Pharmaceutical, Inc. have ongoing programs in HCM and that Novartis AG, Pfizer Inc., Tenaya Therapeutics, Berlin Cures, Zensun (Shanghai) Sci. & Tech. Co., Ltd. and Renovacor, Inc. have ongoing programs in DCM. Additionally, there may be other companies pursuing therapeutic candidates from which we face current or future competition.

Public opinion and heightened regulatory scrutiny of precision medicine for the treatment of cardiovascular disease may impact public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.

Precision medicine remains a novel technology, particularly in the field of cardiovascular disease, with no products approved to date in the United States that are specifically targeted at correcting the underlying biomechanical defects in cardiac contractility associated with HCM and DCM. Public perception may be influenced by claims that these therapies are unproven or unsafe, and our product candidates may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians, who specialize in the treatment of those diseases that our product candidates target, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments they are already familiar with and for which greater clinical data may be available. More restrictive government regulations or negative public opinion could have an adverse effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.

Healthcare legislative changes may have a material adverse effect on our business and results of operations.

In the United States, the European Union and other foreign jurisdictions, there have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the United States federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, the Patient Protection and Affordable Care Act (ACA) changed the way healthcare is financed by both governmental and private insurers and significantly impacted the U.S. pharmaceutical and biotechnology industries. Since its enactment, there have been many judicial, Presidential, and Congressional challenges to numerous aspects of the ACA, and the long ranging effects of these challenges on reimbursement by third-party payors, the viability of the ACA marketplace, providers, and potentially, our business are unknown at this time. In addition, the full impact of the ACA, any law repealing and/or replacing elements of it, and the political uncertainty surrounding any repeal or replacement legislation on our business remains unclear.

Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. The U.S. federal government had set a goal of moving 50% of Medicare payments into these “Alternative Payment Models” by the end of 2018. In addition, recently there has been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their commercial products. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

In addition, other legislative changes have been proposed and adopted in the United States since ACA was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2025 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations.

We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.

As of September 30, 2020, we had 318 full-time employees. As we mature, we expect to expand our full-time employee base and to hire more consultants and contractors. Over the next several years, we expect to expand our development, regulatory and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.

We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial medicines or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable medicines. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.

Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including most recently from December 22, 2018 to January 25, 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.

Our anticipated international operations may expose us to business, regulatory, political, operational, financial, pricing and reimbursement and economic risks associated with doing business outside of the United States.

We have two wholly owned subsidiaries: an Australian subsidiary through which we conduct clinical trials in Australia and a Dutch subsidiary through which we intend to determine the feasibility of commercialization in the EU, and we have entered into an exclusive license agreement with LianBio for the development and commercialization of mavacamten in China. Our business strategy also contemplates potential additional international operations as we seek to continue the development of mavacamten, danicamtiv, MYK-224 and other product candidates that we have or may identify, seek regulatory approval for our product candidates, and commercialize any product candidates that are approved outside the United States. If any product candidates for which we have retained worldwide commercial rights are approved, we may hire sales representatives and conduct physician and patient group outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to:

•

multiple, conflicting, and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;

•

failure by us or our third-party collaborators to obtain and maintain regulatory approvals for the use of our products in various countries;

•

complexities and difficulties in obtaining protection for and enforcing our intellectual property rights;

•

difficulties in staffing and managing foreign operations;

•

complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;

•

limits in our ability to penetrate international markets;

•

financial risks, such as exposure to foreign currency exchange rate fluctuations and their impact on payments required in local currency;

•

natural disasters, political and economic instability, including wars, terrorism, and political unrest, outbreak of disease, boycotts, curtailment of trade, and other business restrictions (such as the outbreak of the novel strain of coronavirus in December 2019);

•

certain expenses including, among others, expenses for travel, translation, and insurance; and

•

regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.

Any of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.

We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate

coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

We or the third parties upon whom we depend may be adversely affected by earthquakes, outbreak of disease or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Earthquakes, outbreak of disease, or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. For example, our corporate headquarters is located in the San Francisco Bay Area, which in the past has experienced severe earthquakes. If a natural disaster, power outage, outbreak of disease, or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. Due to the effects of the COVID-19 pandemic, during March 2020 we temporarily suspended the enrollment of new patients into our Phase 1 study of MYK-224 and the enrollment of existing patients from EXPLORER-HCM rolling over into the MAVA-LTE study; however enrollment in both studies has resumed. In addition, we have delayed the initiation of our Phase 2 HFpEF proof-of-concept study into 2021 and our Phase 2 study of danicamtiv in patients with genetic DCM into the second half of 2020. We will continue to closely monitor the evolving situation and expect to resume patient enrollment and to initiate delayed studies as soon as conditions safely permit. Although no delays have been noted to date, we may experience delays in the supply of drug product for our clinical trials as a result of disruptions to the operations of manufacturing facilities of some of our third-party contract manufacturers due to the COVID-19 pandemic. Any continued or subsequent measures taken by governmental authorities or businesses to contain the spread of COVID-19, or the perception that such measures may be required in the future should another outbreak occur, could adversely affect our business, financial condition or results of operations by limiting our contract manufacturers’ ability to manufacture product and forcing temporary closure of facilities that we rely upon. The extent to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be accurately predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may develop.

We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any medicines that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or medicines caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

•

decreased demand for any product candidates or medicines that we may develop;

•

injury to our reputation and significant negative media attention;

•

withdrawal of clinical trial participants;

•

significant costs to defend the related litigation;

•

substantial monetary awards to study participants or patients;

•

loss of revenue; and

•

the inability to commercialize mavacamten, danicamtiv, MYK-224 or any other product candidates that we may develop.

Although we maintain product liability insurance, including coverage for clinical trials that we sponsor, it may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we commence additional clinical trials and if we successfully commercialize any product candidates. The market for insurance coverage is increasingly expensive, and the costs of insurance coverage will increase as our clinical programs increase in size. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.

Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.

We have incurred substantial losses during our history and do not expect to become profitable in the near future. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code) if a corporation undergoes an “ownership change,” generally defined as a greater than 50% change (by value) in its equity ownership over a rolling three-year period, the corporation’s ability to use its pre-change net operating loss carryforwards (NOLs) and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. While we have determined that an ownership change occurred in April 2015 in connection with our Series B redeemable convertible preferred stock financing and in August 14, 2017 due to a subsequent stock offering, we do not believe that these ownership changes will result in the expiration of any of our existing NOLs prior to utilization. We may experience subsequent shifts in our stock ownership, some of which are outside our control. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.

In addition, the amount of post-2017 NOLs that we are permitted to deduct in any taxable year beginning after December 31, 2020 is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. Any NOL arising in a taxable year beginning after December 31, 2020 may not be carried back to prior taxable years, while post-2017 unused NOLs may be carried forward indefinitely. There is a risk that due to legislative or regulatory changes or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to offset future income tax liabilities.

The United Kingdom’s withdrawal from the EU may have a negative effect on our business, global economic conditions, and financial markets.

As a result of the United Kingdom’s vote to leave the EU in March 2019 (known as Brexit), the EMA relocated its headquarters from London to Amsterdam. Since a significant proportion of the regulatory framework in the United Kingdom is derived from EU directives and regulations, Brexit could materially impact the regulatory regime with respect to the approval of product candidates, disrupt the manufacture of our products and product candidates in the United Kingdom or the EU, disrupt the import and export of active substances and other components of drug formulations, and disrupt the supply chain for clinical trial product and final authorized formulations. While negotiations continue regarding the terms of the United Kingdom’s withdrawal from the EU, the specific impact to the supervision, regulation and supply of medicines in the United Kingdom and Europe remain unclear. The cumulative effect of disruptions to the regulatory framework or supply chains may add considerably to the development lead time to, and expense of, marketing authorization and commercialization of products in the EU and/or the United Kingdom. In view of the uncertainty surrounding the Brexit implementation, we are unable to predict the effects of such disruption to the regulatory framework and supply chain in Europe.

Risks Related to Our Common Stock

The market price of our common stock has been and may continue to be highly volatile.

The market price of our common stock has experienced volatility since our IPO in October 2015 and is likely to continue to be volatile. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:

•

the perceived likelihood of the completion of the proposed transaction with Bristol-Myers Squibb;

•

adverse results or delays in preclinical studies or clinical trials;

•

failure to develop successfully and commercialize our product candidates;

•

inability to obtain additional funding;

•

any delay in filing an IND or NDA for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA’s review of that IND or NDA;

•

failure by us or our licensors and strategic collaborators, if any, to prosecute, maintain or enforce our intellectual property rights;

•

changes in laws or regulations applicable to future products;

•

inability to obtain adequate product supply for our product candidates or the inability to do so at acceptable prices;

•

adverse regulatory decisions affecting our product candidates or development programs;

•

introduction of new products, services or technologies by our competitors;

•

failure to meet or exceed financial projections we may provide to the public or to the investment community;

•

the perception of the pharmaceutical industry by the public, legislatures, regulators and the investment community;

•

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us, our strategic collaboration partner or our competitors;

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•

additions or departures of key scientific or management personnel;

•

significant lawsuits, including patent or stockholder litigation;

•

changes in the market valuations of similar companies;

•

sales of our common stock by us or our stockholders in the future; and

•

trading volume of our common stock.

In addition, companies trading in the stock market in general, and The NASDAQ Global Select Market (NASDAQ) in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors, including the effects of the COVID-19 pandemic on the global economy, may negatively affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management’s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

As of November 1, 2020, our executive officers, directors, 5% or greater stockholders and their affiliates beneficially own approximately 48.6% of our outstanding voting stock. These stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.

We have broad discretion in the use of our cash and cash equivalents and may not use them effectively.

Subject to certain restrictions in our merger agreement with Bristol-Myers Squibb, our management has broad discretion in the application of our existing cash and cash equivalents, and you will not have the opportunity to assess whether our existing cash and cash equivalents are being used appropriately. Because of the number and variability of factors that will determine our use of our existing cash and cash equivalents, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could harm our business. Pending their use, we may invest our cash and cash equivalents in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders.

Our operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.

Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult to predict our future operating results. Our net loss and other operating results will be affected by numerous factors, many of which are outside of our control and may be difficult to predict, including:

•

variations in the level of expenses related to our clinical development programs, our precision medicine platform or our preclinical research and development programs;

•

the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates;

•

our ability to obtain regulatory approval for our product candidates, and the timing and scope of any such approvals we may receive;

•

if any of our product candidates receives regulatory approval, the level of underlying demand for these product candidates and our ability to successfully commercialize any approved product;

•

addition or termination of clinical trials or funding support;

•

our execution of any new collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements;

•

any intellectual property infringement or other lawsuits in which we may become involved; and

•

regulatory developments affecting our product candidates or those of our competitors.

If our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. Additionally, due to the unpredictability of our quarterly and annual operating results, we believe that period-to-period comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.

We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management.

Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that may have the effect of delaying or preventing a change in control of us or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that:

•

authorize “blank check” preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;

•

create a classified board of directors whose members serve staggered three-year terms;

•

specify that special meetings of our stockholders can be called only by our board of directors, the chairperson of our board of directors, our chief executive officer or our president;

•

prohibit stockholder action by written consent;

•

establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;

•

provide that our directors may be removed only for cause and with the vote of the holders of 75% or more of our outstanding capital stock then entitled to vote at an election of directors;

•

provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even if less than a quorum;

•

specify that no stockholder is permitted to cumulate votes at any election of directors;

•

expressly authorize our board of directors to modify, alter or repeal our amended and restated bylaws; and

•

require supermajority votes of the holders of our common stock to amend specified provisions of our amended and restated certificate of incorporation and amended and restated bylaws.

General Risk Factors

Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States.

We prepare our financial statements in conformity with accounting principles generally accepted in the United States. These accounting principles are subject to interpretation by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC). A change in these policies or interpretations could have a significant effect on our reported financial results, may retroactively affect previously reported results, could cause unexpected financial reporting fluctuations, and may require us to make costly changes to our operational processes and accounting systems.

Our future success depends on our ability to retain our key executives, employees and consultants and to attract, retain and motivate qualified personnel.

We are highly dependent on our scientific advisors and the principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are “at will” employees. Recruiting and retaining other qualified employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of skilled executives and scientific experts in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies, as well as from academic and research institutions, for individuals with similar skill sets. In addition, any failure of our programs to succeed in preclinical studies or clinical trials may make it more challenging to recruit and retain qualified personnel. The inability to recruit or the loss of the services of any executive, key employee, consultant or advisor may impede the progress of our research, development and commercialization objectives.

Our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.

We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants, vendors and collaboration partners may engage in fraudulent conduct or other illegal activities. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (i) the regulations of the FDA, EMA and other regulatory authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; (ii) manufacturing standards; (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad; or (iv) laws that require the reporting of true, complete and accurate financial information and data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Unfavorable global economic and political conditions could adversely affect our business, financial condition or results of operations.

Our ability to invest in and expand our business and meet our financial obligations, to attract and retain third-party contractors and collaboration partners and to raise additional capital depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic and political conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the United States, political influences and inflationary pressures. For example, an overall decrease in or loss of insurance coverage among individuals in the United States due to high levels of unemployment (particularly as a result of the COVID-19 pandemic), underemployment or the potential repeal of certain provisions

of the ACA, may decrease the demand for healthcare services and pharmaceuticals. Additionally, the availability of healthcare services and resources is currently constrained due to the COVID-19 pandemic. If fewer patients are seeking medical care because they do not have insurance coverage or are unable to obtain medical care for their conditions due to resource constraints on the healthcare system, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected.

In addition, our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets upon which biopharmaceutical companies such as us are dependent for sources of capital. In the past, global financial crises have caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, including as a result of the COVID-19 pandemic, could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all, and weakened demand for our product candidates. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the COVID-19 pandemic, current economic climate and financial market conditions could adversely impact our business.

Our internal computer systems, or those of our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our operations.

Despite the implementation of security measures, our internal computer systems and those of our third-party CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and experience delays or disruptions to various aspects of our operations, including our financial reporting and the development of our product candidates.

Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.

Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.

In addition, sales of a substantial number of shares of our outstanding common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. A substantial number of our outstanding shares of common stock are held by a relatively small number of stockholders who are not subject to restrictions on trading. Sales by our stockholders of a substantial number of shares, or the expectation that such sales may occur, could significantly reduce the market price of our common stock.

We have also registered all shares of our common stock subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. As a result, these shares will be eligible for sale in the public market to the extent permitted by any applicable vesting requirements and the exercise of options, and restrictions under applicable securities laws. In addition, our directors, executive officers and certain affiliates have established or may in the future establish programmed selling plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, for the purpose of effecting sales of our common stock. If any of these events cause a large number of our shares to be sold in the public market, the sales could reduce the trading price of our common stock and impede our ability to raise future capital. If these additional shares are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.

Pursuant to our 2015 Stock Option and Incentive Plan (the 2015 Plan), we are authorized to grant stock options and other equity-based awards to our employees, directors and consultants. Beginning on January 1, 2017, the number of shares available for future grant under the 2015 Plan will automatically increase each year by up to 4% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. In addition, beginning on January 1, 2017 and ending on January 1, 2025, the number of shares available for future issuance under our 2015 Employee Stock Purchase Plan (the 2015 ESPP) will automatically increase each year by up to the lesser of 3,000,000

shares of common stock or 1% of all shares of our capital stock outstanding as of December 31 of the prior calendar year, subject to the ability of our board of directors to take action to reduce the size of the increase in any given year. Currently, we plan to register the increased number of shares available for issuance under the 2015 Plan and the 2015 ESPP each year. If our board of directors elects to increase the number of shares available for future grant under these plans by the maximum amount each year, our stockholders may experience additional dilution, which could cause our stock price to fall.

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts may not publish an adequate amount of research on our company, which may negatively impact the trading price for our stock. In addition, if one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. Further, if our operating results fail to meet the forecasts of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to existing and new public company compliance and reporting regulations.

As a public company, we incur and will continue to incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and NASDAQ have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.

Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to furnish a report by our management on our internal control over financial reporting with our Annual Report on Form 10-K for each fiscal year and to obtain an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are and will continue to be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adhere to a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting.

Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could impair our ability to produce timely and accurate consolidated financial statements and result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements.

In addition, as a public company we are required to file accurate and timely quarterly, annual and current reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Select Market or other adverse consequences that would materially harm our business.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

Item 6.

Exhibits

The following exhibits are filed or furnished as part of this Quarterly Report on Form 10-Q:

EXHIBIT INDEX

Exhibit Number	Exhibit Description	Incorporated by Reference From	Date	Number	Filed Herewith

2.1†	Agreement and Plan of Merger, dated as of October 3, 2020, by and among Bristol-Myers Squibb Company, Gotham Merger Sub Inc. and the Registrant.	10-Q	10/5/2020	2.1

3.1	Restated Certificate of Incorporation.	10-Q	11/18/2015	3.1

3.2	Amended and Restated Bylaws.	S-1/A	10/13/2015	3.4

4.1	Specimen Common Stock Certificate.	S-1/A	10/19/2015	4.1

10.1#	Change in Control and Severance Policy.				X


31.1	Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.				X

31.2	Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.				X

32.1*	Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.				X


101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.				X

101.SCH	Inline XBRL Taxonomy Extension Schema Document.				X

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document.				X

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document.				X

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document.				X

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document.				X

104	Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)				X

†

Schedules have been omitted pursuant to Item 601(b)(2) of Regulation S-K. MyoKardia, Inc. hereby undertakes to furnish supplemental copies of any of the omitted schedules upon request by the SEC; provided, however, that the Registrant may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934 for any schedules so furnished.

The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

Represents management compensation plan, contract or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 5, 2020	MYOKARDIA, INC.

	By:	/s/ Tassos Gianakakos
		Tassos Gianakakos
		President, Chief Executive Officer
		(Principal Executive Officer)


Date: November 5, 2020	By:	/s/ Taylor Harris
		Taylor Harris Chief Financial Officer (Principal Financial and Accounting Officer)

EX-10.1 2 myok-ex101_331.htm EX-10.1 myok-ex101_331.htm

Exhibit 10.1

MYOKARDIA, Inc. (the “Company”)

change in control and SEVERANCE Policy

Adopted on october 17, 2015

(Amended on october 24, 2018)
(AMENDED ON fEBRUARY 22, 2019)

(AMENDED ON JUNE 3, 2020)

(AMENDED ON October 3, 2020)

In the event a senior management employee of the Company experiences an Involuntary Termination (as defined below), including a Sale Event Termination (as defined below), such senior management employee shall be entitled to receive either the Involuntary Termination Benefits (as defined below) or the Sale Event Termination Benefits (as defined below), as applicable, subject, in either case, to each such employee’s execution and non-revocation of a severance agreement within 60 days following the date of such termination, including a general release of claims (the “Release Agreement”). Prior to a Sale Event, the Release Agreement shall be in a form acceptable to the Company, and on or following a Sale Event, the Release Agreement shall be in a form acceptable to the Company’s acquirer and consistent in all material respects with the form that such acquirer has previously provided to the Company.

Involuntary Termination Benefits:

•

No automatic acceleration of vesting of outstanding stock options and other equity awards with time-based vesting;

•

Company-paid outplacement services by a counselor of a firm nationally recognized as a reputable national provider of such services (the “Outplacement Services”) for a period of time following the Involuntary Termination not to exceed the time set forth below. The Outplacement Services will be provided by an outside organization selected by the Company. If the employee elects not to take advantage of the Outplacement Services within thirty (30) days of the employee’s Involuntary Termination, then unless otherwise agreed in writing by the Company and the employee, the Company will not be obligated to provide the Outplacement Services to the employee. In no circumstance will the Company pay cash or provide any other consideration to any employee in lieu of the Outplacement Services, and in no event will the terms of the Outplacement Services be more favorable than the terms of the Sale Event Outplacement Services (as defined below); and

•

Payment of (a) cash severance in a lump sum in the applicable amount set forth below and (b) if the employee was participating in the Company’s group health plan immediately prior to the date of termination of his or her employment and elects COBRA health continuation, payment of a monthly cash payment for the period set forth below or the employee’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the employee if the employee had remained employed by the Company

Exhibit 10.1

Position	Severance (Amount of Base Salary)	Target Bonus	Benefits Continuation	Outplacement Services
Chief Executive Officer	12 months	None	12 months	12 months
C-Level Executive, Executive Vice President and Senior Vice President	9 months	None	9 months	12 months
Vice President	6 months	None	6 months	12 months

Sale Event Termination Benefits:

•

Full acceleration of vesting of outstanding stock options and other equity awards with time-based vesting;

•

Company-paid outplacement services, on the same terms as provided by the Company’s acquirer to its employees (the “Sale Event Outplacement Services”), for a period of time following the Sale Event Termination not to exceed the time set forth below. If the employee elects not to take advantage of the Sale Event Outplacement Services within thirty (30) days of the employee’s Sale Event Termination, then unless otherwise agreed in writing by the Company and the employee, the Company will not be obligated to provide the Sale Event Outplacement Services to the employee. In no circumstance will the Company pay cash or provide any other consideration to any employee in lieu of the Sale Event Outplacement Services; and

•

Payment of (a) cash severance in a lump sum in the applicable amount set forth below, (b) a lump sum target bonus payment in the applicable amount set forth below, and (c) if the employee was participating in the Company’s group health plan immediately prior to the date of termination of his or her employment and elects COBRA health continuation, payment of a monthly cash payment for the period set forth below or the employee’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the employee if the employee had remained employed by the Company.


Position	Severance (Amount of Base Salary)	Target Bonus	Benefits Continuation	Sale Event Outplacement Services

Exhibit 10.1

Chief Executive Officer

18 months

1.5x Target Bonus

18 months

12 months

Senior Management Employees (1)

12 months

1x Target Bonus

12 months

(1)

Senior Management Employees include all employees of the Company at the level of Vice President and above (other than the Chief Executive Officer).

The amounts payable pursuant to this policy, including both the Involuntary Termination Benefits and the Sale Event Termination Benefits, shall be paid or commence to be paid within sixty (60) days following the date of termination of employment, provided that if the sixty (60)-day period begins in one calendar year and ends in a second calendar year, such payments shall be paid or commence to be paid in the second calendar year by the last day of such sixty (60)-day period.

In addition, except as otherwise provided in a Make Whole Agreement between the employee and the Company that is entered into with the prior consent of the Company’s acquirer, upon the consummation of a Sale Event, to the extent Section 280G of the Internal Revenue Code is applicable to such employee, each employee shall be entitled to receive either: (a) payment of the full amounts set forth above to which the employee is entitled or (b) payment of such lesser amount that does not trigger excise taxes under Section 280G, whichever results in the employee receiving a higher amount after taking into account all federal, state and local income, excise and employment taxes.

For purposes of this policy,

“Base Salary” means the greater of (a) the annual base salary in effect immediately prior to the Involuntary Termination or Sale Event Termination, as applicable and (b) the annual base salary in effect immediately prior to the Sale Event, as applicable.

“Good Reason” means that the affected employee followed the “Good Reason Process” (as defined below) following the occurrence of (a) a material diminution in the employee’s job responsibilities (provided that a mere change in title or reporting relationship shall not be deemed a material diminution in job responsibilities), (b) a 10% or greater reduction in the employee’s base salary (except for across-the-board salary reductions in the salaries of all similarly situated employees based on the Company’s financial performance), or (c) the relocation of the employee’s principal place of business to a location that is more than fifty (50) miles from the employee’s then-current location of employment.

“Good Reason Process” means that (a) the employee reasonably determines in good faith that a “Good Reason” condition has occurred; (b) the employee notifies the Company or its successor in writing of the first occurrence of the Good Reason condition within sixty (60) days of the first occurrence of such a condition; (c) the employee cooperates in good faith with the Company’s or its successor’s efforts for a period of not fewer than thirty (30) days following such notice (the “Cure Period”) to remedy the condition; (d) notwithstanding such efforts, the Good Reason

Exhibit 10.1

continues to exist; and (e) termination of the employee’s employment occurs no later than seven (7) days following the expiration of the Cure Period.

“Involuntary Termination” means termination of employment or other service relationship with the Company (or its successor or acquirer) without Cause (as defined in the Plan) or for Good Reason (other than a Sale Event Termination).

“Involuntary Termination Benefits” means the benefits payable following an Involuntary Termination.

“Plan” means the Company’s 2015 Stock Option and Incentive Plan, as amended from time to time.

“Sale Event” means ‘Sale Event’ as defined in the Plan.

“Sale Event Termination” means an Involuntary Termination that occurs within one (1) year following completion of a Sale Event.

“Sale Event Termination Benefits” means the benefits payable following a Sale Event Termination.

“Target Bonus” means the greater of (a) the target bonus in effect immediately prior to the Sale Event Termination or (b) the target bonus in effect immediately prior to the Sale Event.

This policy shall be administered by the Board of Directors of the Company (the “Board”) or the Compensation Committee of the Board (such administrator, the “Administrator”), and the Administrator shall have the power and authority to interpret the terms and provisions of this policy (including eligibility to receive any benefits hereunder), to make all determinations it deems advisable for the administration of this policy, to decide all disputes arising in connection with this policy and to otherwise supervise administration of this policy. The Administrator retains the right to amend, revise, change or end this policy at any point in the future; provided that the Administrator may not amend or end the policy during the period commencing on the date that the Company enters into a definitive agreement that if consummated, would result in a Sale Event and ending on the earlier of (a) twelve (12) months after consummation of the Sale Event and (b) the termination of the definitive agreement without the consummation of a Sale Event. This policy does not change the “at-will” employment status of any employee.

In the event an employee of the Company is party to an agreement or other arrangement with the Company that provides greater benefits than set forth in this policy, such employee shall be entitled to receive the payments or benefits under such other agreement or arrangement and shall not be eligible to receive any payments or benefits under this policy.

The payments under this policy are intended either to be exempt from Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), under the short-term deferral, separation pay, or other applicable exception, or to otherwise comply with Section 409A. This policy shall be administered in a manner consistent with such intent. For purposes of Section 409A, all payments under this policy shall be considered separate payments. To the extent that any payment or benefit described in this policy constitutes “non-qualified deferred

Exhibit 10.1

compensation” under Section 409A, and to the extent that such payment or benefit is payable upon an employee’s termination of employment, then such payments or benefits shall be payable only upon such employee’s “separation from service” (determined in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h)). Notwithstanding any provision to the contrary, to the extent an employee is considered a specified employee under Section 409A and would be entitled during the six-month period beginning on such employee’s separation from service to a payment that is not otherwise excluded under Section 409A, such payment will not be made until the earlier of (a) the date six (6) months and one (1) day after the employee’s separation from service and (b) the employee’s death. This policy may be amended as may be necessary to fully comply with Section 409A and all related rules and regulations in order to preserve the payments and benefits provided hereunder. The Company makes no representation or warranty and shall have no liability to any employee or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A but do not satisfy an exemption from, or the conditions of, such Section.

EX-31.1 3 myok-ex311_7.htm EX-31.1 myok-ex311_7.htm

Exhibit 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

I, Tassos Gianakakos, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of MyoKardia, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2020

/s/ Tassos Gianakakos

Tassos Gianakakos

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 4 myok-ex312_9.htm EX-31.2 myok-ex312_9.htm

Exhibit 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A)

I, Taylor Harris, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of MyoKardia, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2020

/s/ Taylor Harris

Taylor Harris

Chief Financial Officer

(Principal Financial and Accounting Officer)

EX-32.1 5 myok-ex321_6.htm EX-32.1 myok-ex321_6.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of MyoKardia, Inc. (the “Company”) on Form 10-Q for the fiscal quarter ended September 30, 2020, as filed with the Securities and Exchange Commission (the “Report”), Tassos Gianakakos, Chief Executive Officer of the Company, and Taylor Harris, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

•

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•

The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 5, 2020

/s/ Tassos Gianakakos

Tassos Gianakakos

Chief Executive Officer

(Principal Executive Officer)

/s/ Taylor Harris

Taylor Harris

Chief Financial Officer

(Principal Financial and Accounting Officer)

A signed original of this written statement required by Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), has been provided to MyoKardia, Inc. and will be retained by MyoKardia, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of MyoKardia, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-101.SCH 6 myok-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Organization link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - License and Collaboration Agreements link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Balance Sheet Components link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Net Loss per Share link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Balance Sheet Components (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Net Loss per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Organization - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Cash Reported in Condensed Consolidated Statements of Cash Flows (Details) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - License and Collaboration Agreements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurement of Available-for-sale Securities (Details) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Fair Value Measurements - Summary of Available-for-sale Debt Securities in Continuous Unrealized Loss Position for Less Than and Greater Than Twelve Months (Details) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Fair Value Measurements - Summary of Significant Unobservable Inputs Used to Value Warrant (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Leases - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Leases - Schedule of Information Related to Operating Lease Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Leases - Future Annual Payments of Operating Lease Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Leases - Future Annual Payments of Operating Lease Liabilities (Details)2 link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Balance Sheet Components - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Balance Sheet Components - Summary of Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Commitments and Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Stockholders' Equity - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Equity Awards Granted to Employees and Consultants (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Stock-Based Compensation - Summary of Stock Option and Other Equity Award Activity Under Plans (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Net Loss per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Net Loss per Share - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Subsequent Events - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 myok-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 myok-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 myok-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Lessee operating lease liability payments due after year four . Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Current Reporting Status Entity Current Reporting Status Entity Shell Company Entity Shell Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Interactive Data Current Entity Interactive Data Current Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation State Country Code Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Restricted cash and other noncurrent assets. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Short-term investments Short Term Investments Consideration due from related party Due From Related Parties Current Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use assets Operating Lease Right Of Use Asset Long-term investments Long Term Investments Related party warrant derivative asset Derivative Assets Noncurrent Restricted cash and other Restricted Cash And Other Noncurrent Assets Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Operating lease liabilities - current Operating Lease Liability Current Total current liabilities Liabilities Current Operating lease liability Operating Lease Liability Noncurrent Related party liability Due To Related Parties Noncurrent Other long-term liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 7) Commitments And Contingencies Stockholders’ equity Stockholders Equity [Abstract] Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding Preferred Stock Value Common stock, $0.0001 par value, 150,000,000 shares authorized at September 30, 2020 and December 31, 2019; 53,308,689 and 46,379,073 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated other comprehensive income Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Interest and other income (expense), net. Income Statement [Abstract] Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense Selling, general and administrative Selling General And Administrative Expense Repurchase of royalty rights Royalty Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Interest and other income, net Interest And Other Income Expense Net Loss before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax expense (benefit) Income Tax Expense Benefit Net loss Net Income Loss Other comprehensive (loss) income Other Comprehensive Income Loss Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Net loss per share, basic and diluted Earnings Per Share Basic And Diluted Weighted average number of shares used to compute net loss per share, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Vesting of early exercised stock options. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-In Capital Additional Paid In Capital [Member] Accumulated Other Comprehensive Income/ (Loss) Accumulated Other Comprehensive Income [Member] Accumulated Deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Beginning balance Beginning balance, shares Shares Outstanding Issuance of common stock in connection with the follow-on offering, net of issuance costs Stock Issued During Period Value New Issues Issuance of common stock in connection with the follow-on offering, net of issuance costs, shares Stock Issued During Period Shares New Issues Issuance of common stock upon the exercise of options and release of stock awards Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon the exercise of options and release of stock awards, shares Stock Issued During Period Shares Stock Options Exercised Issuance of common stock pursuant to employee stock purchase plan Stock Issued During Period Value Employee Stock Purchase Plan Issuance of common stock pursuant to employee stock purchase plan, shares Stock Issued During Period Shares Employee Stock Purchase Plans Vesting of early exercised stock options Vesting Of Early Exercised Stock Options Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Unrealized gains (loss), net of tax expense (benefit) Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Net loss Adjustment for issuance costs Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Ending balance Ending balance, shares Issuance costs Income tax benefit of unrealized gains on investments. Increase decrease in operating lease right-of-use assets. Prepayment from collaboration partner. Increase decrease in operating lease liabilities. The increase (decrease) in consideration received from related party. Proceeds from sales of investments. Proceeds from maturities of investments. Proceeds from exercise of stock options and employee stock purchase plan. Vesting of early exercised options and restricted stock. Non cash exercise of stock options. Statement Of Cash Flows [Abstract] Cash flow from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Net loss Profit Loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Stock-based compensation expense Share Based Compensation Depreciation Depreciation Amortization of discount on investments Accretion Amortization Of Discounts And Premiums Investments Income tax benefit of unrealized gains on investments Income Tax Benefit Of Unrealized Gains On Investments Loss on disposal of equipment Gain Loss On Sale Of Property Plant Equipment Change in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Operating lease right-of-use assets Increase Decrease In Operating Lease Right Of Use Assets Other long-term assets Increase Decrease In Other Noncurrent Assets Accounts payable Increase Decrease In Accounts Payable Accrued liabilities Increase Decrease In Accrued Liabilities Prepayment from collaboration partner Prepayment From Collaboration Partner Operating lease liabilities Increase Decrease In Operating Lease Liabilities Consideration received from related party Increase Decrease In Consideration Received From Related Party Other long-term liabilities Increase Decrease In Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash flow from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of investments Payments To Acquire Investments Sales of investments Proceeds From Sales Of Investments Maturities of investments Proceeds From Maturities Of Investments Purchases of property and equipment Payments To Acquire Property Plant And Equipment Net cash provided by (used in) investing activities Net Cash Provided By Used In Investing Activities Cash flow from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from issuance of common stock in follow-on offerings, net of issuance costs Proceeds From Issuance Of Common Stock Proceeds from exercise of stock options and employee stock purchase plan Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plan Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in cash, cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash, beginning of period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash, cash equivalents and restricted cash, end of period Non-cash investing and financing activities: Noncash Investing And Financing Items [Abstract] Unpaid portion of property and equipment purchases included in period-end accounts payable and accrued liabilities Capital Expenditures Incurred But Not Yet Paid Vesting of early exercised options and restricted stock Vesting Of Early Exercised Options And Restricted Stock Non-cash exercise of stock options Non Cash Exercise Of Stock Options Organization Consolidation And Presentation Of Financial Statements [Abstract] Organization Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Basis of Presentation and Summary of Significant Accounting Policies Basis Of Presentation And Significant Accounting Policies [Text Block] Collaboration and license agreement disclosure. Collaboration And License Agreement Disclosure [Abstract] License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Lessee Disclosure [Abstract] Leases Lessee Operating Leases [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Stockholders Equity Note [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Earnings Per Share [Abstract] Net Loss per Share Earnings Per Share [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Reconciliation of cash cash equivalents and restricted cash as reported in consolidated statements of cash flows. Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Consolidated Statements of Cash Flows Reconciliation Of Cash Cash Equivalents And Restricted Cash As Reported In Consolidated Statements Of Cash Flows Policy [Text Block] Use of Estimates Use Of Estimates Recently adopted accounting pronouncements. Recently Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements Policy [Text Block] Fair Value Measurements Fair Value Of Financial Instruments Policy Leases Lessee Leases Policy [Text Block] Property and Equipment Property Plant And Equipment Policy [Text Block] Contingencies Commitments And Contingencies Policy [Text Block] Legal proceedings related to the offer and the merger. Legal Proceedings Related to the Offer and the Merger Legal Proceedings Related To Offer And Merger Policy [Text Block] Guarantees and Indemnifications Guarantees Indemnifications And Warranties Policies Summary of cash balances in consolidated cash flow. Summary of Cash Reported in Condensed Consolidated Statements of Cash Flows Summary Of Cash Balances In Consolidated Cash Flow Table [Text Block] Summary of Fair Value Assets Measured on Recurring Basis Fair Value Assets Measured On Recurring Basis [Text Block] Summary of Fair Value Measurement of Available-for-sale Securities Schedule Of Available For Sale Securities Reconciliation Table [Text Block] Summary of Available-for-sale Debt Securities in Continuous Unrealized Loss Position for Less Than and Greater Than Twelve Months Available For Sale Securities Continuous Unrealized Loss Position Fair Value Table [Text Block] Summary of Significant Unobservable Inputs Used to Value Warrant Schedule Of Effect Of Significant Unobservable Inputs Changes In Plan Assets Table [Text Block] Summary of lessee operating lease. Supplemental Balance Sheet Information Related to Operating Leases Lessee Operating Lease Table [Text Block] Lessee operating lease activity. Schedule of Information Related to Operating Lease Activity Lessee Operating Lease Activity Table [Text Block] Schedule of Future Annual Payment of Operating Lease Liabilities Lessee Operating Lease Liability Maturity Table [Text Block] Summary of Property and Equipment Property Plant And Equipment [Text Block] Summary of Accrued Liabilities Schedule Of Accrued Liabilities Table [Text Block] Schedule of common stock reserved for issuance. Equity [Abstract] Schedule of Common Stock Reserved for Issuance Schedule Of Common Stock Reserved For Issuance Table [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Schedule of Stock-Based Compensation Expense Related to Equity Awards Granted to Employees and Consultants Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Stock Option and Other Equity Award Activity Under Plans Schedule Of Share Based Compensation Activity Table [Text Block] Computation of Basic and Diluted Net Loss per Share EX-101.PRE 10 myok-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 myok-10q_20200930_htm.xml IDEA: XBRL DOCUMENT 0001552451 2020-01-01 2020-09-30 0001552451 2020-11-01 0001552451 2020-09-30 0001552451 2019-12-31 0001552451 2020-07-01 2020-09-30 0001552451 2019-07-01 2019-09-30 0001552451 2019-01-01 2019-09-30 0001552451 us-gaap:CommonStockMember 2019-12-31 0001552451 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001552451 us-gaap:RetainedEarningsMember 2019-12-31 0001552451 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001552451 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001552451 2020-01-01 2020-03-31 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001552451 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001552451 us-gaap:CommonStockMember 2020-03-31 0001552451 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001552451 us-gaap:RetainedEarningsMember 2020-03-31 0001552451 2020-03-31 0001552451 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001552451 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001552451 2020-04-01 2020-06-30 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001552451 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001552451 us-gaap:CommonStockMember 2020-06-30 0001552451 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001552451 us-gaap:RetainedEarningsMember 2020-06-30 0001552451 2020-06-30 0001552451 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001552451 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001552451 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001552451 us-gaap:CommonStockMember 2020-09-30 0001552451 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001552451 us-gaap:RetainedEarningsMember 2020-09-30 0001552451 us-gaap:CommonStockMember 2018-12-31 0001552451 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001552451 us-gaap:RetainedEarningsMember 2018-12-31 0001552451 2018-12-31 0001552451 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001552451 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001552451 2019-01-01 2019-03-31 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001552451 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001552451 us-gaap:CommonStockMember 2019-03-31 0001552451 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001552451 us-gaap:RetainedEarningsMember 2019-03-31 0001552451 2019-03-31 0001552451 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001552451 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001552451 2019-04-01 2019-06-30 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001552451 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001552451 us-gaap:CommonStockMember 2019-06-30 0001552451 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001552451 us-gaap:RetainedEarningsMember 2019-06-30 0001552451 2019-06-30 0001552451 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001552451 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001552451 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001552451 us-gaap:CommonStockMember 2019-09-30 0001552451 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001552451 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001552451 us-gaap:RetainedEarningsMember 2019-09-30 0001552451 2019-09-30 0001552451 2020-05-01 2020-05-31 0001552451 myok:LicenseAgreementMember myok:ExclusiveLicenseAgreementMember 2020-08-01 2020-08-31 0001552451 myok:LicenseAgreementMember myok:ExclusiveLicenseAgreementMember 2020-08-31 0001552451 myok:LicenseAgreementMember srt:MaximumMember myok:ExclusiveLicenseAgreementMember 2020-08-01 2020-08-31 0001552451 myok:LianBioLicencisingLLCMember myok:ExclusiveLicenseAgreementMember 2020-08-31 0001552451 myok:LianBioLicencisingLLCMember myok:ExclusiveLicenseAgreementMember 2020-08-01 2020-08-31 0001552451 myok:FulcrumTherapeuticsIncMember myok:MultiTargetCollaborationAndLicenseAgreementMember 2020-07-01 2020-07-31 0001552451 myok:FulcrumTherapeuticsIncMember srt:MaximumMember myok:MultiTargetCollaborationAndLicenseAgreementMember 2020-07-01 2020-07-31 0001552451 myok:AventisIncMember myok:RoyaltyRightsMember myok:TerminationAgreementMember 2019-07-31 0001552451 us-gaap:MoneyMarketFundsMember 2020-09-30 0001552451 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001552451 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001552451 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001552451 us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001552451 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001552451 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001552451 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001552451 us-gaap:MoneyMarketFundsMember 2019-12-31 0001552451 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001552451 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001552451 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001552451 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001552451 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001552451 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001552451 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001552451 us-gaap:CashAndCashEquivalentsMember 2020-09-30 0001552451 us-gaap:ShortTermInvestmentsMember 2020-09-30 0001552451 us-gaap:CashAndCashEquivalentsMember 2019-12-31 0001552451 us-gaap:ShortTermInvestmentsMember 2019-12-31 0001552451 myok:LongTermInvestmentsMember 2019-12-31 0001552451 myok:CoporateBondsMember 2019-12-31 0001552451 myok:LianBioAgreementMember 2020-08-11 2020-08-11 0001552451 myok:LianBioAgreementMember 2020-08-11 0001552451 2020-08-11 0001552451 us-gaap:MeasurementInputPriceVolatilityMember 2018-08-31 0001552451 us-gaap:MeasurementInputRiskFreeInterestRateMember 2018-08-31 0001552451 us-gaap:MeasurementInputExpectedDividendRateMember 2018-08-31 0001552451 us-gaap:MeasurementInputPriceVolatilityMember 2020-09-30 0001552451 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-09-30 0001552451 us-gaap:MeasurementInputExpectedDividendRateMember 2020-09-30 0001552451 us-gaap:MeasurementInputExpectedTermMember 2018-08-31 0001552451 us-gaap:MeasurementInputExpectedTermMember 2020-09-30 0001552451 myok:CorporateHeadquartersMember 2018-09-30 0001552451 myok:CorporateHeadquartersMember 2020-01-01 2020-01-31 0001552451 myok:CorporateHeadquartersMember 2020-01-31 0001552451 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001552451 myok:SubleasedPropertyMember 2020-06-30 0001552451 myok:SubleasedPropertyMember 2020-01-01 2020-06-30 0001552451 srt:MinimumMember 2020-01-01 2020-09-30 0001552451 srt:MaximumMember 2020-01-01 2020-09-30 0001552451 us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-09-30 0001552451 us-gaap:MachineryAndEquipmentMember 2020-09-30 0001552451 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001552451 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001552451 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001552451 us-gaap:SoftwareDevelopmentMember 2020-09-30 0001552451 us-gaap:SoftwareDevelopmentMember 2019-12-31 0001552451 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001552451 us-gaap:ConstructionInProgressMember 2020-09-30 0001552451 us-gaap:ConstructionInProgressMember 2019-12-31 0001552451 myok:FollowOnOfferingMember 2020-05-01 2020-05-31 0001552451 myok:FollowOnOfferingMember 2020-05-31 0001552451 us-gaap:OverAllotmentOptionMember 2020-05-01 2020-05-31 0001552451 myok:FollowOnOfferingMember 2020-01-01 2020-09-30 0001552451 srt:MaximumMember 2020-01-03 0001552451 myok:FollowOnOfferingMember 2019-03-01 2019-03-31 0001552451 myok:FollowOnOfferingMember 2019-03-31 0001552451 us-gaap:OverAllotmentOptionMember 2019-03-01 2019-03-31 0001552451 myok:FollowOnOfferingMember 2019-01-01 2019-09-30 0001552451 us-gaap:EmployeeStockOptionMember 2020-09-30 0001552451 us-gaap:EmployeeStockOptionMember 2019-12-31 0001552451 myok:TwoThousandFifteenStockOptionAndIncentivePlanMember 2020-09-30 0001552451 myok:TwoThousandFifteenStockOptionAndIncentivePlanMember 2019-12-31 0001552451 myok:TwoThousandFifteenEmployeeStockPurchasePlanMember 2020-09-30 0001552451 myok:TwoThousandFifteenEmployeeStockPurchasePlanMember 2019-12-31 0001552451 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001552451 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001552451 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001552451 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001552451 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0001552451 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0001552451 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0001552451 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0001552451 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001552451 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001552451 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001552451 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001552451 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001552451 myok:TwoThousandFifteenEmployeeStockPurchasePlanMember 2020-01-01 2020-09-30 0001552451 myok:TwoThousandFifteenEmployeeStockPurchasePlanMember 2019-01-01 2019-09-30 0001552451 us-gaap:SubsequentEventMember 2020-10-03 0001552451 us-gaap:SubsequentEventMember 2020-10-03 2020-10-03 shares iso4217:USD iso4217:USD shares myok:Segment pure utr:sqft false 2020 Q3 0001552451 --12-31 2021-03

P10Y

P9Y10M24D

P9Y3M18D

P3M18D

10-Q true 2020-09-30 false 001-37609 MYOKARDIA, INC. DE 44-5500552 1000 Sierra Point Parkway Brisbane CA 94005 650 741-0900 Common Stock MYOK NASDAQ Yes Yes Large Accelerated Filer false false false 53322904

675541000

101436000

220338000

314691000

35000000

12865000

7709000

943744000

423836000

19982000

15743000

50433000

417000

14153000

18765000

2737000 1945000

1035661000

456094000

4554000

6237000

40043000

41292000

7891000

383000

52488000

47912000

43717000

93765000

713000

1908000

190683000

49820000

0.0001

5000000

0.0001

150000000

53308689

46379073

5000

1541679000

884486000

257000

549000

-696963000

-478766000

844978000

406274000

1035661000

456094000

59074000

47372000

155286000

101270000

26329000

17746000

66482000

45153000

80000000

85403000

145118000

221768000

226423000

-85403000

-145118000

-221768000

-226423000

668000 3332000 3592000 8775000

-84735000

-141786000

-218176000

-217648000

9000

16000

21000

-202000

-84744000

-141802000

-218197000

-217446000

-495000

-44000

-292000

520000

-85239000

-141846000

-218489000

-216926000

-1.60

-3.07

-4.38

-4.91

53101453

46133068

49860879

44255657

46379073

5000

884486000

549000

-478766000

406274000

233113

1820000

10752000

122000

-69868000

46612186

5000

897058000

671000

-548634000

349100000

28909000

6037500

605028000

290977

5910000

24370

1229000

10876000

81000

-63585000

52965033

5000

1520101000

752000

-612219000

908639000

343656

10195000

11347000

-495000

-84744000

36000

53308689

5000

1541679000

257000

-696963000

844978000

40288949

4000

573183000

-67000

-202553000

370567000

17638000

5663750

1000

271212000

271213000

49076

280000

8000 8000

6981000

363000

-37470000

46001775

5000

851664000

296000

-240023000

611942000

75326

716000

20958

855000

7000 7000

8638000

201000

-38174000

46098059

5000

861880000

497000

-278197000

584185000

120866

1739000

8275000

-44000

-141802000

46218925

5000

871894000

453000

-419999000

452353000

-218197000

-217446000

32975000

23894000

2459000

1441000

469000

1034000

202000

-49000

4897000

2457000

-2573000 -2007000

370000

169000

-1321000

3589000

7517000

14702000

12973000 -1364000 -2171000 40000000

1195000

-1907000

-142240000

-188912000

128892000

145792000

4000000 4000000 233575000 47000000

15875000

1978000

92808000

-96770000

605064000

271224000

18848000 3573000

623912000

274797000

574480000

-10885000

103630000

248265000

678110000

237380000

628000

1689000

15000 306000 17000

1. Organization MyoKardia, Inc. (the Company) is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases. The Company was incorporated in 2012 in Delaware and its corporate headquarters are in Brisbane, California. The Company’s initial focus is on the treatment of cardiomyopathies, a group of diseases of the heart muscle. The Company’s pipeline includes: mavacamten and MYK-224, which are being studied for the treatment of hypertrophic cardiomyopathy; LUS-1, being studied for the treatment of diseases of diastolic dysfunction; and danicamtiv (formerly MYK-491) and ACT-1, being studied for the treatment of diseases of systolic dysfunction. Liquidity The Company has incurred significant operating losses since inception and has an accumulated deficit of $697.0 million as of September 30, 2020. The Company has relied on its ability to fund its operations through private and public equity financings and to a lesser extent, through a license and collaboration arrangement with a collaboration partner, Sanofi S.A. (Sanofi) via its subsidiary, Aventis Inc. The collaboration agreement ended on December 31, 2018 and the Company had no revenues relating to its Sanofi collaboration after December 31, 2018, nor has it received reimbursements of research and development expenses after June 30, 2019. In May 2020, the Company completed a follow-on offering and received proceeds totaling approximately $605.0 million from the offering, net of underwriting discounts and commissions and offering expenses. The Company has not yet received regulatory approval to commercialize or sell any product and does not have customers. Management expects operating losses and negative operating cash flows to continue for the foreseeable future. The Company’s ultimate success depends on the outcome of its research and development activities and anticipates the need to raise additional capital to fully implement its business plan. The Company intends to raise such capital through the issuance of additional equity, debt and/or strategic alliances with partner companies. There is no assurance that such financing will be available or that such strategic alliances will be executed on terms acceptable to the Company, or at all. As of September 30, 2020, the Company had $895.9 million of cash, cash equivalents and investments, which management believes will be sufficient to meet the Company’s anticipated operating and capital expenditure requirements for the twelve months following the date of issuance of these financial statements. Management’s belief with respect to its ability to fund operations is based on estimates that are subject to risks and uncertainties. If actual results are different from management’s estimates, the Company may need to seek additional funding. In addition, the Company is closely monitoring ongoing developments in connection with the COVID-19 pandemic, which may negatively impact its financial and operating results. The Company will continue to assess its operating expenses and cash and cash equivalents and, if circumstances warrant, the Company will make appropriate adjustments to its operating plan.

-697000000.0

605000000.0

895900000

2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements are unaudited, include the Company’s accounts and those of its wholly owned subsidiaries MyoKardia Australia Pty Ltd and MyoKardia Europe B.V., and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated balance sheet at December 31, 2019, presented herein, has been derived from the audited consolidated financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year or any interim period and should be read in conjunction with the audited financial statements for the year ended December 31, 2019 and the notes thereto, which are included in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2019. The significant accounting policies used in preparation of these condensed consolidated financial statements for the periods shown are consistent with those discussed in notes to the consolidated financial statements in the Company’s 2019 Annual Report on Form 10-K and are updated below as necessary. The Company currently operates in one business segment, which is the identification, development and commercialization of therapies for the treatment of serious cardiovascular diseases and has a single reporting unit and operating segment. These interim statements, in the opinion of management, reflect all normal recurring adjustments necessary for the fair statement of the Company’s financial position and results of operations for the interim periods ended September 30, 2020 and 2019, respectively. Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Consolidated Statements of Cash Flows Cash as reported in the consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents and restricted cash as presented on the consolidated balance sheets. Restricted cash at September 30, 2020 and December 31, 2019 represents cash balances held as security in connection with the Company’s facility lease agreements. The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets to the total shown in the consolidated statements of cash flows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675,541</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,436</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in prepaid expenses and other current assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">290</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in restricted cash and other</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,279</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,857</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the consolidated statements <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of cash flows</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678,110</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,630</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trials accrued liabilities, income tax valuation allowance, stock-based compensation and warrant valuation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Recently Adopted Accounting Pronouncements In November 2018, the Financial Accounting Standards Board (FASB) issued ASU 2018-18 (Topic 808), Clarifying the Interaction Between Topic 808 and Topic 606, which provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The ASU also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. It accomplishes this by allowing organizations to only present units of account in collaborative arrangements that are within the scope of the revenue recognition standard together with revenue accounted for under the revenue recognition standard. The parts of the collaborative arrangement that are not in the scope of the revenue recognition standard should be presented separately from revenue accounted for under the revenue recognition standard. The Company adopted this amendment in the first quarter of 2020 and the adoption did not have a material impact to the Company’s financial statements. In August 2018, the FASB issued ASU 2018-13 (Topic 820), Fair Value Measurement, which modifies the disclosure requirements in Topic 820 by removing requirements for disclosing (i) amounts of and reasons for transfers between the Level 1 and Level 2 hierarchies, (ii) the policy for timing of transfers between levels and (iii) the valuation processes for Level 3 fair value measurements. The ASU 2018-13 amendment also adds requirements for disclosure of changes in unrealized gains and losses for the period relating to Level 3 fair value measurements and other factors considered in the valuation of Level 3 investments. The Company adopted this amendment in the first quarter of 2020 and the adoption did not have a material impact to the Company’s financial statements. In June 2016, the FASB issued ASU No. 2016-13 (Topic 326), Financial Instruments –Measurement of Credit Losses on Financial Instruments, which requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The Company adopted this amendment in the first quarter of 2020 and the adoption did not have a material impact to the Company’s financial statements.

Basis of Presentation The accompanying condensed consolidated financial statements are unaudited, include the Company’s accounts and those of its wholly owned subsidiaries MyoKardia Australia Pty Ltd and MyoKardia Europe B.V., and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The condensed consolidated balance sheet at December 31, 2019, presented herein, has been derived from the audited consolidated financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year or any interim period and should be read in conjunction with the audited financial statements for the year ended December 31, 2019 and the notes thereto, which are included in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2019. The significant accounting policies used in preparation of these condensed consolidated financial statements for the periods shown are consistent with those discussed in notes to the consolidated financial statements in the Company’s 2019 Annual Report on Form 10-K and are updated below as necessary. The Company currently operates in one business segment, which is the identification, development and commercialization of therapies for the treatment of serious cardiovascular diseases and has a single reporting unit and operating segment. These interim statements, in the opinion of management, reflect all normal recurring adjustments necessary for the fair statement of the Company’s financial position and results of operations for the interim periods ended September 30, 2020 and 2019, respectively.

Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Consolidated Statements of Cash Flows Cash as reported in the consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents and restricted cash as presented on the consolidated balance sheets. Restricted cash at September 30, 2020 and December 31, 2019 represents cash balances held as security in connection with the Company’s facility lease agreements. The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets to the total shown in the consolidated statements of cash flows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675,541</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,436</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in prepaid expenses and other current assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">290</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in restricted cash and other</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,279</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,857</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the consolidated statements <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of cash flows</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678,110</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,630</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Cash as reported in the consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents and restricted cash as presented on the consolidated balance sheets. Restricted cash at September 30, 2020 and December 31, 2019 represents cash balances held as security in connection with the Company’s facility lease agreements. The following table provides a reconciliation of cash, cash equivalents and restricted cash within the consolidated balance sheets to the total shown in the consolidated statements of cash flows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.28%; border-bottom:solid 0.75pt transparent;" valign="middle"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-bottom:solid 0.75pt #000000;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675,541</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,436</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.28%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in prepaid expenses and other current assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">290</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.28%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash included in restricted cash and other</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,279</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,857</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:70.28%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash, cash equivalents and restricted cash shown in the consolidated statements <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of cash flows</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">678,110</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,630</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

675541000

101436000

290000

337000

2279000

1857000

678110000

103630000

Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trials accrued liabilities, income tax valuation allowance, stock-based compensation and warrant valuation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Recently Adopted Accounting Pronouncements In November 2018, the Financial Accounting Standards Board (FASB) issued ASU 2018-18 (Topic 808), Clarifying the Interaction Between Topic 808 and Topic 606, which provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The ASU also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. It accomplishes this by allowing organizations to only present units of account in collaborative arrangements that are within the scope of the revenue recognition standard together with revenue accounted for under the revenue recognition standard. The parts of the collaborative arrangement that are not in the scope of the revenue recognition standard should be presented separately from revenue accounted for under the revenue recognition standard. The Company adopted this amendment in the first quarter of 2020 and the adoption did not have a material impact to the Company’s financial statements. In August 2018, the FASB issued ASU 2018-13 (Topic 820), Fair Value Measurement, which modifies the disclosure requirements in Topic 820 by removing requirements for disclosing (i) amounts of and reasons for transfers between the Level 1 and Level 2 hierarchies, (ii) the policy for timing of transfers between levels and (iii) the valuation processes for Level 3 fair value measurements. The ASU 2018-13 amendment also adds requirements for disclosure of changes in unrealized gains and losses for the period relating to Level 3 fair value measurements and other factors considered in the valuation of Level 3 investments. The Company adopted this amendment in the first quarter of 2020 and the adoption did not have a material impact to the Company’s financial statements. In June 2016, the FASB issued ASU No. 2016-13 (Topic 326), Financial Instruments –Measurement of Credit Losses on Financial Instruments, which requires measurement and recognition of expected credit losses for financial assets by requiring an allowance to be recorded as an offset to the amortized cost of such assets. For available-for-sale debt securities, expected credit losses should be estimated when the fair value of the debt securities is below their associated amortized costs. The Company adopted this amendment in the first quarter of 2020 and the adoption did not have a material impact to the Company’s financial statements.

40000000.0

35000000.0 2020-10-29

170000

275.00

0.17

18700000

60000000.0 87500000 P90D 0.17

93700000

40000000.0

35000000.0

18700000

35000000.0

10000000.0 2500000 302500000 150000000.0 298500000

10000000.0

80000000.0

4. Fair Value Measurements The Company’s financial instruments consist primarily of cash and cash equivalents, restricted cash, marketable debt securities, accounts receivable, warrant derivative, accounts payable and accrued liabilities. Cash and cash equivalents, restricted cash, marketable debt securities, and warrant derivative asset are reported at their respective fair values in our consolidated balance sheets. The carrying amount of remaining financial instruments approximate fair value due to their short-term nature. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2—Inputs other than quoted market prices included in Level 1 are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Marketable securities and the warrant derivative asset are stated at their estimated fair values. The counterparties to the agreements relating to the Company’s investment securities consist of the U.S. Treasury, governmental agencies, various major corporations and financial institutions with reputable credit and therefore bear minimal credit risk. The carrying amounts for financial instruments consist of cash and cash equivalents, accounts payable and accrued liabilities and approximate fair value due to their short maturities. Debt Securities The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326, Financial Instruments – Credit Losses, as of each reporting date in order to determine if a portion of any decline in fair value below amortized cost basis has resulted from a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other expense, net, which is limited to the difference between the fair value and the amortized cost of the security. Accrued interest related to the Company's available-for-sale debt securities is presented within other current assets on the Company's condensed consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not recorded any losses from accrued interest receivables associated with its marketable securities. The following table sets forth the Company’s marketable securities that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at September 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,410</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,410</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency obligations</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,032</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,032</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,306</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,306</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894,748</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,410</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,338</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,441</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,441</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency obligations</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,055</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,055</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,789</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,789</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429,285</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,441</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328,844</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following table is a summary of amortized cost, unrealized gain and loss, and fair value of the Company’s marketable securities by contractual maturities (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at September 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gain</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents (due within 90 days)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,410</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,410</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (due within one year)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,076</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,338</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894,486</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894,748</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gain</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents (due within 90 days)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,440</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,441</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (due within one year)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,181</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,691</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (due between one and two years)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,110</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,153</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428,731</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429,285</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> As of September 30, 2020, the Company did not have any available-for-sale debt securities in a continuous unrealized position. The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months as of December 31, 2019 (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12 months or greater</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,265</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,265</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency obligations</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,989</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,989</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,254</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,254</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> Warrant Derivative Asset Pursuant to the LianBio Agreement, on August 11, 2020, the Company received a warrant to purchase 170,000 ordinary shares of Lian Cardiovascular at an exercise price of $275.00 per share. The warrant represented 17% of the then-fully diluted equity of Lian Cardiovascular. The Company accounts for the warrant as a derivative instrument in accordance with ASC 815, Derivatives and Hedging, adjusting the fair value at the end of each reporting period, with changes in fair value recorded as other income (expense), net. The fair value of the warrant was estimated to be $18.7 million at inception; there was no material change in the value of the warrant as of September 30, 2020 and therefore no gain or loss was recorded during the three and nine months ended September 30, 2020. The Company estimates the fair value of the warrant with a two-step process. On the date acquired, the fair value of the total stockholder’s equity of Lian Cardiovascular was estimated using a discounted cash flow approach. The projected cash flows from Lian Cardiovascular are based on various assumptions, including projected revenues in the territories, the potential development and commercial timeline, regulatory risks, and estimated costs to be incurred by Lian Cardiovascular for clinical trials and selling and marketing expense. The cash flows are discounted at a rate commensurate with the level of risk associated with the projected cash flows. In the second step, the option pricing method is used to estimate the fair value of the warrant. The Company has determined that the warrant derivative asset should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the two-step process against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification. The significant unobservable inputs used to value the warrant were as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation Technique</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">At Inception</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option pricing method</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.0%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.0%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.9</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free rate</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.59%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.59%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Significant changes in these unobservable inputs could result in a significantly lower or higher fair value measurement.

Fair Value Measurements The Company’s financial instruments consist primarily of cash and cash equivalents, restricted cash, marketable debt securities, accounts receivable, warrant derivative, accounts payable and accrued liabilities. Cash and cash equivalents, restricted cash, marketable debt securities, and warrant derivative asset are reported at their respective fair values in our consolidated balance sheets. The carrying amount of remaining financial instruments approximate fair value due to their short-term nature. The accounting guidance for fair value provides a framework for measuring fair value, clarifies the definition of fair value and expands disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows: Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2—Inputs other than quoted market prices included in Level 1 are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Marketable securities and the warrant derivative asset are stated at their estimated fair values. The counterparties to the agreements relating to the Company’s investment securities consist of the U.S. Treasury, governmental agencies, various major corporations and financial institutions with reputable credit and therefore bear minimal credit risk. The carrying amounts for financial instruments consist of cash and cash equivalents, accounts payable and accrued liabilities and approximate fair value due to their short maturities. Debt Securities The Company assesses its available-for-sale debt securities under the available-for-sale debt security impairment model in ASC 326, Financial Instruments – Credit Losses, as of each reporting date in order to determine if a portion of any decline in fair value below amortized cost basis has resulted from a credit loss. The Company records credit losses in the consolidated statements of operations and comprehensive loss as credit loss expense within other expense, net, which is limited to the difference between the fair value and the amortized cost of the security. Accrued interest related to the Company's available-for-sale debt securities is presented within other current assets on the Company's condensed consolidated balance sheets. The Company has elected the practical expedient available to exclude accrued interest from both the fair value and the amortized cost basis of available-for-sale debt securities for the purposes of identifying and measuring any impairment. The Company writes off accrued interest once it has determined that the asset is not realizable. Any write offs of accrued interest receivable are recorded by reversing interest income, recognizing credit loss expense, or a combination of both. To date, the Company has not recorded any losses from accrued interest receivables associated with its marketable securities.

The following table sets forth the Company’s marketable securities that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at September 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,410</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,410</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency obligations</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,032</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,032</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,306</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,306</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894,748</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,410</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,338</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,441</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,441</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency obligations</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,055</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,055</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate securities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,789</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,789</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429,285</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,441</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328,844</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

674410000

157032000

63306000

894748000

674410000

220338000

100441000

134055000

194789000

429285000

100441000

328844000

The following table is a summary of amortized cost, unrealized gain and loss, and fair value of the Company’s marketable securities by contractual maturities (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at September 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gain</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents (due within 90 days)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,410</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">674,410</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (due within one year)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,076</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">220,338</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894,486</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">262</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">894,748</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements at December 31, 2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized Cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Gain</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents (due within 90 days)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,440</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,441</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (due within one year)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,181</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,691</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (due between one and two years)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,110</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,153</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">428,731</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429,285</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

674410000

220076000

262000

220338000

894486000

262000

894748000

100440000

1000

100441000

314181000

523000

13000

314691000

14110000

47000

4000

14153000

428731000

571000

17000

429285000

As of September 30, 2020, the Company did not have any available-for-sale debt securities in a continuous unrealized position. The following table summarizes available-for-sale debt securities in a continuous unrealized loss position for less than and greater than twelve months as of December 31, 2019 (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12 months or greater</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized Loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.68%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate bonds</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,265</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,265</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency obligations</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,989</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,989</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:32.68%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,254</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,254</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>

34265000

15000

34265000

15000

34989000

2000

34989000

2000

69254000

17000

69254000

17000

170000

275.00

0.17

18700000

The Company has determined that the warrant derivative asset should be classified within Level 3 of the fair-value hierarchy by evaluating each input for the two-step process against the fair-value hierarchy criteria and using the lowest level of input as the basis for the fair-value classification. The significant unobservable inputs used to value the warrant were as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation Technique</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Significant Unobservable Inputs</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">At Inception</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Option pricing method</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.0%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73.0%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.0</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.9</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free rate</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.59%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.59%</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.84%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

0.730

0.0059

0.000

Leases The Company determines if an arrangement is or contains a lease at inception. Operating lease right-of-use (ROU) assets and liabilities are presented separately on its consolidated balance sheets. The Company does not have any material finance leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term beginning at the commencement date. As the Company’s leases do not provide enough information to determine an implicit interest rate, the Company determines its incremental borrowing rate based on the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term in a similar economic environment. The operating lease ROU assets also include any lease payments made and excludes lease incentives and initial direct costs incurred. Lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

129800

2020-01

52600000

P10Y

5500000

8500000

11100000

10400000

Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate). <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,433</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - current</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,891</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - noncurrent</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,717</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,608</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term (years)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.3</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.5</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.0</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

50433000

417000

7891000

383000

43717000

51608000

383000

0.135

0.060

Information related to operating lease activity during the three months ended September 30, 2020 and 2019 was as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,103</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,163</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease cost</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,235</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease cost</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,338</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,163</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets obtained in exchange for lease obligations</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,589</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease payments</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,888</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,330</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

7103000

2163000

1235000

8338000

2163000

52589000

1095000

5888000

2330000

Future annual payments of operating lease liabilities as of September 30, 2020 are as follows (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31:</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 (three months remaining)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,045</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,449</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,745</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,051</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,368</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,442</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future lease payments</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,100</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,492</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,608</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

2045000

8449000

8745000

9051000

9368000

52442000

90100000

38492000

51608000

34500

P9Y

19900000

6. Balance Sheet Components Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from two to five years. Leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations and comprehensive loss. Property and equipment consist of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scientific equipment</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,645</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,642</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and equipment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,127</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,572</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized software</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,925</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">509</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">485</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,568</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,542</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,680</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,560</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,937</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,982</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,743</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Depreciation expense was $0.9 million and $0.5 million for the three months ended September 30, 2020 and 2019, respectively, and $2.5 million and $1.4 million for the nine months ended September 30, 2020 and 2019, respectively. Accrued Liabilities Accrued liabilities consist of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical research and development</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,386</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,494</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside services</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,987</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,592</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll related liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,935</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,724</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,139</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,281</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,343</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,043</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,292</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, ranging from two to five years. Leasehold improvements are amortized over the shorter of their estimated useful lives or the related lease term. Upon retirement or sale, the cost and related accumulated depreciation are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations and comprehensive loss.

cost

the straight-line method over the estimated useful lives of the assets

P2Y

P5Y

shorter of their estimated useful lives or the related lease term

Property and equipment consist of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Scientific equipment</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,645</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,642</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and equipment</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,127</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,572</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized software</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">389</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,925</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">509</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">485</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,568</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,542</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,680</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,560</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,937</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,982</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,743</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

13645000

10642000

3127000

2572000

360000

389000

11925000

509000

485000

9568000

29542000

23680000

9560000

7937000

19982000

15743000

900000

500000

2500000

1400000

Accrued liabilities consist of the following (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical research and development</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,386</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,494</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outside services</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,987</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,592</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll related liabilities</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,935</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,724</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">454</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,139</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,281</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,343</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,043</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,292</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

5386000 11494000 9987000 6592000

15935000

11724000

454000 9139000

8281000

2343000

40043000

41292000

P30D

Contingencies From time to time, the Company may have contingent liabilities that arise in the ordinary course of business activities. The Company accrues for such liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. There were no contingent liabilities requiring accrual or disclosure as of September 30, 2020 or December 31, 2019.

Legal Proceedings Related to the Offer and the Merger As further described in Note 11, Subsequent Events, on October 3, 2020, the Company entered into an Agreement and Plan of Merger (“Merger Agreement”) by and among the Company, Bristol-Myers Squibb Company, a Delaware corporation (“Bristol-Myers Squibb”), and Gotham Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Bristol-Myers Squibb (“Merger Sub”). On October 19, 2020, a purported stockholder of the Company filed a complaint in the United States District Court for the Northern District of California, entitled Wang v. MyoKardia, Inc. et al., 3:20-cv-07342, against the Company and each of its directors. On October 26, 2020, a purported stockholder of the Company filed a substantially similar complaint in the United States District Court for the District of Delaware, entitled Adams v. MyoKardia, Inc. et al., 1:20-cv-01445-UNA, against the Company, each of its directors, Bristol Myers Squibb, and Merger Sub. On October 27, 2020, a purported stockholder of the Company filed a substantially similar complaint in the United States District Court for the Eastern District of New York, entitled Gray v. MyoKardia, Inc. et al., 1:20-cv-05176, against the Company and each of its directors. On October 29, 2020, a purported stockholder of the Company filed a substantially similar complaint in the United States District Court for the Southern District of New York, entitled Farina v. MyoKardia, Inc et al.,1:20-cv-09194, against the Company and each of its directors. Each complaint alleges that the defendants violated federal securities laws by misrepresenting and/or omitting material information in the Schedule 14D-9. The complaints seek, among other things, (i) injunctive relief preventing the consummation of the transactions contemplated by the Merger Agreement, (ii) rescissory damages or rescission in the event that the transactions contemplated by the Merger Agreement have already been consummated, (iii) damages and (iv) plaintiff’s attorneys’ and experts’ fees and expenses. The Company believes that the claims asserted in the complaints are without merit. Additional lawsuits may be filed.

Guarantees and Indemnifications The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to certain of these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third-party with respect to the Company’s technology. The term of these indemnification arrangements is generally perpetual. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future but have not yet been made. The Company indemnifies its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with its certificate of incorporation and bylaws and agreements providing for indemnification entered into with its officers and directors. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding arising out of acts or omissions of such officer or director in such capacity. The maximum amount of potential future indemnification of directors and officers is unlimited; however, the Company currently holds director and officer liability insurance. This insurance allows the transfer of risk associated with its exposure and may enable it to recover a portion of any future amounts paid. The Company believes that the fair value of these indemnification obligations is minimal. Accordingly, the Company has not recognized any liabilities relating to these obligations for any period presented.

8. Stockholders’ Equity In May 2020, the Company completed a follow-on offering and issued 6,037,500 shares of common stock at a price of $105.00 per share, which included 787,500 shares sold directly to the underwriters upon exercise of their over-allotment option. The Company received proceeds totaling approximately $605.0 million from the offering, net of underwriting discounts and commissions and offering expenses. On January 3, 2020, the Company entered into a sales agreement with a sales agent to establish an at-the-market (ATM) offering program, under which the Company is permitted to offer and sell, from time to time, shares of common stock having a maximum aggregate offering price of up to $200.0 million. As of September 30, 2020, no securities have been issued pursuant to the ATM agreement. In March 2019, the Company completed a follow-on offering and issued 5,663,750 shares of common stock at a price of $51.00 per share, which included 738,750 shares sold directly to the underwriters upon exercise of their over-allotment option. During the nine months ended September 30, 2019, the Company received proceeds totaling approximately $271.2 million from the offering, net of underwriting discounts and commissions and offering expenses. Common Stock Reserved for Issuance The Company has reserved shares of common stock for issuance as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and awards issued and outstanding</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,656,261</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,315,254</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for issuance under 2015 Stock Option and Incentive Plan</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,331,844</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">685,435</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for issuance under 2015 Employee Stock Purchase Plan</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,579,961</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,140,541</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,568,066</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,141,230</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

6037500

105.00

787500

605000000.0

200000000.0

5663750

51.00

738750

271200000

The Company has reserved shares of common stock for issuance as follows: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and awards issued and outstanding</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,656,261</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,315,254</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for issuance under 2015 Stock Option and Incentive Plan</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,331,844</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">685,435</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for issuance under 2015 Employee Stock Purchase Plan</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,579,961</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,140,541</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,568,066</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,141,230</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

5656261

5315254

1331844

685435

1579961

1140541

8568066

7141230

9. Stock-Based Compensation The Company classifies stock-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss based on the department to which a recipient belongs. The following table sets forth stock-based compensation expense related to equity awards granted to employees and consultants for all periods presented (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,621</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,644</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,152</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,402</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,726</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,631</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,823</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,492</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,347</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,275</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,975</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,894</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following summarizes option and other equity award activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,574,158</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.81</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,064,174</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.16</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(696,937</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.72</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options canceled/forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(240,298</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.70</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,701,097</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.59</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741,096</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.59</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs awarded</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,956</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.00</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs released</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(170,809</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.09</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,079</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.81</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">955,164</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.58</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Restricted stock units (“RSUs”) settle into shares of common stock upon vesting and the fair value is the market price on the date of grant. In relation to stock options and awards that vest upon the achievement of performance criteria, there was $0.3 million and zero in stock-based compensation expense recorded for the three months ended September 30, 2020 and 2019, respectively and $1.0 million and zero was recorded for the nine months ended September 30, 2020 and 2019, respectively. The Company begins to recognize expenses related to these stock options and awards during the period upon concluding that certain performance criteria are considered probable.

Stock-Based Compensation The Company classifies stock-based compensation expense in the accompanying condensed consolidated statements of operations and comprehensive loss based on the department to which a recipient belongs. The following table sets forth stock-based compensation expense related to equity awards granted to employees and consultants for all periods presented (in thousands): In relation to stock options and awards that vest upon the achievement of performance criteria, there was $0.3 million and zero in stock-based compensation expense recorded for the three months ended September 30, 2020 and 2019, respectively and $1.0 million and zero was recorded for the nine months ended September 30, 2020 and 2019, respectively. The Company begins to recognize expenses related to these stock options and awards during the period upon concluding that certain performance criteria are considered probable.

The following table sets forth stock-based compensation expense related to equity awards granted to employees and consultants for all periods presented (in thousands): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.52%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.2%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,621</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,644</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,152</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,402</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,726</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,631</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,823</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,492</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,347</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,275</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,975</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,894</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

5621000

3644000

16152000

10402000

5726000

4631000

16823000

13492000

11347000

8275000

32975000

23894000

The following summarizes option and other equity award activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">per Share</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,574,158</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.81</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,064,174</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.16</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(696,937</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.72</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options canceled/forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(240,298</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.70</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,701,097</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.59</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares Subject to</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted Average</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Awards</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">741,096</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46.59</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs awarded</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">450,956</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74.00</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs released</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(170,809</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.09</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs forfeited</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(66,079</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.81</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">955,164</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="middle"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59.58</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

4574158

31.81

1064174

74.16

696937

25.72

240298

45.70

4701097

41.59

741096

46.59

450956

74.00

170809

45.09

66079

49.81

955164

59.58

300000

1000000.0

10. Net Loss per Share The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,744</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(141,802</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218,197</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(217,446</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,101,453</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,133,068</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,860,879</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,258,437</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted average shares subject to repurchase</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,780</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used to compute basic and diluted net loss per share</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,101,453</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,133,068</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,860,879</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,255,657</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.60</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.07</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.38</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.91</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div> The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and awards issued and outstanding</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,656,261</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,278,515</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> As of September 30, 2020, the Company has contributions from plan participants of $1.2 million under the 2015 ESPP, which if converted, would be equivalent to approximately 25,000 shares based on 85% of the stock price at the beginning of the offering period. As of September 30, 2019, the Company had contributions from plan participants of $0.8 million under the 2015 ESPP, which if converted, would have been equivalent to approximately 20,000 shares using the offering price at the beginning of the offering period.

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts): <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nine Months Ended September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.32%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,744</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(141,802</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218,197</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(217,446</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,101,453</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,133,068</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,860,879</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.44%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,258,437</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: weighted average shares subject to repurchase</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,780</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used to compute basic and diluted net loss per share</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,101,453</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,133,068</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,860,879</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,255,657</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.60</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3.07</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.38</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.44%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.32%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.91</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>

-84744000

-141802000

-218197000

-217446000

53101453

46133068

49860879

44258437

2780

53101453

46133068

49860879

44255657

-1.60

-3.07

-4.38

-4.91

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30,</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and awards issued and outstanding</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,656,261</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,278,515</td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

5656261

5278515

1200000

25000

0.85

800000

20000

225.00

458000000.0

XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2020	Nov. 01, 2020
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Trading Symbol	MYOK
Entity Registrant Name	MYOKARDIA, INC.
Entity Central Index Key	0001552451
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		53,322,904
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-37609
Entity Tax Identification Number	44-5500552
Entity Address, Address Line One	1000 Sierra Point Parkway
Entity Address, City or Town	Brisbane
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94005
City Area Code	650
Local Phone Number	741-0900
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 675,541	$ 101,436
Short-term investments	220,338	314,691
Consideration due from related party	35,000
Prepaid expenses and other current assets	12,865	7,709
Total current assets	943,744	423,836
Property and equipment, net	19,982	15,743
Operating lease right-of-use assets	50,433	417
Long-term investments		14,153
Related party warrant derivative asset	18,765
Restricted cash and other	2,737	1,945
Total assets	1,035,661	456,094
Current liabilities
Accounts payable	4,554	6,237
Accrued liabilities	40,043	41,292
Operating lease liabilities - current	7,891	383
Total current liabilities	52,488	47,912
Operating lease liability	43,717
Related party liability	93,765
Other long-term liabilities	713	1,908
Total liabilities	190,683	49,820
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.0001 par value, 150,000,000 shares authorized at September 30, 2020 and December 31, 2019; 53,308,689 and 46,379,073 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively	5	5
Additional paid-in capital	1,541,679	884,486
Accumulated other comprehensive income	257	549
Accumulated deficit	(696,963)	(478,766)
Total stockholders’ equity	844,978	406,274
Total liabilities and stockholders’ equity	$ 1,035,661	$ 456,094

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	53,308,689	46,379,073
Common stock, shares outstanding	53,308,689	46,379,073

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Operating expenses:
Research and development	$ 59,074	$ 47,372	$ 155,286	$ 101,270
Selling, general and administrative	26,329	17,746	66,482	45,153
Repurchase of royalty rights		80,000		80,000
Total operating expenses	85,403	145,118	221,768	226,423
Loss from operations	(85,403)	(145,118)	(221,768)	(226,423)
Interest and other income, net	668	3,332	3,592	8,775
Loss before income taxes	(84,735)	(141,786)	(218,176)	(217,648)
Income tax expense (benefit)	9	16	21	(202)
Net loss	(84,744)	(141,802)	(218,197)	(217,446)
Other comprehensive (loss) income	(495)	(44)	(292)	520
Comprehensive loss	$ (85,239)	$ (141,846)	$ (218,489)	$ (216,926)
Net loss per share, basic and diluted	$ (1.60)	$ (3.07)	$ (4.38)	$ (4.91)
Weighted average number of shares used to compute net loss per share, basic and diluted	53,101,453	46,133,068	49,860,879	44,255,657

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income/ (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2018	$ 370,567	$ 4	$ 573,183	$ (67)	$ (202,553)
Beginning balance, shares at Dec. 31, 2018		40,288,949
Issuance of common stock in connection with the follow-on offering, net of issuance costs	271,213	$ 1	271,212
Issuance of common stock in connection with the follow-on offering, net of issuance costs, shares		5,663,750
Issuance of common stock upon the exercise of options and release of stock awards	280		280
Issuance of common stock upon the exercise of options and release of stock awards, shares		49,076
Vesting of early exercised stock options	8		8
Stock-based compensation	6,981		6,981
Unrealized gains (loss), net of tax expense (benefit)	363			363
Net loss	(37,470)				(37,470)
Adjustment for issuance costs		$ 17,638
Ending balance at Mar. 31, 2019	611,942	$ 5	851,664	296	(240,023)
Ending balance, shares at Mar. 31, 2019		46,001,775
Beginning balance at Dec. 31, 2018	370,567	$ 4	573,183	(67)	(202,553)
Beginning balance, shares at Dec. 31, 2018		40,288,949
Net loss	(217,446)
Ending balance at Sep. 30, 2019	452,353	$ 5	871,894	453	(419,999)
Ending balance, shares at Sep. 30, 2019		46,218,925
Beginning balance at Mar. 31, 2019	611,942	$ 5	851,664	296	(240,023)
Beginning balance, shares at Mar. 31, 2019		46,001,775
Issuance of common stock upon the exercise of options and release of stock awards	716		716
Issuance of common stock upon the exercise of options and release of stock awards, shares		75,326
Issuance of common stock pursuant to employee stock purchase plan	855		855
Issuance of common stock pursuant to employee stock purchase plan, shares		20,958
Vesting of early exercised stock options	7		7
Stock-based compensation	8,638		8,638
Unrealized gains (loss), net of tax expense (benefit)	201			201
Net loss	(38,174)				(38,174)
Ending balance at Jun. 30, 2019	584,185	$ 5	861,880	497	(278,197)
Ending balance, shares at Jun. 30, 2019		46,098,059
Issuance of common stock upon the exercise of options and release of stock awards	1,739		1,739
Issuance of common stock upon the exercise of options and release of stock awards, shares		120,866
Stock-based compensation	8,275		8,275
Unrealized gains (loss), net of tax expense (benefit)	(44)			(44)
Net loss	(141,802)				(141,802)
Ending balance at Sep. 30, 2019	452,353	$ 5	871,894	453	(419,999)
Ending balance, shares at Sep. 30, 2019		46,218,925
Beginning balance at Dec. 31, 2019	406,274	$ 5	884,486	549	(478,766)
Beginning balance, shares at Dec. 31, 2019		46,379,073
Issuance of common stock upon the exercise of options and release of stock awards	1,820		1,820
Issuance of common stock upon the exercise of options and release of stock awards, shares		233,113
Stock-based compensation	10,752		10,752
Unrealized gains (loss), net of tax expense (benefit)	122			122
Net loss	(69,868)				(69,868)
Ending balance at Mar. 31, 2020	349,100	$ 5	897,058	671	(548,634)
Ending balance, shares at Mar. 31, 2020		46,612,186
Beginning balance at Dec. 31, 2019	$ 406,274	$ 5	884,486	549	(478,766)
Beginning balance, shares at Dec. 31, 2019		46,379,073
Issuance of common stock upon the exercise of options and release of stock awards, shares	696,937
Net loss	$ (218,197)
Ending balance at Sep. 30, 2020	844,978	$ 5	1,541,679	257	(696,963)
Ending balance, shares at Sep. 30, 2020		53,308,689
Beginning balance at Mar. 31, 2020	349,100	$ 5	897,058	671	(548,634)
Beginning balance, shares at Mar. 31, 2020		46,612,186
Issuance of common stock in connection with the follow-on offering, net of issuance costs	605,028		605,028
Issuance of common stock in connection with the follow-on offering, net of issuance costs, shares		6,037,500
Issuance of common stock upon the exercise of options and release of stock awards	5,910		5,910
Issuance of common stock upon the exercise of options and release of stock awards, shares		290,977
Issuance of common stock pursuant to employee stock purchase plan	1,229		1,229
Issuance of common stock pursuant to employee stock purchase plan, shares		24,370
Stock-based compensation	10,876		10,876
Unrealized gains (loss), net of tax expense (benefit)	81			81
Net loss	(63,585)				(63,585)
Adjustment for issuance costs		$ 28,909
Ending balance at Jun. 30, 2020	908,639	$ 5	1,520,101	752	(612,219)
Ending balance, shares at Jun. 30, 2020		52,965,033
Issuance of common stock upon the exercise of options and release of stock awards	10,195		10,195
Issuance of common stock upon the exercise of options and release of stock awards, shares		343,656
Stock-based compensation	11,347		11,347
Unrealized gains (loss), net of tax expense (benefit)	(495)			(495)
Net loss	(84,744)				(84,744)
Adjustment for issuance costs	36		36
Ending balance at Sep. 30, 2020	$ 844,978	$ 5	$ 1,541,679	$ 257	$ (696,963)
Ending balance, shares at Sep. 30, 2020		53,308,689

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2019
Issuance costs	$ 36
Common Stock
Issuance costs		$ 28,909	$ 17,638

XML 18 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flow from operating activities:
Net loss	$ (218,197)	$ (217,446)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	32,975	23,894
Depreciation	2,459	1,441
Amortization of discount on investments	(469)	(1,034)
Income tax benefit of unrealized gains on investments		(202)
Loss on disposal of equipment	49
Change in operating assets and liabilities:
Prepaid expenses and other current assets	(4,897)	(2,457)
Operating lease right-of-use assets	2,573	2,007
Other long-term assets	(370)	(169)
Accounts payable	(1,321)	3,589
Accrued liabilities	7,517	14,702
Prepayment from collaboration partner		(12,973)
Operating lease liabilities	(1,364)	(2,171)
Consideration received from related party	40,000
Other long-term liabilities	(1,195)	1,907
Net cash used in operating activities	(142,240)	(188,912)
Cash flow from investing activities:
Purchases of investments	(128,892)	(145,792)
Sales of investments	4,000	4,000
Maturities of investments	233,575	47,000
Purchases of property and equipment	(15,875)	(1,978)
Net cash provided by (used in) investing activities	92,808	(96,770)
Cash flow from financing activities:
Proceeds from issuance of common stock in follow-on offerings, net of issuance costs	605,064	271,224
Proceeds from exercise of stock options and employee stock purchase plan	18,848	3,573
Net cash provided by financing activities	623,912	274,797
Net increase in cash, cash equivalents and restricted cash	574,480	(10,885)
Cash, cash equivalents and restricted cash, beginning of period	103,630	248,265
Cash, cash equivalents and restricted cash, end of period	678,110	237,380
Non-cash investing and financing activities:
Unpaid portion of property and equipment purchases included in period-end accounts payable and accrued liabilities	628	1,689
Vesting of early exercised options and restricted stock		15
Non-cash exercise of stock options	$ 306	$ 17

XML 19 R8.htm IDEA: XBRL DOCUMENT

Organization

9 Months Ended

Sep. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization

1. Organization

Liquidity

The Company will continue to assess its operating expenses and cash and cash equivalents and, if circumstances warrant, the Company will make appropriate adjustments to its operating plan.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Consolidated Statements of Cash Flows

	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	675,541	$	101,436
Restricted cash included in prepaid expenses and other current assets		290		337
Restricted cash included in restricted cash and other		2,279		1,857
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	678,110	$	103,630

Use of Estimates

Recently Adopted Accounting Pronouncements

XML 21 R10.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements

9 Months Ended

Sep. 30, 2020

Collaboration And License Agreement Disclosure [Abstract]

License and Collaboration Agreements

3. License and Collaboration Agreements

LianBio

Exclusive License Agreement with LianBio Licensing, LLC

Fulcrum Therapeutics, Inc.

Multi-Target Collaboration and License Agreement with Fulcrum Therapeutics, Inc.

Sanofi (Aventis Inc.)

Agreement Overview, Termination and Repurchase of Royalty Rights

XML 22 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Debt Securities

The following table sets forth the Company’s marketable securities that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

	Fair Value Measurements at September 30, 2020
	Total		Level 1		Level 2		Level 3
Assets
Money market funds	$	674,410	$	674,410	$	—	$	—
U.S. government agency obligations		157,032		—		157,032		—
Corporate securities		63,306		—		63,306		—
Total	$	894,748	$	674,410	$	220,338	$	—

	Fair Value Measurements at December 31, 2019
	Total		Level 1		Level 2		Level 3
Assets
Money market funds	$	100,441	$	100,441	$	—	$	—
U.S. government agency obligations		134,055		—		134,055		—
Corporate securities		194,789		—		194,789		—
Total	$	429,285	$	100,441	$	328,844	$	—

The following table is a summary of amortized cost, unrealized gain and loss, and fair value of the Company’s marketable securities by contractual maturities (in thousands):

	Fair Value Measurements at September 30, 2020
	Amortized Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash equivalents (due within 90 days)	$	674,410	$	—	$	—		$	674,410
Short-term investments (due within one year)		220,076		262		—			220,338
Total	$	894,486	$	262	$	—		$	894,748

	Fair Value Measurements at December 31, 2019
	Amortized Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash equivalents (due within 90 days)	$	100,440	$	1	$	—		$	100,441
Short-term investments (due within one year)		314,181		523		(13	)		314,691
Long-term investments (due between one and two years)		14,110		47		(4	)		14,153
Total	$	428,731	$	571	$	(17	)	$	429,285

	Less than 12 months					12 months or greater				Total
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss		Fair Value		Unrealized Loss
December 31, 2019
Corporate bonds	$	34,265	$	(15	)	$	—	$	—	$	34,265	$	(15	)
U.S. government agency obligations		34,989		(2	)		—		—		34,989		(2	)
Total	$	69,254	$	(17	)	$	—	$	—	$	69,254	$	(17	)

Warrant Derivative Asset

Valuation Technique	Significant Unobservable Inputs	At Inception		September 30, 2020
Option pricing method	Volatility	73.0%		73.0%
	Expected term (in years)		10.0		9.9
	Risk-free rate	0.59%		0.59%
	Dividend yield	0.0%		0.0%

Significant changes in these unobservable inputs could result in a significantly lower or higher fair value measurement.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended

Sep. 30, 2020

Lessee Disclosure [Abstract]

Leases

5. Leases

As of September 30, 2020, the Company has capitalized $10.4 million of leasehold improvements within property and equipment and amortizes the improvements over the lease term.

Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate).

	September 30, 2020			December 31, 2019
Assets
Operating lease right-of-use assets	$	50,433		$	417

Liabilities
Operating lease liabilities - current	$	7,891		$	383
Operating lease liabilities - noncurrent		43,717			—
	$	51,608		$	383

Weighted average remaining lease term (years)		9.3			0.3
Weighted average discount rate		13.5	%		6.0	%

Information related to operating lease activity during the three months ended September 30, 2020 and 2019 was as follows (in thousands):

	Nine Months Ended September 30,
	2020		2019
Operating lease cost	$	7,103	$	2,163
Variable lease cost		1,235		—
Total lease cost	$	8,338	$	2,163

Operating lease right-of-use assets obtained in exchange for lease obligations	$	52,589	$	1,095

Operating lease payments	$	5,888	$	2,330

Future annual payments of operating lease liabilities as of September 30, 2020 are as follows (in thousands):

Year ending December 31:	Amount
2020 (three months remaining)	$	2,045
2021		8,449
2022		8,745
2023		9,051
2024		9,368
Thereafter		52,442
Total future lease payments		90,100
Less: imputed interest		(38,492	)
Total operating lease liabilities	$	51,608

XML 24 R13.htm IDEA: XBRL DOCUMENT

Balance Sheet Components

9 Months Ended

Sep. 30, 2020

Balance Sheet Related Disclosures [Abstract]

Balance Sheet Components

6. Balance Sheet Components

Property and Equipment

Property and equipment consist of the following (in thousands):

	September 30, 2020			December 31, 2019
Scientific equipment	$	13,645		$	10,642
Furniture and equipment		3,127			2,572
Capitalized software		360			389
Leasehold improvements		11,925			509
Construction in progress		485			9,568
Total		29,542			23,680
Less: Accumulated depreciation		(9,560	)		(7,937	)
Property and equipment, net	$	19,982		$	15,743

Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	September 30, 2020		December 31, 2019
Clinical research and development	$	5,386	$	11,494
Outside services		9,987		6,592
Payroll related liabilities		15,935		11,724
Construction in progress		454		9,139
Other		8,281		2,343
Total accrued liabilities	$	40,043	$	41,292

XML 25 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2020

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

7. Commitments and Contingencies

Purchase Commitments

Contingencies

Legal Proceedings Related to the Offer and the Merger

Guarantees and Indemnifications

XML 26 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2020

Stockholders Equity Note [Abstract]

Stockholders' Equity

8. Stockholders’ Equity

Common Stock Reserved for Issuance

The Company has reserved shares of common stock for issuance as follows:

	September 30, 2020		December 31, 2019
Options and awards issued and outstanding		5,656,261		5,315,254
Shares available for issuance under 2015 Stock Option and Incentive Plan		1,331,844		685,435
Shares available for issuance under 2015 Employee Stock Purchase Plan		1,579,961		1,140,541
Total		8,568,066		7,141,230

XML 27 R16.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

9. Stock-Based Compensation

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development	$	5,621	$	3,644	$	16,152	$	10,402
Selling, general and administrative		5,726		4,631		16,823		13,492
Total	$	11,347	$	8,275	$	32,975	$	23,894

The following summarizes option and other equity award activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan:

	Shares Subject to			Weighted Average
	Outstanding Options			Exercise Price per Share
Balance at December 31, 2019		4,574,158		$	31.81
Options granted		1,064,174		$	74.16
Options exercised		(696,937	)	$	25.72
Options canceled/forfeited		(240,298	)	$	45.70
Balance at September 30, 2020		4,701,097		$	41.59

	Shares Subject to			Weighted Average
	Outstanding Awards			Grant Date Fair Value
Balance at December 31, 2019		741,096		$	46.59
RSUs awarded		450,956		$	74.00
RSUs released		(170,809	)	$	45.09
RSUs forfeited		(66,079	)	$	49.81
Balance at September 30, 2020		955,164		$	59.58

Restricted stock units (“RSUs”) settle into shares of common stock upon vesting and the fair value is the market price on the date of grant.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Net Loss per Share

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Net Loss per Share

10. Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Numerator
Net loss	$	(84,744	)	$	(141,802	)	$	(218,197	)	$	(217,446	)
Denominator
Weighted average shares outstanding		53,101,453			46,133,068			49,860,879			44,258,437
Less: weighted average shares subject to repurchase		—			—			—			(2,780	)
Weighted average shares used to compute basic and diluted net loss per share		53,101,453			46,133,068			49,860,879			44,255,657
Net loss per share, basic and diluted	$	(1.60	)	$	(3.07	)	$	(4.38	)	$	(4.91	)

	As of September 30,
	2020		2019
Common stock subject to repurchase		—		—
Options and awards issued and outstanding		5,656,261		5,278,515

XML 29 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Sep. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

XML 30 R19.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation

Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Consolidated Statements of Cash Flows

	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	675,541	$	101,436
Restricted cash included in prepaid expenses and other current assets		290		337
Restricted cash included in restricted cash and other		2,279		1,857
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	678,110	$	103,630

Use of Estimates

Recently Adopted Accounting Pronouncements

Fair Value Measurements

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Debt Securities

Leases

Property and Equipment

Contingencies

Legal Proceedings Related to the Offer and the Merger

Guarantees and Indemnifications

Stock-Based Compensation

XML 31 R20.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Accounting Policies [Abstract]

Summary of Cash Reported in Condensed Consolidated Statements of Cash Flows

	September 30, 2020		December 31, 2019
Cash and cash equivalents	$	675,541	$	101,436
Restricted cash included in prepaid expenses and other current assets		290		337
Restricted cash included in restricted cash and other		2,279		1,857
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$	678,110	$	103,630

XML 32 R21.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2020

Fair Value Disclosures [Abstract]

Summary of Fair Value Assets Measured on Recurring Basis

The following table sets forth the Company’s marketable securities that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

	Fair Value Measurements at September 30, 2020
	Total		Level 1		Level 2		Level 3
Assets
Money market funds	$	674,410	$	674,410	$	—	$	—
U.S. government agency obligations		157,032		—		157,032		—
Corporate securities		63,306		—		63,306		—
Total	$	894,748	$	674,410	$	220,338	$	—

	Fair Value Measurements at December 31, 2019
	Total		Level 1		Level 2		Level 3
Assets
Money market funds	$	100,441	$	100,441	$	—	$	—
U.S. government agency obligations		134,055		—		134,055		—
Corporate securities		194,789		—		194,789		—
Total	$	429,285	$	100,441	$	328,844	$	—

Summary of Fair Value Measurement of Available-for-sale Securities

The following table is a summary of amortized cost, unrealized gain and loss, and fair value of the Company’s marketable securities by contractual maturities (in thousands):

	Fair Value Measurements at September 30, 2020
	Amortized Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash equivalents (due within 90 days)	$	674,410	$	—	$	—		$	674,410
Short-term investments (due within one year)		220,076		262		—			220,338
Total	$	894,486	$	262	$	—		$	894,748

	Fair Value Measurements at December 31, 2019
	Amortized Cost		Unrealized Gain		Unrealized Loss			Fair Value
Cash equivalents (due within 90 days)	$	100,440	$	1	$	—		$	100,441
Short-term investments (due within one year)		314,181		523		(13	)		314,691
Long-term investments (due between one and two years)		14,110		47		(4	)		14,153
Total	$	428,731	$	571	$	(17	)	$	429,285

Summary of Available-for-sale Debt Securities in Continuous Unrealized Loss Position for Less Than and Greater Than Twelve Months

	Less than 12 months					12 months or greater				Total
	Fair Value		Unrealized Loss			Fair Value		Unrealized Loss		Fair Value		Unrealized Loss
December 31, 2019
Corporate bonds	$	34,265	$	(15	)	$	—	$	—	$	34,265	$	(15	)
U.S. government agency obligations		34,989		(2	)		—		—		34,989		(2	)
Total	$	69,254	$	(17	)	$	—	$	—	$	69,254	$	(17	)

Summary of Significant Unobservable Inputs Used to Value Warrant

Valuation Technique	Significant Unobservable Inputs	At Inception		September 30, 2020
Option pricing method	Volatility	73.0%		73.0%
	Expected term (in years)		10.0		9.9
	Risk-free rate	0.59%		0.59%
	Dividend yield	0.0%		0.0%

XML 33 R22.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended

Sep. 30, 2020

Lessee Disclosure [Abstract]

Supplemental Balance Sheet Information Related to Operating Leases

Supplemental balance sheet information related to operating leases was as follows (in thousands, except lease term and discount rate).

	September 30, 2020			December 31, 2019
Assets
Operating lease right-of-use assets	$	50,433		$	417

Liabilities
Operating lease liabilities - current	$	7,891		$	383
Operating lease liabilities - noncurrent		43,717			—
	$	51,608		$	383

Weighted average remaining lease term (years)		9.3			0.3
Weighted average discount rate		13.5	%		6.0	%

Schedule of Information Related to Operating Lease Activity

Information related to operating lease activity during the three months ended September 30, 2020 and 2019 was as follows (in thousands):

	Nine Months Ended September 30,
	2020		2019
Operating lease cost	$	7,103	$	2,163
Variable lease cost		1,235		—
Total lease cost	$	8,338	$	2,163

Operating lease right-of-use assets obtained in exchange for lease obligations	$	52,589	$	1,095

Operating lease payments	$	5,888	$	2,330

Schedule of Future Annual Payment of Operating Lease Liabilities

Future annual payments of operating lease liabilities as of September 30, 2020 are as follows (in thousands):

Year ending December 31:	Amount
2020 (three months remaining)	$	2,045
2021		8,449
2022		8,745
2023		9,051
2024		9,368
Thereafter		52,442
Total future lease payments		90,100
Less: imputed interest		(38,492	)
Total operating lease liabilities	$	51,608

XML 34 R23.htm IDEA: XBRL DOCUMENT

Balance Sheet Components (Tables)

9 Months Ended

Sep. 30, 2020

Balance Sheet Related Disclosures [Abstract]

Summary of Property and Equipment

Property and equipment consist of the following (in thousands):

	September 30, 2020			December 31, 2019
Scientific equipment	$	13,645		$	10,642
Furniture and equipment		3,127			2,572
Capitalized software		360			389
Leasehold improvements		11,925			509
Construction in progress		485			9,568
Total		29,542			23,680
Less: Accumulated depreciation		(9,560	)		(7,937	)
Property and equipment, net	$	19,982		$	15,743

Summary of Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

	September 30, 2020		December 31, 2019
Clinical research and development	$	5,386	$	11,494
Outside services		9,987		6,592
Payroll related liabilities		15,935		11,724
Construction in progress		454		9,139
Other		8,281		2,343
Total accrued liabilities	$	40,043	$	41,292

XML 35 R24.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Equity [Abstract]

Schedule of Common Stock Reserved for Issuance

The Company has reserved shares of common stock for issuance as follows:

	September 30, 2020		December 31, 2019
Options and awards issued and outstanding		5,656,261		5,315,254
Shares available for issuance under 2015 Stock Option and Incentive Plan		1,331,844		685,435
Shares available for issuance under 2015 Employee Stock Purchase Plan		1,579,961		1,140,541
Total		8,568,066		7,141,230

XML 36 R25.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of Stock-Based Compensation Expense Related to Equity Awards Granted to Employees and Consultants

The following table sets forth stock-based compensation expense related to equity awards granted to employees and consultants for all periods presented (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Research and development	$	5,621	$	3,644	$	16,152	$	10,402
Selling, general and administrative		5,726		4,631		16,823		13,492
Total	$	11,347	$	8,275	$	32,975	$	23,894

Summary of Stock Option and Other Equity Award Activity Under Plans

The following summarizes option and other equity award activity under the 2012 Equity Incentive Plan and 2015 Stock Option and Incentive Plan:

	Shares Subject to			Weighted Average
	Outstanding Options			Exercise Price per Share
Balance at December 31, 2019		4,574,158		$	31.81
Options granted		1,064,174		$	74.16
Options exercised		(696,937	)	$	25.72
Options canceled/forfeited		(240,298	)	$	45.70
Balance at September 30, 2020		4,701,097		$	41.59

	Shares Subject to			Weighted Average
	Outstanding Awards			Grant Date Fair Value
Balance at December 31, 2019		741,096		$	46.59
RSUs awarded		450,956		$	74.00
RSUs released		(170,809	)	$	45.09
RSUs forfeited		(66,079	)	$	49.81
Balance at September 30, 2020		955,164		$	59.58

XML 37 R26.htm IDEA: XBRL DOCUMENT

Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2020

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss per Share

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share amounts):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Numerator
Net loss	$	(84,744	)	$	(141,802	)	$	(218,197	)	$	(217,446	)
Denominator
Weighted average shares outstanding		53,101,453			46,133,068			49,860,879			44,258,437
Less: weighted average shares subject to repurchase		—			—			—			(2,780	)
Weighted average shares used to compute basic and diluted net loss per share		53,101,453			46,133,068			49,860,879			44,255,657
Net loss per share, basic and diluted	$	(1.60	)	$	(3.07	)	$	(4.38	)	$	(4.91	)

Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share

	As of September 30,
	2020		2019
Common stock subject to repurchase		—		—
Options and awards issued and outstanding		5,656,261		5,278,515

XML 38 R27.htm IDEA: XBRL DOCUMENT

Organization - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended
	May 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit		$ 696,963	$ 478,766
Proceeds from follow-on offering	$ 605,000
Cash, cash equivalents and investments		$ 895,900

XML 39 R28.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)	9 Months Ended
	Sep. 30, 2020 Segment
Basis Of Presentation And Summary Of Significant Accounting Policies [Abstract]
Number of reportable and operating segment	1

XML 40 R29.htm IDEA: XBRL DOCUMENT

Basis of Presentation and Summary of Significant Accounting Policies - Summary of Cash Reported in Condensed Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Cash and cash equivalents	$ 675,541	$ 101,436
Restricted cash included in prepaid expenses and other current assets	290	337
Restricted cash included in restricted cash and other	2,279	1,857
Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows	$ 678,110	$ 103,630	$ 237,380	$ 248,265

XML 41 R30.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Aug. 31, 2020	Jul. 31, 2020	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Aug. 11, 2020	Jul. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Fair value of warrant							$ 18,700,000
Consideration due from related party			$ 35,000,000		$ 35,000,000
Research and development			$ 59,074,000	$ 47,372,000	$ 155,286,000	$ 101,270,000
Exclusive License Agreement \| LianBio Licencising,, LLC.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from license fees received	$ 40,000,000.0
Additional proceeds from license fees received	$ 35,000,000.0
Financing event occurring date	Oct. 29, 2020
Number of warrants	170,000
Warrants exercise price	$ 275.00
Percentage of ordinary shares represents warrants	17.00%
Fair value of warrant	$ 18,700,000
Negotiation period	90 days
Exclusive License Agreement \| LianBio Licencising,, LLC. \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Regulatory milestone payments	$ 60,000,000.0
Sales milestone payments	$ 87,500,000
Exclusive License Agreement \| LianBio Licencising,, LLC.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of ordinary shares represents warrants	17.00%
Fair value of warrant	$ 18,700,000
Total consideration	93,700,000
Cash consideration	40,000,000.0
Consideration due from related party non-current	35,000,000.0
Consideration due from related party	$ 35,000,000.0
Multi-Target Collaboration and License Agreement \| Fulcrum Therapeutics Inc
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment of license fees		$ 10,000,000.0
Prepaid research funding at close of transaction		2,500,000
Milestone payments eligible for additional cardiomyopathy target		298,500,000
Research and development		10,000,000.0
Multi-Target Collaboration and License Agreement \| Fulcrum Therapeutics Inc \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research, development and commercial milestone payments and additional research reimbursements		302,500,000
Milestone payments eligible for a follow-on target		$ 150,000,000.0
Termination Agreement \| Sanofi (Aventis Inc.) \| Royalty Rights
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amount Payable to reacquire research and development asset								$ 80,000,000.0

XML 42 R31.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Assets
Assets fair value	$ 894,748	$ 429,285
Money market funds
Assets
Assets fair value	674,410	100,441
Fair Value Measurements on Recurring Basis \| Level 1
Assets
Assets fair value	674,410	100,441
Fair Value Measurements on Recurring Basis \| Level 2
Assets
Assets fair value	220,338	328,844
Fair Value Measurements on Recurring Basis \| Money market funds \| Level 1
Assets
Assets fair value	674,410	100,441
U.S. government agency obligations
Assets
Assets fair value	157,032	134,055
U.S. government agency obligations \| Fair Value Measurements on Recurring Basis \| Level 2
Assets
Assets fair value	157,032	134,055
Corporate securities
Assets
Assets fair value	63,306	194,789
Corporate securities \| Fair Value Measurements on Recurring Basis \| Level 2
Assets
Assets fair value	$ 63,306	$ 194,789

XML 43 R32.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Fair Value Measurement of Available-for-sale Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 894,486	$ 428,731
Unrealized Gain	262	571
Unrealized Loss		(17)
Fair Value	894,748	429,285
Cash equivalents (due within 90 days)
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	674,410	100,440
Unrealized Gain		1
Fair Value	674,410	100,441
Short-term investments (due within one year)
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	220,076	314,181
Unrealized Gain	262	523
Unrealized Loss		(13)
Fair Value	$ 220,338	314,691
Long-term investments (due between one and two years)
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		14,110
Unrealized Gain		47
Unrealized Loss		(4)
Fair Value		$ 14,153

XML 44 R33.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Available-for-sale Debt Securities in Continuous Unrealized Loss Position for Less Than and Greater Than Twelve Months (Details) $ in Thousands	Dec. 31, 2019 USD ($)
Schedule Of Available For Sale Securities [Line Items]
Fair Value, Less than 12 Months	$ 69,254
Unrealized Loss, Less than 12 Months	(17)
Fair Value, Total	69,254
Unrealized Loss, Total	(17)
Corporate bonds
Schedule Of Available For Sale Securities [Line Items]
Fair Value, Less than 12 Months	34,265
Unrealized Loss, Less than 12 Months	(15)
Fair Value, Total	34,265
Unrealized Loss, Total	(15)
U.S. government agency obligations
Schedule Of Available For Sale Securities [Line Items]
Fair Value, Less than 12 Months	34,989
Unrealized Loss, Less than 12 Months	(2)
Fair Value, Total	34,989
Unrealized Loss, Total	$ (2)

XML 45 R34.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Additional Information (Details) - USD ($)		3 Months Ended	9 Months Ended
	Aug. 11, 2020	Sep. 30, 2020	Sep. 30, 2020
Schedule Of Available For Sale Securities [Line Items]
Fair value of warrant	$ 18,700,000
Gain or loss on sale of derivatives		$ 0	$ 0
LianBio Agreement
Schedule Of Available For Sale Securities [Line Items]
Warrant to purchase ordinary shares	170,000
Warrants exercise price	$ 275.00
Percentage of ordinary shares represents warrants	17.00%

XML 46 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Summary of Significant Unobservable Inputs Used to Value Warrant (Details)	Sep. 30, 2020	Aug. 31, 2018
Significant Unobservable Inputs, Volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants, percentage	0.730	0.730
Significant Unobservable Inputs, Expected Term
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Expected term (in years)	9 years 10 months 24 days	10 years
Significant Unobservable Inputs, Risk-Free-Rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants, percentage	0.0059	0.0059
Significant Unobservable Inputs, Dividend Yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Warrants, percentage	0.000	0.000

XML 47 R36.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Details) $ in Thousands	1 Months Ended	6 Months Ended
Leases - Additional Information (Details) $ in Thousands	Jan. 31, 2020 USD ($)	Jun. 30, 2020 USD ($) ft²	Sep. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2018 ft²
Lessee Lease Description [Line Items]
Operating lease right-of-use assets			$ 50,433	$ 417
Annual base rent, First year			5,500
Annual base rent, Second year			8,500
Annual base rent, Thereafter			11,100
Leasehold improvements within property and equipment			19,982	$ 15,743
Corporate Headquarters
Lessee Lease Description [Line Items]
Area of leased property \| ft²					129,800
Rent commencement date	2020-01
Additional period of extension in lease contract					10 years
Operating lease right-of-use assets	$ 52,600
Leasehold Improvements
Lessee Lease Description [Line Items]
Leasehold improvements within property and equipment			$ 10,400
Sublease
Lessee Lease Description [Line Items]
Area of leased property \| ft²		34,500
Rent commencement date		2021-03
Operating lease term of contract		9 years
Aggregate future minimum rental payments due		$ 19,900

XML 48 R37.htm IDEA: XBRL DOCUMENT

Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Operating Leases [Abstract]
Operating lease right-of-use assets	$ 50,433	$ 417
Operating lease liabilities - current	7,891	383
Operating lease liabilities - noncurrent	43,717
Operating lease, liability	$ 51,608	$ 383
Weighted average remaining lease term (years)	9 years 3 months 18 days	3 months 18 days
Weighted average discount rate	13.50%	6.00%

XML 49 R38.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Information Related to Operating Lease Activity (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Lease Cost [Abstract]
Operating lease cost	$ 7,103	$ 2,163
Variable lease cost	1,235
Total lease cost	8,338	2,163
Operating lease right-of-use assets obtained in exchange for lease obligations	52,589	1,095
Operating lease payments	$ 5,888	$ 2,330

XML 50 R39.htm IDEA: XBRL DOCUMENT

Leases - Future Annual Payments of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Operating Lease Liabilities Payments Due [Abstract]
2020 (three months remaining)	$ 2,045
2021	8,449
2022	8,745
2023	9,051
2024	9,368
Thereafter	52,442
Total future lease payments	90,100
Less: imputed interest	(38,492)
Total operating lease liabilities	$ 51,608	$ 383

XML 51 R40.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Property Plant And Equipment [Line Items]
Property plant and equipment basis of valuation			cost
Property plant and equipment depreciation methods			the straight-line method over the estimated useful lives of the assets
Depreciation expense	$ 900	$ 500	$ 2,459	$ 1,441
Minimum
Property Plant And Equipment [Line Items]
Property plant and equipment useful life			2 years
Maximum
Property Plant And Equipment [Line Items]
Property plant and equipment useful life			5 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment estimated useful lives			shorter of their estimated useful lives or the related lease term

XML 52 R41.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment	$ 29,542	$ 23,680
Less: Accumulated depreciation	(9,560)	(7,937)
Property and equipment, net	19,982	15,743
Scientific Equipment
Property Plant And Equipment [Line Items]
Property and equipment	13,645	10,642
Furniture and Equipment
Property Plant And Equipment [Line Items]
Property and equipment	3,127	2,572
Capitalized Software
Property Plant And Equipment [Line Items]
Property and equipment	360	389
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment	11,925	509
Property and equipment, net	10,400
Construction in Progress
Property Plant And Equipment [Line Items]
Property and equipment	$ 485	$ 9,568

XML 53 R42.htm IDEA: XBRL DOCUMENT

Balance Sheet Components - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Clinical research and development	$ 5,386	$ 11,494
Outside services	9,987	6,592
Payroll related liabilities	15,935	11,724
Construction in progress	454	9,139
Other	8,281	2,343
Total accrued liabilities	$ 40,043	$ 41,292

XML 54 R43.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Purchase commitment cancellation notice period	30 days
Contingent liability for accrual	$ 0	$ 0

XML 55 R44.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		9 Months Ended
	May 31, 2020	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019	Jan. 03, 2020
Class Of Stock [Line Items]
Proceeds from offering, net of underwriting discounts and commissions and offering expenses			$ 605,064	$ 271,224
Maximum
Class Of Stock [Line Items]
Market offering aggregate offering price					$ 200,000
Follow-On-Offering
Class Of Stock [Line Items]
Common stock shares issued	6,037,500	5,663,750
Common stock shares issued, price per share	$ 105.00	$ 51.00
Proceeds from offering, net of underwriting discounts and commissions and offering expenses			$ 605,000	$ 271,200
Over Allotment Option
Class Of Stock [Line Items]
Common stock shares issued	787,500	738,750

XML 56 R45.htm IDEA: XBRL DOCUMENT

Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Details) - shares	Sep. 30, 2020	Dec. 31, 2019
Class Of Stock [Line Items]
Shares reserved for future issuance, shares	8,568,066	7,141,230
Options and Awards Issued and Outstanding
Class Of Stock [Line Items]
Shares reserved for future issuance, shares	5,656,261	5,315,254
2015 Stock Option and Incentive Plan
Class Of Stock [Line Items]
Shares reserved for future issuance, shares	1,331,844	685,435
2015 Employee Stock Purchase Plan
Class Of Stock [Line Items]
Shares reserved for future issuance, shares	1,579,961	1,140,541

XML 57 R46.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Equity Awards Granted to Employees and Consultants (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 11,347	$ 8,275	$ 32,975	$ 23,894
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	5,621	3,644	16,152	10,402
Selling, general and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 5,726	$ 4,631	$ 16,823	$ 13,492

XML 58 R47.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Stock Option and Other Equity Award Activity Under Plans (Details)	9 Months Ended
	Sep. 30, 2020 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Subject to Outstanding Options, Beginning Balance \| shares	4,574,158
Shares Subject to Outstanding Options, granted \| shares	1,064,174
Shares Subject to Outstanding Options, exercised \| shares	(696,937)
Shares Subject to Outstanding Options, canceled/forfeited \| shares	(240,298)
Shares Subject to Outstanding Options, Ending Balance \| shares	4,701,097
Weighted Average Exercise Price per Share, Beginning Balance \| $ / shares	$ 31.81
Weighted Average Exercise Price Per Share, granted \| $ / shares	74.16
Weighted Average Exercise Price per Share, exercised \| $ / shares	25.72
Weighted Average Exercise Price Per Share, canceled/forfeited \| $ / shares	45.70
Weighted Average Exercise Price Per Share, Ending Balance \| $ / shares	$ 41.59
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Subject to Outstanding Awards, Beginning Balance \| shares	741,096
Shares Subject to Outstanding Awards, RSUs awarded \| shares	450,956
Shares Subject to Outstanding Awards, RSUs released \| shares	(170,809)
Shares Subject to Outstanding Awards, RSUs forfeited \| shares	(66,079)
Shares Subject to Outstanding Awards, Ending Balance \| shares	955,164
Weighted Average Grant Date Fair Value. Beginning Balance \| $ / shares	$ 46.59
Weighted Average Grant Date Fair Value. RSUs awarded \| $ / shares	74.00
Weighted Average Grant Date Fair Value. RSUs released \| $ / shares	45.09
Weighted Average Grant Date Fair Value. RSUs forfeited \| $ / shares	49.81
Weighted Average Grant Date Fair Value. Ending Balance \| $ / shares	$ 59.58

XML 59 R48.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Unrecognized share based compensation expense	$ 0.3	$ 0.0	$ 1.0	$ 0.0

XML 60 R49.htm IDEA: XBRL DOCUMENT

Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Numerator
Net loss	$ (84,744)	$ (63,585)	$ (69,868)	$ (141,802)	$ (38,174)	$ (37,470)	$ (218,197)	$ (217,446)
Denominator
Weighted average shares outstanding	53,101,453			46,133,068			49,860,879	44,258,437
Less: weighted average shares subject to repurchase								(2,780)
Weighted average shares used to compute basic and diluted net loss per share	53,101,453			46,133,068			49,860,879	44,255,657
Net loss per share, basic and diluted	$ (1.60)			$ (3.07)			$ (4.38)	$ (4.91)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 61 R50.htm IDEA: XBRL DOCUMENT

Net Loss per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) - shares	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Options and Awards Issued and Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from earnings per share	5,656,261	5,278,515

XML 62 R51.htm IDEA: XBRL DOCUMENT

Net Loss per Share - Additional Information (Details) - 2015 Employee Stock Purchase Plan - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Line Items]
ESPP contributions from plan participants	$ 1.2	$ 0.8
Contributions converted shares under benefit plan	25,000	20,000
Percentage of stock price at the beginning of offering period	85.00%

XML 63 R52.htm IDEA: XBRL DOCUMENT

Subsequent Events - Additional Information (Details) - Subsequent Event $ / shares in Units, $ in Millions	Oct. 03, 2020 USD ($) $ / shares
Subsequent Event [Line Items]
Business combination, price per share \| $ / shares	$ 225.00
Termination fee \| $	$ 458.0

EXCEL 64 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 66 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 165 322 1 false 46 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Sheet http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 100070 - Disclosure - Organization Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureOrganization Organization Notes 8 false false R9.htm 100080 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 9 false false R10.htm 100090 - Disclosure - License and Collaboration Agreements Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreements License and Collaboration Agreements Notes 10 false false R11.htm 100100 - Disclosure - Fair Value Measurements Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 100110 - Disclosure - Leases Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeases Leases Notes 12 false false R13.htm 100120 - Disclosure - Balance Sheet Components Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponents Balance Sheet Components Notes 13 false false R14.htm 100130 - Disclosure - Commitments and Contingencies Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 100140 - Disclosure - Stockholders' Equity Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 100150 - Disclosure - Stock-Based Compensation Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 16 false false R17.htm 100160 - Disclosure - Net Loss per Share Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShare Net Loss per Share Notes 17 false false R18.htm 100170 - Disclosure - Subsequent Events Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 18 false false R19.htm 100180 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 19 false false R20.htm 100190 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 20 false false R21.htm 100200 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurements 21 false false R22.htm 100210 - Disclosure - Leases (Tables) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeases 22 false false R23.htm 100220 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponents 23 false false R24.htm 100230 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquity 24 false false R25.htm 100240 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensation 25 false false R26.htm 100250 - Disclosure - Net Loss per Share (Tables) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareTables Net Loss per Share (Tables) Tables http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShare 26 false false R27.htm 100260 - Disclosure - Organization - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails Organization - Additional Information (Details) Details 27 false false R28.htm 100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) Details 28 false false R29.htm 100280 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Cash Reported in Condensed Consolidated Statements of Cash Flows (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfCashReportedInCondensedConsolidatedStatementsOfCashFlowsDetails Basis of Presentation and Summary of Significant Accounting Policies - Summary of Cash Reported in Condensed Consolidated Statements of Cash Flows (Details) Details 29 false false R30.htm 100290 - Disclosure - License and Collaboration Agreements - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails License and Collaboration Agreements - Additional Information (Details) Details 30 false false R31.htm 100300 - Disclosure - Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details) Details 31 false false R32.htm 100310 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurement of Available-for-sale Securities (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails Fair Value Measurements - Summary of Fair Value Measurement of Available-for-sale Securities (Details) Details 32 false false R33.htm 100320 - Disclosure - Fair Value Measurements - Summary of Available-for-sale Debt Securities in Continuous Unrealized Loss Position for Less Than and Greater Than Twelve Months (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails Fair Value Measurements - Summary of Available-for-sale Debt Securities in Continuous Unrealized Loss Position for Less Than and Greater Than Twelve Months (Details) Details 33 false false R34.htm 100330 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 34 false false R35.htm 100340 - Disclosure - Fair Value Measurements - Summary of Significant Unobservable Inputs Used to Value Warrant (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails Fair Value Measurements - Summary of Significant Unobservable Inputs Used to Value Warrant (Details) Details 35 false false R36.htm 100350 - Disclosure - Leases - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 36 false false R37.htm 100360 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details) Details 37 false false R38.htm 100370 - Disclosure - Leases - Schedule of Information Related to Operating Lease Activity (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesScheduleOfInformationRelatedToOperatingLeaseActivityDetails Leases - Schedule of Information Related to Operating Lease Activity (Details) Details 38 false false R39.htm 100380 - Disclosure - Leases - Future Annual Payments of Operating Lease Liabilities (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails Leases - Future Annual Payments of Operating Lease Liabilities (Details) Details 39 false false R40.htm 100400 - Disclosure - Balance Sheet Components - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails Balance Sheet Components - Additional Information (Details) Details 40 false false R41.htm 100410 - Disclosure - Balance Sheet Components - Summary of Property and Equipment (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails Balance Sheet Components - Summary of Property and Equipment (Details) Details 41 false false R42.htm 100420 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails Balance Sheet Components - Summary of Accrued Liabilities (Details) Details 42 false false R43.htm 100430 - Disclosure - Commitments and Contingencies - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments and Contingencies - Additional Information (Details) Details 43 false false R44.htm 100440 - Disclosure - Stockholders' Equity - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails Stockholders' Equity - Additional Information (Details) Details 44 false false R45.htm 100450 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Details) Details 45 false false R46.htm 100460 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Equity Awards Granted to Employees and Consultants (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToEquityAwardsGrantedToEmployeesAndConsultantsDetails Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Equity Awards Granted to Employees and Consultants (Details) Details 46 false false R47.htm 100470 - Disclosure - Stock-Based Compensation - Summary of Stock Option and Other Equity Award Activity Under Plans (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails Stock-Based Compensation - Summary of Stock Option and Other Equity Award Activity Under Plans (Details) Details 47 false false R48.htm 100480 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 48 false false R49.htm 100490 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details) Details 49 false false R50.htm 100500 - Disclosure - Net Loss per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails Net Loss per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details) Details 50 false false R51.htm 100510 - Disclosure - Net Loss per Share - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails Net Loss per Share - Additional Information (Details) Details 51 false false R52.htm 100520 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 52 false false All Reports Book All Reports myok-10q_20200930.htm myok-20200930.xsd myok-20200930_cal.xml myok-20200930_def.xml myok-20200930_lab.xml myok-20200930_pre.xml myok-ex101_331.htm myok-ex311_7.htm myok-ex312_9.htm myok-ex321_6.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 70 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "myok-10q_20200930.htm": { "axisCustom": 0, "axisStandard": 19, "contextCount": 165, "dts": { "calculationLink": { "local": [ "myok-20200930_cal.xml" ] }, "definitionLink": { "local": [ "myok-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "myok-10q_20200930.htm" ] }, "labelLink": { "local": [ "myok-20200930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "myok-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "myok-20200930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 405, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 6, "http://www.myokardia.com/20200930": 1, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 12 }, "keyCustom": 43, "keyStandard": 279, "memberCustom": 16, "memberStandard": 29, "nsprefix": "myok", "nsuri": "http://www.myokardia.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - License and Collaboration Agreements", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreements", "shortName": "License and Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Fair Value Measurements", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Leases", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Balance Sheet Components", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponents", "shortName": "Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Commitments and Contingencies", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Stockholders' Equity", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Stock-Based Compensation", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Net Loss per Share", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShare", "shortName": "Net Loss per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Subsequent Events", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "lang": null, "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "myok:ReconciliationOfCashCashEquivalentsAndRestrictedCashAsReportedInConsolidatedStatementsOfCashFlowsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "myok:SummaryOfCashBalancesInConsolidatedCashFlowTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "myok:ReconciliationOfCashCashEquivalentsAndRestrictedCashAsReportedInConsolidatedStatementsOfCashFlowsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "myok:SummaryOfCashBalancesInConsolidatedCashFlowTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "myok:LesseeOperatingLeaseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Leases (Tables)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "myok:LesseeOperatingLeaseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Balance Sheet Components (Tables)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsTables", "shortName": "Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "myok:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "myok:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Net Loss per Share (Tables)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareTables", "shortName": "Net Loss per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Organization - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails", "shortName": "Organization - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200501_20200531", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_myokSegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_myokSegment", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Cash Reported in Condensed Consolidated Statements of Cash Flows (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfCashReportedInCondensedConsolidatedStatementsOfCashFlowsDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Summary of Cash Reported in Condensed Consolidated Statements of Cash Flows (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "myok:SummaryOfCashBalancesInConsolidatedCashFlowTableTextBlock", "myok:ReconciliationOfCashCashEquivalentsAndRestrictedCashAsReportedInConsolidatedStatementsOfCashFlowsPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "lang": null, "name": "us-gaap:RestrictedCashCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200811", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - License and Collaboration Agreements - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "shortName": "License and Collaboration Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_srtCounterpartyNameAxis_myokLicenseAgreementMember_us-gaapTypeOfArrangementAxis_myokExclusiveLicenseAgreementMember_20200801_20200831", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromLicenseFeesReceived", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Fair Value Assets Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Fair Value Measurements - Summary of Fair Value Measurement of Available-for-sale Securities (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails", "shortName": "Fair Value Measurements - Summary of Fair Value Measurement of Available-for-sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Fair Value Measurements - Summary of Available-for-sale Debt Securities in Continuous Unrealized Loss Position for Less Than and Greater Than Twelve Months (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails", "shortName": "Fair Value Measurements - Summary of Available-for-sale Debt Securities in Continuous Unrealized Loss Position for Less Than and Greater Than Twelve Months (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200811", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200701_20200930", "decimals": "INF", "lang": null, "name": "us-gaap:GainLossOnSaleOfDerivatives", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20200930", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Fair Value Measurements - Summary of Significant Unobservable Inputs Used to Value Warrant (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails", "shortName": "Fair Value Measurements - Summary of Significant Unobservable Inputs Used to Value Warrant (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_20200930", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Leases - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "shortName": "Leases - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:LesseeOperatingLeasesTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-5", "lang": null, "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails", "shortName": "Leases - Supplemental Balance Sheet Information Related to Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "myok:LesseeOperatingLeaseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "3", "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "myok:LesseeOperatingLeaseActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Leases - Schedule of Information Related to Operating Lease Activity (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesScheduleOfInformationRelatedToOperatingLeaseActivityDetails", "shortName": "Leases - Schedule of Information Related to Operating Lease Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "myok:LesseeOperatingLeaseActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Leases - Future Annual Payments of Operating Lease Liabilities (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails", "shortName": "Leases - Future Annual Payments of Operating Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200701_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "role": "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200701_20200930", "decimals": "-3", "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentBasisOfValuation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Balance Sheet Components - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "shortName": "Balance Sheet Components - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentBasisOfValuation", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Balance Sheet Components - Summary of Property and Equipment (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "shortName": "Balance Sheet Components - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "myok:AccruedClinicalResearchAndDevelopmentCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails", "shortName": "Balance Sheet Components - Summary of Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "-3", "first": true, "lang": null, "name": "myok:AccruedClinicalResearchAndDevelopmentCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "myok:PurchaseCommitmentCancellationNoticePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "myok:PurchaseCommitmentCancellationNoticePeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Stockholders' Equity - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "Stockholders' Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_srtRangeAxis_srtMaximumMember_20200103", "decimals": "-5", "lang": null, "name": "myok:AtTheMarketOfferingAggregateOfferingPrice", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "myok:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails", "shortName": "Stockholders' Equity - Schedule of Common Stock Reserved for Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "myok:ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200701_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Equity Awards Granted to Employees and Consultants (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToEquityAwardsGrantedToEmployeesAndConsultantsDetails", "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Related to Equity Awards Granted to Employees and Consultants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200701_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Stock-Based Compensation - Summary of Stock Option and Other Equity Award Activity Under Plans (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails", "shortName": "Stock-Based Compensation - Summary of Stock Option and Other Equity Award Activity Under Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200701_20200930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200701_20200930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200701_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "shortName": "Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200701_20200930", "decimals": "0", "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20190101_20190331", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Net Loss per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails", "shortName": "Net Loss per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200930", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_us-gaapPlanNameAxis_myokTwoThousandFifteenEmployeeStockPurchasePlanMember_20200101_20200930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Net Loss per Share - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "shortName": "Net Loss per Share - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_us-gaapPlanNameAxis_myokTwoThousandFifteenEmployeeStockPurchasePlanMember_20200101_20200930", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201003", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Subsequent Events - Additional Information (Details)", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201003", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionSharePrice", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200701_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "role": "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - Organization", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureOrganization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "role": "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "myok-10q_20200930.htm", "contextRef": "C_0001552451_20200101_20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 46, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "verboseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "verboseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r388" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r389" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r391" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r390" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r386" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "myok_AccruedClinicalResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued clinical research and development current.", "label": "Accrued Clinical Research And Development Current", "terseLabel": "Clinical research and development" } } }, "localname": "AccruedClinicalResearchAndDevelopmentCurrent", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "myok_AdditionalProceedsFromLicenseFeesReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Additional proceeds from license fees received.", "label": "Additional Proceeds From License Fees Received", "terseLabel": "Additional proceeds from license fees received" } } }, "localname": "AdditionalProceedsFromLicenseFeesReceived", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_AtTheMarketOfferingAggregateOfferingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "At the market offering aggregate offering price.", "label": "At The Market Offering Aggregate Offering Price", "terseLabel": "Market offering aggregate offering price" } } }, "localname": "AtTheMarketOfferingAggregateOfferingPrice", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_AventisIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aventis Inc.", "label": "Aventis Inc [Member]", "terseLabel": "Sanofi (Aventis Inc.)" } } }, "localname": "AventisIncMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of presentation and summary of significant accounting policies.", "label": "Basis Of Presentation And Summary Of Significant Accounting Policies [Abstract]" } } }, "localname": "BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAbstract", "nsuri": "http://www.myokardia.com/20200930", "xbrltype": "stringItemType" }, "myok_CashConsiderationReceivedFromRelatedParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Cash consideration received from related party.", "label": "Cash Consideration Received From Related Party", "terseLabel": "Cash consideration" } } }, "localname": "CashConsiderationReceivedFromRelatedParty", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_ClassOfWarrantsOrRightsIssued": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Class of warrants or rights issued.", "label": "Class Of Warrants Or Rights Issued", "terseLabel": "Warrant to purchase ordinary shares" } } }, "localname": "ClassOfWarrantsOrRightsIssued", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "myok_CollaborationAndLicenseAgreementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaboration and license agreement disclosure.", "label": "Collaboration And License Agreement Disclosure [Abstract]" } } }, "localname": "CollaborationAndLicenseAgreementDisclosureAbstract", "nsuri": "http://www.myokardia.com/20200930", "xbrltype": "stringItemType" }, "myok_CommonStockSubjectToRepurchaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common stock subject to repurchase.", "label": "Common Stock Subject To Repurchase [Member]", "terseLabel": "Common stock subject to repurchase" } } }, "localname": "CommonStockSubjectToRepurchaseMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "myok_ConstructionInProgressAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Construction in progress accrued liabilities current.", "label": "Construction In Progress Accrued Liabilities Current", "terseLabel": "Construction in progress" } } }, "localname": "ConstructionInProgressAccruedLiabilitiesCurrent", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "myok_CoporateBondsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Coporate bonds.", "label": "Coporate Bonds [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CoporateBondsMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails" ], "xbrltype": "domainItemType" }, "myok_CorporateHeadquartersMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters.", "label": "Corporate Headquarters [Member]", "terseLabel": "Corporate Headquarters" } } }, "localname": "CorporateHeadquartersMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings per share.", "label": "Earnings Per Share [Line Items]", "terseLabel": "Earnings Per Share [Line Items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "myok_EarningsPerShareTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings per share.", "label": "Earnings Per Share [Table]", "terseLabel": "Earnings Per Share [Table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "myok_ExclusiveLicenseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Exclusive license agreement.", "label": "Exclusive License Agreement [Member]", "terseLabel": "Exclusive License Agreement" } } }, "localname": "ExclusiveLicenseAgreementMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_FinancingEventOccurringDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financing event occurring date.", "label": "Financing Event Occurring Date", "terseLabel": "Financing event occurring date" } } }, "localname": "FinancingEventOccurringDate", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "myok_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Follow on offering.", "label": "Follow On Offering [Member]", "terseLabel": "Follow-On-Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_FulcrumTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fulcrum Therapeutics, Inc.", "label": "Fulcrum Therapeutics Inc [Member]", "terseLabel": "Fulcrum Therapeutics Inc" } } }, "localname": "FulcrumTherapeuticsIncMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_IncomeTaxBenefitOfUnrealizedGainsOnInvestments": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Income tax benefit of unrealized gains on investments.", "label": "Income Tax Benefit Of Unrealized Gains On Investments", "negatedLabel": "Income tax benefit of unrealized gains on investments" } } }, "localname": "IncomeTaxBenefitOfUnrealizedGainsOnInvestments", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_IncreaseDecreaseInConsiderationReceivedFromRelatedParty": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) in consideration received from related party.", "label": "Increase Decrease In Consideration Received From Related Party", "terseLabel": "Consideration received from related party" } } }, "localname": "IncreaseDecreaseInConsiderationReceivedFromRelatedParty", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase decrease in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase decrease in operating lease right-of-use assets.", "label": "Increase Decrease In Operating Lease Right Of Use Assets", "negatedLabel": "Operating lease right-of-use assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_InterestAndOtherIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10060.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Interest and other income (expense), net.", "label": "Interest And Other Income Expense Net", "terseLabel": "Interest and other income, net" } } }, "localname": "InterestAndOtherIncomeExpenseNet", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_InvestmentsCashAndCashEquivalents": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment cash and cash equivalent.", "label": "Investments Cash And Cash Equivalents", "terseLabel": "Cash, cash equivalents and investments" } } }, "localname": "InvestmentsCashAndCashEquivalents", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_LegalProceedingsRelatedToOfferAndMergerPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal proceedings related to the offer and the merger.", "label": "Legal Proceedings Related To Offer And Merger Policy [Text Block]", "terseLabel": "Legal Proceedings Related to the Offer and the Merger" } } }, "localname": "LegalProceedingsRelatedToOfferAndMergerPolicyTextBlock", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "myok_LesseeOperatingLeaseActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee operating lease activity.", "label": "Lessee Operating Lease Activity Table [Text Block]", "terseLabel": "Schedule of Information Related to Operating Lease Activity" } } }, "localname": "LesseeOperatingLeaseActivityTableTextBlock", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "myok_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails": { "order": 10060.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee operating lease liability payments due after year four .", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "myok_LesseeOperatingLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of lessee operating lease.", "label": "Lessee Operating Lease Table [Text Block]", "terseLabel": "Supplemental Balance Sheet Information Related to Operating Leases" } } }, "localname": "LesseeOperatingLeaseTableTextBlock", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "myok_LianBioAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lianbio agreement.", "label": "Lian Bio Agreement [Member]", "terseLabel": "LianBio Agreement" } } }, "localname": "LianBioAgreementMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_LianBioLicencisingLLCMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "LianBio Licencising,, LLC.", "label": "Lian Bio Licencising L L C [Member]", "terseLabel": "LianBio Licencising,, LLC." } } }, "localname": "LianBioLicencisingLLCMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "License agreement.", "label": "License Agreement [Member]", "terseLabel": "LianBio Licencising,, LLC." } } }, "localname": "LicenseAgreementMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_LongTermInvestmentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long term investments.", "label": "Long Term Investments [Member]", "terseLabel": "Long-term investments (due between one and two years)" } } }, "localname": "LongTermInvestmentsMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "myok_MilestonePaymentsEligibleForAFollowOnTarget": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Milestone payments eligible for a follow-on target.", "label": "Milestone Payments Eligible For A Follow On Target", "terseLabel": "Milestone payments eligible for a follow-on target" } } }, "localname": "MilestonePaymentsEligibleForAFollowOnTarget", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_MilestonePaymentsEligibleForAdditionalCardiomyopathyTarget": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Milestone payments eligible for additional cardiomyopathy target.", "label": "Milestone Payments Eligible For Additional Cardiomyopathy Target", "terseLabel": "Milestone payments eligible for additional cardiomyopathy target" } } }, "localname": "MilestonePaymentsEligibleForAdditionalCardiomyopathyTarget", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_MultiTargetCollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Multi target collaboration and license agreement.", "label": "Multi Target Collaboration And License Agreement [Member]", "terseLabel": "Multi-Target Collaboration and License Agreement" } } }, "localname": "MultiTargetCollaborationAndLicenseAgreementMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_NegotiationPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Negotiation period.", "label": "Negotiation Period", "terseLabel": "Negotiation period" } } }, "localname": "NegotiationPeriod", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "myok_NonCashExerciseOfStockOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Non cash exercise of stock options.", "label": "Non Cash Exercise Of Stock Options", "terseLabel": "Non-cash exercise of stock options" } } }, "localname": "NonCashExerciseOfStockOptions", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_OperatingLeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating leases.", "label": "Operating Leases [Abstract]" } } }, "localname": "OperatingLeasesAbstract", "nsuri": "http://www.myokardia.com/20200930", "xbrltype": "stringItemType" }, "myok_OutsideServicesAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Outside services accrued liabilities current.", "label": "Outside Services Accrued Liabilities Current", "terseLabel": "Outside services" } } }, "localname": "OutsideServicesAccruedLiabilitiesCurrent", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "myok_PayableToReacquireResearchAndDevelopmentAsset": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payable to reacquire research and development asset.", "label": "Payable To Reacquire Research And Development Asset", "terseLabel": "Amount Payable to reacquire research and development asset" } } }, "localname": "PayableToReacquireResearchAndDevelopmentAsset", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_PaymentOfLicenseFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payment of license fees.", "label": "Payment Of License Fees", "verboseLabel": "Payment of license fees" } } }, "localname": "PaymentOfLicenseFees", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_PercentageOfCommonStockRepresentsWarrants": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of common stock represents warrants.", "label": "Percentage Of Common Stock Represents Warrants", "terseLabel": "Percentage of ordinary shares represents warrants" } } }, "localname": "PercentageOfCommonStockRepresentsWarrants", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "myok_PrepaidResearchFundingAtCloseOfTransaction": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Prepaid research funding at close of transaction.", "label": "Prepaid Research Funding At Close Of Transaction", "terseLabel": "Prepaid research funding at close of transaction" } } }, "localname": "PrepaidResearchFundingAtCloseOfTransaction", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_PrepaymentFromCollaborationPartner": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Prepayment from collaboration partner.", "label": "Prepayment From Collaboration Partner", "negatedLabel": "Prepayment from collaboration partner" } } }, "localname": "PrepaymentFromCollaborationPartner", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from exercise of stock options and employee stock purchase plan.", "label": "Proceeds From Exercise Of Stock Options And Employee Stock Purchase Plan", "terseLabel": "Proceeds from exercise of stock options and employee stock purchase plan" } } }, "localname": "ProceedsFromExerciseOfStockOptionsAndEmployeeStockPurchasePlan", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_ProceedsFromMaturitiesOfInvestments": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from maturities of investments.", "label": "Proceeds From Maturities Of Investments", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromMaturitiesOfInvestments", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_ProceedsFromSalesOfInvestments": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from sales of investments.", "label": "Proceeds From Sales Of Investments", "terseLabel": "Sales of investments" } } }, "localname": "ProceedsFromSalesOfInvestments", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_PurchaseCommitmentCancellationNoticePeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase commitment cancellation notice period.", "label": "Purchase Commitment Cancellation Notice Period", "terseLabel": "Purchase commitment cancellation notice period" } } }, "localname": "PurchaseCommitmentCancellationNoticePeriod", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "myok_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recently adopted accounting pronouncements.", "label": "Recently Adopted Accounting Pronouncements Policy [Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "myok_ReconciliationOfCashCashEquivalentsAndRestrictedCashAsReportedInConsolidatedStatementsOfCashFlowsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Reconciliation of cash cash equivalents and restricted cash as reported in consolidated statements of cash flows.", "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash As Reported In Consolidated Statements Of Cash Flows Policy [Text Block]", "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash as Reported in Consolidated Statements of Cash Flows" } } }, "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashAsReportedInConsolidatedStatementsOfCashFlowsPolicyTextBlock", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "myok_RegulatoryMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Regulatory milestone payments.", "label": "Regulatory Milestone Payments", "terseLabel": "Regulatory milestone payments" } } }, "localname": "RegulatoryMilestonePayments", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_RentCommencementDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rent commencement date.", "label": "Rent Commencement Date", "terseLabel": "Rent commencement date" } } }, "localname": "RentCommencementDate", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "gYearMonthItemType" }, "myok_ResearchDevelopmentAndCommercialMilestonePaymentsAndAdditionalResearchReimbursement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Research, development and commercial milestone payments and additional research reimbursement.", "label": "Research Development And Commercial Milestone Payments And Additional Research Reimbursement", "terseLabel": "Research, development and commercial milestone payments and additional research reimbursements" } } }, "localname": "ResearchDevelopmentAndCommercialMilestonePaymentsAndAdditionalResearchReimbursement", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_RestrictedCashAndOtherNoncurrentAssets": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restricted cash and other noncurrent assets.", "label": "Restricted Cash And Other Noncurrent Assets", "terseLabel": "Restricted cash and other" } } }, "localname": "RestrictedCashAndOtherNoncurrentAssets", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_RoyaltyRightsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty rights.", "label": "Royalty Rights [Member]", "terseLabel": "Royalty Rights" } } }, "localname": "RoyaltyRightsMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_SalesMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sales milestone payments.", "label": "Sales Milestone Payments", "terseLabel": "Sales milestone payments" } } }, "localname": "SalesMilestonePayments", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_ScheduleOfCommonStockReservedForIssuanceTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of common stock reserved for issuance.", "label": "Schedule Of Common Stock Reserved For Issuance Table [Text Block]", "terseLabel": "Schedule of Common Stock Reserved for Issuance" } } }, "localname": "ScheduleOfCommonStockReservedForIssuanceTableTextBlock", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "myok_SubleasedPropertyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sublease.", "label": "Subleased Property [Member]", "terseLabel": "Sublease" } } }, "localname": "SubleasedPropertyMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_SummaryOfCashBalancesInConsolidatedCashFlowTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of cash balances in consolidated cash flow.", "label": "Summary Of Cash Balances In Consolidated Cash Flow Table [Text Block]", "terseLabel": "Summary of Cash Reported in Condensed Consolidated Statements of Cash Flows" } } }, "localname": "SummaryOfCashBalancesInConsolidatedCashFlowTableTextBlock", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "myok_TerminationAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Termination agreement.", "label": "Termination Agreement [Member]", "terseLabel": "Termination Agreement" } } }, "localname": "TerminationAgreementMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "myok_TerminationFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Termination fee.", "label": "Termination Fee", "terseLabel": "Termination fee" } } }, "localname": "TerminationFee", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "myok_TwoThousandFifteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand fifteen employee stock purchase plan.", "label": "Two Thousand Fifteen Employee Stock Purchase Plan [Member]", "terseLabel": "2015 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandFifteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails" ], "xbrltype": "domainItemType" }, "myok_TwoThousandFifteenStockOptionAndIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two thousand fifteen stock option and incentive plan.", "label": "Two Thousand Fifteen Stock Option And Incentive Plan [Member]", "terseLabel": "2015 Stock Option and Incentive Plan" } } }, "localname": "TwoThousandFifteenStockOptionAndIncentivePlanMember", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails" ], "xbrltype": "domainItemType" }, "myok_VestingOfEarlyExercisedOptionsAndRestrictedStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Vesting of early exercised options and restricted stock.", "label": "Vesting Of Early Exercised Options And Restricted Stock", "verboseLabel": "Vesting of early exercised options and restricted stock" } } }, "localname": "VestingOfEarlyExercisedOptionsAndRestrictedStock", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "myok_VestingOfEarlyExercisedStockOptions": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Vesting of early exercised stock options.", "label": "Vesting Of Early Exercised Stock Options", "terseLabel": "Vesting of early exercised stock options" } } }, "localname": "VestingOfEarlyExercisedStockOptions", "nsuri": "http://www.myokardia.com/20200930", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r46", "r88" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r197", "r198", "r301", "r302", "r303", "r304", "r305", "r306", "r325", "r355", "r357" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r197", "r198", "r301", "r302", "r303", "r304", "r305", "r306", "r325", "r355", "r357" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r132", "r185", "r186", "r326", "r354", "r356" ], "lang": { "en-US": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r132", "r185", "r186", "r326", "r354", "r356" ], "lang": { "en-US": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r188", "r197", "r198", "r301", "r302", "r303", "r304", "r305", "r306", "r325", "r355", "r357" ], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r188", "r197", "r198", "r301", "r302", "r303", "r304", "r305", "r306", "r325", "r355", "r357" ], "lang": { "en-US": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r76" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Amortization of discount on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r33", "r162" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r50", "r51", "r52", "r344", "r362", "r363" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10070.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r49", "r52", "r53", "r91", "r92", "r93", "r243", "r358", "r359" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Income/ (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r19" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r91", "r92", "r93", "r220", "r221", "r222" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r199", "r201", "r225", "r226" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r175", "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs", "terseLabel": "Adjustment for issuance costs", "verboseLabel": "Issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r201", "r218", "r224" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToEquityAwardsGrantedToEmployeesAndConsultantsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area of a real estate property.", "label": "Area Of Real Estate Property", "terseLabel": "Area of leased property" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r85", "r124", "r126", "r130", "r145", "r239", "r244", "r261", "r328", "r343" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r44", "r85", "r145", "r239", "r244", "r261" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Assets fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecurities": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.", "label": "Available For Sale Securities", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r134" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Unrealized Gain" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Unrealized Loss" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available For Sale Securities Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.", "label": "Available For Sale Securities Continuous Unrealized Loss Position Fair Value Table [Text Block]", "terseLabel": "Summary of Available-for-sale Debt Securities in Continuous Unrealized Loss Position for Less Than and Greater Than Twelve Months" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r202", "r219" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition Share Price", "terseLabel": "Business combination, price per share" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r78", "r79", "r80" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Unpaid portion of property and equipment purchases included in period-end accounts payable and accrued liabilities" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r28", "r77" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfCashReportedInCondensedConsolidatedStatementsOfCashFlowsDetails": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 }, "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10220.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfCashReportedInCondensedConsolidatedStatementsOfCashFlowsDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash And Cash Equivalents [Member]", "terseLabel": "Cash equivalents (due within 90 days)" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r71", "r77", "r81" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfCashReportedInCondensedConsolidatedStatementsOfCashFlowsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfCashReportedInCondensedConsolidatedStatementsOfCashFlowsDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r71", "r262" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r183", "r200" ], "lang": { "en-US": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r176" ], "lang": { "en-US": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Warrants exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Outstanding", "terseLabel": "Number of warrants" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r234", "r235", "r237" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "License and Collaboration Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r169", "r332", "r348" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r166", "r167", "r168", "r170" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r82", "r171", "r381", "r382" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments And Contingencies Policy [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r42" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Shares reserved for future issuance, shares" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r91", "r92" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r175" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.0001 par value, 150,000,000 shares authorized at September 30, 2020 and December 31, 2019; 53,308,689 and 46,379,073 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r56", "r58", "r59", "r64", "r336", "r351" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction In Progress [Member]", "terseLabel": "Construction in Progress" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r189", "r196", "r364" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r142", "r155", "r158" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails": { "order": 10040.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer", "terseLabel": "Fair Value, 12 months or greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [ "r142", "r155" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails": { "order": 10020.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss", "negatedLabel": "Unrealized Loss, 12 months or greater" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r142", "r155", "r158" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails": { "order": 10030.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months", "terseLabel": "Fair Value, Less than 12 Months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r142", "r155" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails": { "order": 10010.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss", "negatedLabel": "Unrealized Loss, Less than 12 Months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r139", "r152", "r158" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities Available For Sale Unrealized Loss Position", "totalLabel": "Fair Value, Total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r140", "r153" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss", "negatedTotalLabel": "Unrealized Loss, Total" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r25" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue Noncurrent", "terseLabel": "Total consideration" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.", "label": "Defined Benefit Plan Benefit Obligation Contributions By Plan Participant", "terseLabel": "ESPP contributions from plan participants" } } }, "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r75", "r160" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetsNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Assets Noncurrent", "terseLabel": "Related party warrant derivative asset" } } }, "localname": "DerivativeAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r3", "r11", "r18", "r87", "r291" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due From Related Parties Current", "terseLabel": "Consideration due from related party" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedPartiesNoncurrent": { "auth_ref": [ "r29", "r89", "r291" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).", "label": "Due From Related Parties Noncurrent", "terseLabel": "Consideration due from related party non-current" } } }, "localname": "DueFromRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesNoncurrent": { "auth_ref": [ "r38", "r89", "r291" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.", "label": "Due To Related Parties Noncurrent", "terseLabel": "Related party liability" } } }, "localname": "DueToRelatedPartiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r108", "r109", "r110", "r111" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Payroll related liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToEquityAwardsGrantedToEmployeesAndConsultantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r218" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Tax Benefit From Compensation Expense", "verboseLabel": "Unrecognized share based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r216" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Options and Awards Issued and Outstanding" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r91", "r92", "r93", "r95", "r100", "r102", "r112", "r146", "r175", "r182", "r220", "r221", "r222", "r230", "r231", "r263", "r264", "r265", "r266", "r267", "r269", "r358", "r359", "r360" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r249", "r250", "r251", "r257" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r249", "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value Assets Measured On Recurring Basis [Text Block]", "terseLabel": "Summary of Fair Value Assets Measured on Recurring Basis" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r249", "r257" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r250", "r298", "r299", "r300" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r249", "r250", "r253", "r254", "r258" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r256" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r189", "r190", "r195", "r196", "r250", "r298" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r189", "r190", "r195", "r196", "r250", "r299" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r250", "r300" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r298", "r299", "r300" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r256", "r258" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value Measurements on Recurring Basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r82", "r259", "r260" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r137", "r138", "r147", "r148", "r149", "r150", "r151", "r154", "r156", "r157", "r158", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfDerivatives": { "auth_ref": [ "r75", "r337" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.", "label": "Gain Loss On Sale Of Derivatives", "terseLabel": "Gain or loss on sale of derivatives" } } }, "localname": "GainLossOnSaleOfDerivatives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r75" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain Loss On Sale Of Property Plant Equipment", "negatedLabel": "Loss on disposal of equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteesIndemnificationsAndWarrantiesPolicies": { "auth_ref": [ "r82", "r171" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for guarantees, indemnifications and product warranties, and methodologies used in determining the amount of such liabilities.", "label": "Guarantees Indemnifications And Warranties Policies", "terseLabel": "Guarantees and Indemnifications" } } }, "localname": "GuaranteesIndemnificationsAndWarrantiesPolicies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r61", "r124", "r125", "r128", "r129", "r131", "r327", "r333", "r338", "r352" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10030.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToEquityAwardsGrantedToEmployeesAndConsultantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToEquityAwardsGrantedToEmployeesAndConsultantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r86", "r101", "r102", "r123", "r229", "r232", "r233", "r353" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10040.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r74" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r74" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase Decrease In Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Change in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r74" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase Decrease In Other Noncurrent Assets", "negatedLabel": "Other long-term assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.", "label": "Increase Decrease In Other Noncurrent Liabilities", "negatedLabel": "Other long-term liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r74" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investment Type Categorization [Member]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r286", "r288" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesScheduleOfInformationRelatedToOperatingLeaseActivityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesScheduleOfInformationRelatedToOperatingLeaseActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lease Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r161" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee Disclosure [Abstract]" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Schedule of Future Annual Payment of Operating Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r287" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total future lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r287" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r287" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r287" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r287" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r287" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year", "terseLabel": "2020 (three months remaining)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r287" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Renewal Term", "terseLabel": "Additional period of extension in lease contract" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r278" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Term Of Contract", "terseLabel": "Operating lease term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor Operating Lease Payments To Be Received Next Twelve Months", "terseLabel": "Annual base rent, First year" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor Operating Lease Payments To Be Received Thereafter", "terseLabel": "Annual base rent, Thereafter" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessor Operating Lease Payments To Be Received Two Years", "terseLabel": "Annual base rent, Second year" } } }, "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r35", "r85", "r127", "r145", "r240", "r244", "r245", "r261" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r85", "r145", "r261", "r329", "r346" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r37", "r85", "r145", "r240", "r244", "r245", "r261" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r30" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long Term Investments", "terseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r169" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual At Carrying Value", "terseLabel": "Contingent liability for accrual" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment [Member]", "terseLabel": "Scientific Equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input Discount Rate [Member]", "terseLabel": "Significant Unobservable Inputs, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input Expected Dividend Rate [Member]", "terseLabel": "Significant Unobservable Inputs, Dividend Yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input Expected Term [Member]", "terseLabel": "Significant Unobservable Inputs, Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input Price Volatility [Member]", "terseLabel": "Significant Unobservable Inputs, Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input Risk Free Interest Rate [Member]", "terseLabel": "Significant Unobservable Inputs, Risk-Free-Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r252" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r189" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flow from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r71" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flow from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r71", "r73", "r76" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flow from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r54", "r57", "r62", "r76", "r85", "r94", "r96", "r97", "r98", "r99", "r101", "r102", "r105", "r124", "r125", "r128", "r129", "r131", "r145", "r261", "r334", "r349" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income Loss [Abstract]", "terseLabel": "Numerator" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing And Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reportable and operating segment" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10070.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r124", "r125", "r128", "r129", "r131" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10050.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r280", "r288" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesScheduleOfInformationRelatedToOperatingLeaseActivityDetails": { "order": 10010.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesScheduleOfInformationRelatedToOperatingLeaseActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Lease Liabilities Payments Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r274" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "totalLabel": "Operating lease, liability", "verboseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesFutureAnnualPaymentsOfOperatingLeaseLiabilitiesDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r274" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Operating lease liabilities - current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r274" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liability", "verboseLabel": "Operating lease liabilities - noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List", "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r276", "r282" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesScheduleOfInformationRelatedToOperatingLeaseActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r273" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r285", "r288" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r284", "r288" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted average remaining lease term (years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesSupplementalBalanceSheetInformationRelatedToOperatingLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r271", "r272" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases Future Minimum Payments Due", "terseLabel": "Aggregate future minimum rental payments due" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r248" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureOrganization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r36" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails": { "order": 10050.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r55", "r58", "r60", "r63", "r175", "r263", "r268", "r269", "r335", "r350" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r48", "r50" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized gains (loss), net of tax expense (benefit)" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Over Allotment Option" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r68" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments To Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r67" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r202", "r219" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r26", "r27" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10250.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds From Issuance Initial Public Offering", "terseLabel": "Proceeds from follow-on offering" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r69" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Proceeds from issuance of common stock in follow-on offerings, net of issuance costs", "verboseLabel": "Proceeds from offering, net of underwriting discounts and commissions and offering expenses" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLicenseFeesReceived": { "auth_ref": [ "r72" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received from licensees for license fees during the current period.", "label": "Proceeds From License Fees Received", "terseLabel": "Proceeds from license fees received" } } }, "localname": "ProceedsFromLicenseFeesReceived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r54", "r57", "r70", "r85", "r94", "r101", "r102", "r124", "r125", "r128", "r129", "r131", "r145", "r238", "r241", "r242", "r246", "r247", "r261", "r338" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentBasisOfValuation": { "auth_ref": [ "r31" ], "lang": { "en-US": { "role": { "documentation": "Describes the basis at which an entity records its property, plant and equipment (for example at cost, fair value).", "label": "Property Plant And Equipment Basis Of Valuation", "terseLabel": "Property plant and equipment basis of valuation" } } }, "localname": "PropertyPlantAndEquipmentBasisOfValuation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r33", "r164" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDepreciationMethods": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Description of the methodology for computing depreciation for classes of depreciable assets.", "label": "Property Plant And Equipment Depreciation Methods", "terseLabel": "Property plant and equipment depreciation methods" } } }, "localname": "PropertyPlantAndEquipmentDepreciationMethods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r82", "r159" ], "lang": { "en-US": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Property Plant And Equipment Estimated Useful Lives", "terseLabel": "Property plant and equipment estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r32", "r161" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r164", "r347" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10170.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "verboseLabel": "Leasehold improvements within property and equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r31", "r82", "r164", "r383", "r384" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r12", "r164" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Summary of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r12", "r161" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Property plant and equipment useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r228", "r385" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10080.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToEquityAwardsGrantedToEmployeesAndConsultantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r2", "r10", "r81" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfCashReportedInCondensedConsolidatedStatementsOfCashFlowsDetails": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Current", "terseLabel": "Restricted cash included in prepaid expenses and other current assets" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfCashReportedInCondensedConsolidatedStatementsOfCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r6", "r14", "r81", "r380" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfCashReportedInCondensedConsolidatedStatementsOfCashFlowsDetails": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "terseLabel": "Restricted cash included in restricted cash and other" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfCashReportedInCondensedConsolidatedStatementsOfCashFlowsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r182", "r223", "r345", "r361", "r363" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureOrganizationAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r91", "r92", "r93", "r95", "r100", "r102", "r146", "r220", "r221", "r222", "r230", "r231", "r358", "r360" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r283", "r288" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Operating lease right-of-use assets obtained in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesScheduleOfInformationRelatedToOperatingLeaseActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r65" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10100.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Repurchase of royalty rights" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule Of Accrued Liabilities Table [Text Block]", "terseLabel": "Summary of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r108" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Available For Sale Securities [Line Items]", "terseLabel": "Schedule Of Available For Sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]", "terseLabel": "Summary of Fair Value Measurement of Available-for-sale Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r135", "r136", "r141", "r142", "r143", "r144", "r340", "r341" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule Of Available For Sale Securities [Table]", "terseLabel": "Schedule Of Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Computation of Basic and Diluted Net Loss per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.", "label": "Schedule Of Effect Of Significant Unobservable Inputs Changes In Plan Assets Table [Text Block]", "terseLabel": "Summary of Significant Unobservable Inputs Used to Value Warrant" } } }, "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r201", "r217", "r224" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToEquityAwardsGrantedToEmployeesAndConsultantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r201", "r217", "r224" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense Related to Equity Awards Granted to Employees and Consultants" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r33", "r164" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r209", "r214", "r215" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Activity Table [Text Block]", "terseLabel": "Summary of Stock Option and Other Equity Award Activity Under Plans" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r202", "r219" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r41", "r83", "r113", "r114", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r66" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": { "order": 10090.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling General And Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling General And Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseRelatedToEquityAwardsGrantedToEmployeesAndConsultantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r74" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Discount rate from fair value on offering date that participants pay for shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date", "terseLabel": "Percentage of stock price at the beginning of offering period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Shares Subject to Outstanding Awards, RSUs forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value. RSUs forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Shares Subject to Outstanding Awards, RSUs awarded" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r211" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value. RSUs awarded" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Shares Subject to Outstanding Awards, Ending Balance", "periodStartLabel": "Shares Subject to Outstanding Awards, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value. Ending Balance", "periodStartLabel": "Weighted Average Grant Date Fair Value. Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Shares Subject to Outstanding Awards, RSUs released" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value. RSUs released" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Shares Subject to Outstanding Options, canceled/forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Shares Subject to Outstanding Options, granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r206", "r219" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Shares Subject to Outstanding Options, Ending Balance", "periodStartLabel": "Shares Subject to Outstanding Options, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r205" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Per Share, Ending Balance", "periodStartLabel": "Weighted Average Exercise Price per Share, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r200", "r203" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityScheduleOfCommonStockReservedForIssuanceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per Share, canceled/forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price Per Share, granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r82", "r202", "r204" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Common stock shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r15", "r330", "r331", "r342" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r376", "r377", "r378", "r379" ], "lang": { "en-US": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short Term Investments [Member]", "terseLabel": "Short-term investments (due within one year)" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueMeasurementOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SoftwareDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Internally developed software for sale, licensing or long-term internal use.", "label": "Software Development [Member]", "terseLabel": "Capitalized Software" } } }, "localname": "SoftwareDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponentsSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r43", "r91", "r92", "r93", "r95", "r100", "r102", "r112", "r146", "r175", "r182", "r220", "r221", "r222", "r230", "r231", "r263", "r264", "r265", "r266", "r267", "r269", "r358", "r359", "r360" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r91", "r92", "r93", "r112", "r326" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnauditedParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.", "label": "Stock Issued During Period Shares Employee Benefit Plan", "terseLabel": "Contributions converted shares under benefit plan" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r16", "r17", "r175", "r182" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock pursuant to employee stock purchase plan, shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r175", "r182" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common stock in connection with the follow-on offering, net of issuance costs, shares", "verboseLabel": "Common stock shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r175", "r182", "r207" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Shares Subject to Outstanding Options, exercised", "terseLabel": "Issuance of common stock upon the exercise of options and release of stock awards, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionAndOtherEquityAwardActivityUnderPlansDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r16", "r17", "r175", "r182" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock pursuant to employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r175", "r182" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock in connection with the follow-on offering, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r43", "r175", "r182" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuance of common stock upon the exercise of options and release of stock awards" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r22", "r23", "r85", "r133", "r145", "r261" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": { "order": 10030.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r84", "r182", "r184" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r270", "r293" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r270", "r293" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r270", "r293" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r270", "r293" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r292", "r294" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r137", "r138", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r189", "r339" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U S Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency obligations" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfAvailableForSaleDebtSecuritiesInContinuousUnrealizedLossPositionForLessThanAndGreaterThanTwelveMonthsDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFairValueAssetsMeasuredOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r115", "r116", "r117", "r118", "r119", "r120", "r121" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r281", "r288" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesScheduleOfInformationRelatedToOperatingLeaseActivityDetails": { "order": 10020.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLeasesScheduleOfInformationRelatedToOperatingLeaseActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants And Rights Outstanding Measurement Input", "terseLabel": "Warrants, percentage" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r254" ], "lang": { "en-US": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants And Rights Outstanding Term", "terseLabel": "Expected term (in years)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfSignificantUnobservableInputsUsedToValueWarrantDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": { "auth_ref": [ "r249" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of warrants not settleable in cash classified as equity.", "label": "Warrants Not Settleable In Cash Fair Value Disclosure", "terseLabel": "Fair value of warrant" } } }, "localname": "WarrantsNotSettleableInCashFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.myokardia.com/20200930/taxonomy/role/DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted average number of shares used to compute net loss per share, basic and diluted", "totalLabel": "Weighted average shares used to compute basic and diluted net loss per share" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails", "http://www.myokardia.com/20200930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": { "auth_ref": [ "r104" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": 10020.0, "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).", "label": "Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation", "negatedLabel": "Less: weighted average shares subject to repurchase" } } }, "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Denominator" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r103", "r107" ], "calculation": { "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails": { "order": 10010.0, "parentTag": "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number Of Shares Outstanding Basic", "terseLabel": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myokardia.com/20200930/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(11))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r237": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.11)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r294": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.23)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r386": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r387": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r388": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r389": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r391": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r47": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" } }, "version": "2.1" } ZIP 71 0001564590-20-051420-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-051420-xbrl.zip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end